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Abstract 
 
Methamphetamine dependence remains a worldwide problem and 
Malaysia is no exception. The widespread of methamphetamine 
dependent has given an impact that can be felt at various levels, from 
the individual, to the individual’s family, community and society. 
Unfortunately, there are not many studies done on the issues of 
methamphetamine dependence in Malaysia. We are still lacking in 
published data especially in terms of prevalence, psychiatry morbidity, 
genetic risk factors and treatment aspect.  
Based on the result of the study, we found that the prevalence of 
psychiatric co-morbidity was 54.4% and the prevalence of suicidality 
was 12.1 %. The subjects had high rates for methamphetamine-
induced psychosis with 47.9% had at least one episode of psychotic 
symptoms and 13.0% were still having psychotic symptoms at the time 
of assessment.  
Our results showed that the distribution of the BDNF Val66Met 
genotype in Chinese subjects with methamphetamine dependence and 
methamphetamine psychosis were significant compared with controls. 
The frequency of the 66Val allele in methamphetamine-dependent 
subjects was higher than that in the control group, suggesting that the 
66Val carriers are more susceptible to methamphetamine dependence. 
However, 66Val allele frequency in other ethnicities was not 
significantly different from the controls.  
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Among those who were having methamphetamine-induced psychosis, 
treatment with aripiprazole was associated with significant decline in 
the Positive And Negative Symptoms Scale (PANSS) and Clinical 
Global Impression of Severity (CGI-S) score. Aripiprazole was 
generally well tolerated with no serious adverse event occur. In the 
randomised controlled trial study, 84.2% of participants randomized to 
aripiprazole completed the study compared to only 50% of the placebo 
group completed. There was a statistically significant difference 
between groups in the amount of time spent in treatment, with those 
given aripiprazole retained for an average of 48.7 days (+ 4.0) 
compared with only 37.1 days (+ 5.0) for the placebo group. The 
survival curves results showed that participants in the aripiprazole 
group were less likely to drop out of the study than those in the placebo 
group. The difference was statistically significant. Psychotic symptoms 
as measured by PANSS and CGI were decreased among participants 
who were randomized to aripiprazole treatment but those who were 
randomized to placebo showed an increased in the total PANSS and 
CGI score. However there were no statistically significant effects for 
aripiprazole relative to placebo on methamphetamine use verified by 
urine drug screen. Aripiprazole treatment was not associated with any 
serious adverse event. 
Based on the findings: 
- Support the fact that methamphetamine users are a high-risk 
population for psychosis.  
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- Suggest that the BDNF Val66Met polymorphism may contribute to 
methamphetamine dependence and psychosis in the Chinese 
population but not in other Malaysian ethnicities.  
- Suggest that aripiprazole was efficacious and safe options for the 
treatment of methamphetamine-induced psychosis.  
- Aripiprazole was no more effective than placebo in maintaining 
abstinence from methamphetamine use. However, it facilitated 
treatment retention and reduced the occurrence of psychotic 
symptoms in patients with methamphetamine dependence.  
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Abstrak  
 
Ketagihan dadah methamphetamin masih menjadi masalah di seluruh 
dunia dan di Malaysia perkara tersebut tidak terkecuali. Ketagihan 
methamphetamin yang berleluasa ini telah mendatangkan kesan yang 
besar terhadap setiap individu yang terbabit, keluarga, komuniti dan  
setiap lapisan masyarakat. 
Malangnya tidak banyak kajian yang telah dilakukan terhadap isu-isu 
berkaitan penagihan methamphetamin di Malaysia.  Kita masih lagi 
kekurangan dari segi penerbitan data untuk prevalen, psikiatrik 
morbiditi, faktor risiko genetik dan dari segi rawatan.  
Berdasarkan kajian yang dilakukan kami dapati prevalen psikiatrik ko-
morbiditi adalah sebanyak 54.4% dan prevalen bunuh diri pula adalah 
12.1%. 
Kadar psikosis disebabkan oleh penggunaan methamphetamin adalah 
tinggi iaitu 47.9% daripada peserta mengalami sekurang-kurangnya 
satu episod simptom psikosis dan 13% dari peserta masih lagi 
mengalami simptom psikosis semasa kajian dilakukan.  
Keputusan kami menunjukkan taburan BDNF Val66Met genotipal 
dikalangan peserta berbangsa Cina yang ketagih methamphetamin 
dan mengalami psikosis disebabkan oleh methamphetamin adalah 
ketara berbanding peserta kawalan.  Kekerapan allel 66Val  dikalangan 
penagih methamphetamin adalah lebih tinggi berbanding kumpulan 
kawalan,  menunjukkan pembawa 66Val adalah lebih terdedah untuk 
mengalami ketagihan methamphetamin. Walau bagaimanapun 
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kekerapan allel 66Val untuk kumpulan etnik lain adalah tidak berbeza 
dengan kumpulan kawalan.  
Dikalangan mereka yang mengalami psikosis disebabkan oleh 
methamphetamin, rawatan menggunakan aripiprazole telah 
menunjukkan penurunan ketara skala Positif dan Negatif 
Simptom(PANSS) dan skala Kesan Global Klinikal - Keterukkan (CGI-
S) sepanjang tempoh kajian. Secara amnya aripiprazole tidak 
menimbulkan kesan sampingan yang serious. 
Semasa kajian rawak terkawal, 84.2% peserta yang dirawakkan 
mendapat aripiprazole menamatkan kajian berbanding hanya 50% 
peserta yang dirawakkan mendapat placebo menamatkan kajian. 
Terdapat perbezaan statistik yang ketara diantara kumpulan di dalam 
jumlah masa kekal didalam rawatan, dengan peserta yang diberikan 
aripiprazole kekal didalam rawatan secara purata selama 48.7 hari 
(+4.0) berbanding dengan hanya  37.1 hari (+5) untuk kumpulan 
placebo. Keputusan lengkok kehidupan  menunjukkan peserta 
dikumpulan aripiprazole mempunyai kebarangkalian yang kurang untuk 
berhenti dari kajian berbanding kumpulan yang mendapat placebo.  
Simptom psikotik yang diukur menggunakan PANSS dan CGI juga 
menunjukkan pengurangan dikalangan peserta yang dirawakkan 
mendapat aripiprazole tetapi bagi peserta yang dirawakkan mendapat 
placebo  menunjukkan peningkatan di dalam jumlah markah PANSS 
dan CGI. Walau bagaimanapun tidak terdapat perbezaan ketara dari 
segi statistik di antara kumpulan aripiprazole dan placebo untuk 
penggunaan methamphetamin dikalangan penagih melalui ujian dadah 
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air kencing. Secara amnya aripiprazole tidak menimbulkan kesan 
sampingan yang serious.  
Berdasarkan kepada keputusan kajian: 
- Menyokong fakta bahawa penagih methamphetamin adalah 
terdedah kepada risiko untuk mendapat psikosis . 
- Mencadangkan bahawa polimorfisme BDNF Val66Met mungkin 
menyumbang kepada ketagihan methamphetamin dan psikosis 
di kalangan etnik Cina tetapi tidak kepada etnik-etnik lain di 
Malaysia. 
- Aripiprazole mengurangkan simptom psikotik disebabkan oleh 
penagihan methamphetamin dan rawatan tersebut tidak 
menimbulkan kesan sampingan yang serious. 
- Aripiprazole tidak lebih berkesan berbanding placebo untuk 
mempertahankan pantang dari penggunaan methamphetamin. 
Bagaimanapun aripiprazole membantu peserta terus kekal 
dalam rawatan dan dapat menggurangkan kejadian psikotik 
dikalangan penagih methamphetamin. 
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Chapter ONE: INTRODUCTION 
1.1   Background and Conceptual Framework  
Substance dependence remains a worldwide problem and Malaysia is 
no exception. Substance dependence, characterized by compulsive 
uncontrollable drug use despite clear negative consequences, is 
among the most prevalent psychiatric disorders, contributing 
significantly to mortality, physical and social morbidity. 
The United Nations Office on Drugs and Crime (UNODC) estimated 
that in 2007, 26 million people in the world have used 
methamphetamine, 21 million have used opiates and 20.7 million have 
used cocaine (Unodc, 2009a). The past decade has seen a remarkable 
increase in the popularity of methamphetamine within East Asia and 
the Pacific region. It was also reported that 60% of methamphetamine 
users live in Asia, and that misuse of this illicit substance has become 
a major problem in countries such as China, Philippine, Myanmar, 
Thailand and Malaysia (Unodc, 2009a). 
In Malaysia, within the first three months of 2010, the National Anti-
Drug Agency has identified 3,611 who are substance dependent, which 
is an increase of about 110% compared to the same period in the 
previous year. Among these identified addicts, 18% were dependent on 
amphetamine-type-stimulants (ATS), which include amphetamine, 
methamphetamine and ecstasy pills. This represents a 117% increase 
in ATS addicts compared with the same period in the previous year 
(Kdn, 2010).  
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The Malaysian government has declared that drug addiction is the 
number one enemy of the country (Afp, 2000). One of the initiatives 
against drug abuse and trafficking taken by Malaysian government is 
the launching of the ‘drug-free by 2015’ policy (Utusan, 2006). This 
long-term effort aims to reduce domestic drug use to negligible levels 
by 2015. The Malaysian government spent more than RM 1.5 billion 
over the past five years trying to make this policy a reality (Nst, 2010). 
In order to show its seriousness in combating drug problem, Malaysia 
strictly enforces its drug laws. Possession, use, and trafficking in illicit 
drugs in Malaysia are severe criminal offences. Malaysian legislation 
provides for a mandatory death penalty for convicted drug traffickers 
(Akta, 1952).  
The widespread of methamphetamine dependence has given an 
impact that can be felt at various levels, from the individual, to the 
individual’s family, community and society. At the country level, 
methamphetamine dependence gives rise to serious behavioural, 
medical and psychiatric consequences, imposing an immense burden 
on the medical, public health and criminal justice systems. 
According to a 2004 research on the socio-economic impact of ATS 
(Wilkins et al., 2004), it was reported that about one third of those who 
had used an ATS drug in the last year reported experiencing harm in at 
least one area of their lives from the use of these drug. About half of 
the frequent methamphetamine users reported harm in the areas of 
friendship and social life (55%), health (55%), and energy and vitality 
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(53%). Work and work opportunities were also rated as seriously 
affected by frequent methamphetamine users. 
More recently, methamphetamine use has also been associated with 
increased crime and violence such as feuds between trafficking gangs, 
robbery, homicide (Kosten and Singha, 1999). Compared with other 
psychoactive drugs, chronic methamphetamine use is more closely 
related to violent behaviour.  
On a wider scope, illicit drug use and trafficking also poses a significant 
impact on the economic sectors in consumer countries. Important and 
valuable resources are sacrificed, diverting from legitimate and more 
sustainable investments to drug production and consumption, which in 
turn impacts negatively on the productivity of the users (Unodc, 1998b). 
Drug abuse also raises the government expenditure, the largest part of 
which is used for drug-related crime and law enforcement costs 
(Unodc, 1998b). For instance, the Malaysian government has to spend 
more than RM300 million each year in its endeavour against illicit drug 
activities, half of which are used to set up rehabilitation centres 
(Utusan, 2006).  
On the individual level, the increasing trend in methamphetamine use 
raises particular concern because of its deleterious effects on 
individuals and related health costs. The health costs of a drug addict 
have been reported to be almost 80% higher than those of an average 
citizen (Unodc, 1998b). Methamphetamine consumption is constantly 
linked to high-risk HIV behaviours (Semple et al., 2004, Kurtz and 
1 Introduction  
 
 4 
Inciardi, 2003, Reback et al., 2004, Marshall et al., 2011) and more 
recently, cardiovascular problems (Mau et al., 2009, Kaye et al., 2007, 
Droogmans et al., 2007, De Silva et al., 2007). The most serious 
problem, however, reported by frequent methamphetamine users was 
psychological rather than physical. About two-thirds of frequent 
methamphetamine users reported anxiety, mood swings, short temper, 
paranoia and depression, while 21% of them reported suicidal thoughts 
and 13% suicide attempts after using the drug (Wilkins et al., 2004). As 
a potent psycho-stimulant with a high dependence liability, 
methamphetamine dependent is closely associated with the risk of 
acute and chronic psychological disturbance, including psychosis 
(Who, 1997). 
Unfortunately, there are not many studies done on the issues of 
methamphetamine dependence in Malaysia. We are still lacking in 
published data especially in terms of prevalence, psychiatry morbidity, 
genetic risk factors and treatment aspect. 
My study will focus on few important issues related to 
methamphetamine dependence including: 
1. Psychiatric comorbidity and suicidality among treatment seeking 
methamphetamine dependence patients. 
2. Prevalence and associations of metahamphetamine psychosis 
among treatment seeking methamphetamine dependence 
patients. 
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3. Association of brain-derived neurotrophic factor (Val66Met) 
genetic polymorphism with male methamphetamine 
dependence in Malaysia. 
4. Open label study of the safety and efficacy of aripiprazole in the 
treatment of methamphetamine induced psychosis. 
5. Randomized placebo controlled trial of the safety and efficacy of 
aripiprazole in the treatment of methamphetamine dependence. 
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Figure 1.1 Conceptual Framework 
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1.2   What is Amphetamine-Type Stimulant (ATS)?   
Amphetamine-type stimulants (ATS) in general refer to a group of 
psychothropic drugs whose principal members include amphetamine, 
methamphetamine (pharmaceutically known as methylamphetamine), 
and 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’). 
Other substances that also fall into this category of drug are such as 
methcathinone, fenetylline, ephedrine, pseudoephedrine, 
methylphenidate (Who, 2011).  
ATS are sometimes prescribed for medical reasons, mainly in the 
treatment of attention-deficit hyperactivity disorder (ADHD) in adults 
and children (Bejerot et al., 2010, Swanson et al., 2010), as well as 
symptoms of traumatic brain injury (Warden et al., 2006) and 
drowsiness in narcolepsy (Bruck et al., 2005) and chronic fatigue 
syndrome(Blockmans et al., 2006). Unfortunately, today these drugs, 
mainly amphetamine, methamphetamine and MDMA, are illegally used 
for recreational purposes in clubs and discos, leading to various 
consequences.    
1.3  Types of methamphetamine and routes of administration 
ATS come in different forms and with different names. The route of 
administration for each form also varies. While smoking, sniffing, 
inhaling and injecting are the most popular methods of ATS use, but 
ways of using the drug differ widely across the region (Unodc, 2009e).  
The primary forms of ATS in East Asia and the Pacific include crystals 
(‘ice’), methamphetamine powder, tablets/pills, MDMA/Ecstacy, and 
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"base" (Unodc, 2009e).  Methamphetamine found on the street comes 
in the form of powder, crystals or pills. It is white, odourless, bitter-
tasting, and easily dissolves in water or alcohol. The substance is often 
adulterated with chemicals that were used to synthesize it.  
i). Crystal methamphetamine 
‘Ice’, also known as ‘Crystal’, ‘glass’ or ‘syabu’, is purified form of 
methamphetamine that has been ‘washed’ in a solvent to remove 
impurities. The purity level of this form of methamphetamine is usually 
above 80% (Unodc, 2009e, Doj, 2010), and thus has longer-lasting 
physical effects. It can be smoked in a glass pipe or on a piece of 
aluminium foil (known as ‘chasing the dragon’). ‘Ice’ is also sometimes 
administered via snorting, swallowing or injection.   
ii). Methamphetamine powder 
‘Speed’ (‘meth’, ‘crank’) is a powdered methamphetamine of relatively 
low purity and sold in grams or ounces. Its colour ranges from dingy 
white to reddish brown. It can be snorted or injected. It can also be 
orally ingested or smoked. It is not common in Southeast Asia, but has 
been found in Cambodia, Indonesia, Japan and Thailand. However, it 
is the most popular form of methamphetamine in Australia and the US 
(Unodc, 2009e, Unodc, 2009c).   
iii). Methamphetamine tablets/pills 
Methamphetamine tablets/pills, which are generally a composite of 
methamphetamine and caffeine, are often referred to by their Thai 
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name, yaba ("crazy medicine").(Unodc, 2009e) Tablets are the 
predominant form of methamphetamine used in mainland Southeast 
Asia - Cambodia, Lao PDR, Thailand, and Vietnam. Pills are often 
ingested orally, and they can also be crushed into powder for 
inhalation, or dissolved in water for injection (Unodc, 2009c). 
iv). MDMA/Ecstacy 
A hallucinogen marketed as a ‘feel good drug’, MDMA is mainly used 
as a recreational drug. MDMA is a chemical derivative of 
methamphetamine, but is less common than methamphetamine in 
Southeast Asia.   
MDMA comes in the form of powder or crystal, and is used by snorting, 
or by oral administration either by applying a dab to the tongue and 
washing it down with water, or mixing it into a drink. The white MDMA 
is also mixed with substances, such as chalk, to form tablets (e.g. 
Ecstacy) or pills, or filled in capsules. In many parts of the world, 
however, the usage of plain MDMA powder instead of pills is popular. 
 Ecstasy is usually sold as tablets of various shapes and colours, and 
imprinted with monograms. It can also be found in the form of 
capsules. The predominant form of ingestion is swallowing (Unodc, 
2009c).   
v). Base methamphetamine 
A damp, sticky powder that has a yellow or brown hue due to the 
presence of impurities. ‘Base’ is manufactured and more commonly 
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used in Australia than in countries in the Southeast Asia (Jenkinson 
and Johnston, 2006). This type of methamphetamine generally 
requires heating to sufficiently dissolve it for injection (Unodc, 2009e). 
1.4  ATS production    
ATS are synthetic central nervous system (CNS) stimulants 
manufactured in laboratories. The manufacturing process requires 
various types of substances, precursors, chemical reagents and 
solvents, mixing and heating equipment to synthesize ATS. Other 
equipment is required to make ATS tablets.  
i). Producing amphetamine and methamphetamine 
Methamphetamine can be quite easily produced in clandestine 
laboratory, as the required ingredients are commercially available and 
relatively inexpensive. In addition, the manufacture process does not 
need specialised equipment or advanced technical skills. Perhaps 
these are part of the reasons why methamphetamine is a drug with 
high potential of widespread abuse. 
While norephedrine is the precursor that is converted to amphetamine, 
ephedrine is the precursor for methamphetamine. A reduction process 
is carried out by adding a reducing reagent, such as acetic anhydride, 
to produce pure amphetamine or methamphetamine (Figure 1.2) 
(Unodc, 2009f).  
Pure methamphetamine and amphetamine have the chemical 
characteristics of bases, which are both lipid-soluble and volatile, and 
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thus chemically and physically less stable. Therefore these 
amphetamines must be mixed with acids to produce a salt. For 
example, hydrochloric acid or sulphate acid is added to the 
amphetamine base to produce amphetamine hydrochloride powder 
that is water-soluble and chemically more stable. Therefore most 
amphetamines are marketed in their crystalline form.   
 
Figure 1.2   Production of amphetamine and methamphetamine(Unodc, 
2009f) 
Phenylacetic acid
1-phenyl-2-propanone Norephedrine
Ephedrine/
pseudoephedrine
Pure 
methamphetamine
Pure 
amphetamine
Hydrochloride salt Sulphate salt
Acetic anhydride
Hydrochloric acid Sulphuric acid
 
 
 
ii).  Producing MDMA 
The precursors and intermediate products in the manufacturing 
process of MDMA are outlined below (Figure 1.3) (Unodc, 2009f). The 
term ‘ecstasy’ specifies the tablet form of MDMA, although it is 
occasionally found in crystalline form or liquid form. 
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Figure 1.3      Production of MDMA(Unodc, 2009f) 
Intermediate3,4-MDP-2-P
MDMA (Ecstacy)
Isosafrole Safrole
3,4-MDP-2-P = 3,4-methylendioxyphenyl-2-propanone
 
 
iii).  Producing ‘ice’ 
To make the ‘ice’, methamphetamine hydrochloride is added slowly to 
water and then brought to a temperature of just under 100C, thus 
forming a super-saturated solution.(Derlet and Heischober, 1990) The 
solution is then allowed to cool and the ‘ice’ precipitates from the 
solution itself to become large crystals. The ephedrine required in the 
production can be extracted from over-the-counter cold and flu 
medicines, although it can also be obtained from the black market 
(Mcketin et al., 2005).  
1.5  Mechanism of Action of methamphetamine and Ecstacy 
Although both methamphetamine and Ecstacy are CNS stimulants, 
they produce different chemical interactions in the brain. 
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i).  Methamphetamine 
Abusers of methamphetamine often follow the “binge and crash” abuse 
pattern (Gard, 2004). Once enters the body, methamphetamine works 
directly on the brain, causing a release of high levels of dopamine – the 
neurotransmitter that stimulates the brain cells and regulate feelings of 
pleasure. This artificially raises the dopamine level and a person feels 
extra good or “high”, followed by increased mental alertness, 
decreased appetite and a general sense of well-being (Gard, 2004). 
The pleasurable effects of methamphetamine dissipate before the drug 
levels drop. Therefore users usually binge on methamphetamine by 
taking it continuously for several days. The drug does not produce 
energy, but permits access to energy reserves in the body. Once the 
effects of methamphetamine wear off, i.e. the energy reserves are 
used up, the body must replenish them. This leads to the “crash”, and 
the exhausted abuser experiences withdrawal symptoms such as 
depression, paranoia and aggression (Gard, 2004). To get rid of these 
undesirable feelings, the person takes more methamphetamine, 
resuming the binge-and-crash cycle all over again.   
As doses administered increase, tolerance develops. Consequently, 
drug abusers need to take even higher doses to reach the same effect. 
Therefore when used long term, methamphetamine causes very strong 
dependence.   
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ii).  MDMA 
MDMA primarily affects the serotonin (Unodc, 2009e), a 
neurotransmitter that plays an important role in regulating mood and 
emotions, sexual activity, sleep, and sensitivity to pain.  
Compared with methamphetamine, MDMA causes greater serotonin 
release and lesser dopamine release. The excess release of serotonin 
by MDMA likely causes a mood elevation in MDMA users, producing 
an energizing effect, as well as distortions in time and perception and 
enhanced enjoyment from tactile experiences (Unodc, 2009d). 
However, by releasing large amounts of serotonin, the brain becomes 
markedly depleted of this important neurotransmitter, thus contributing 
to negative behavioural after-effects that last several days after taking 
MDMA. 
1.6  ATS abuse and dependence 
From the United Nation Office on Drugs Crimes(UNODC), an estimate 
of 50 million people in the world used ATSs compared with 21 million 
who used opiates and 20.7 million who used cocaine in 2007 (Unodc, 
2009a). It was also reported that 60% of ATS users (mostly 
methamphetamine users) live in Asia. 
Amphetamines, particularly methamphetamines, are among the most 
commonly abused illicit stimulants in the United States (US). According 
to their 2001 National Household Survey on Drug Abuse (Dhhs, 2001), 
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the number of new methamphetamine users more than doubled 
between 1990 and 2000, an increase from 164,000 to 344,000 over 10 
years. Among the new users, half of them aged between 12 and 17 
years. The rising number of ATS abuse is also reflected in the 
increased number of treatment admissions of persons with primary 
methamphetamine use problems, from 21,000 in 1993 to 117,000 in 
2003 (Baskin-Sommers and Sommers.I, 2006). 
There is evidence that some individuals used ATSs in the work arena. 
As shown in the Quest Diagnostics’ 2003 Drug Testing Index, there 
was an increased use of amphetamines among general US workforce 
employees, from 0.34% in 2002 to 0.49% in 2003, which is a whopping 
44% increase (Quest-Diagnostics, 2003).   
1.7  Primary form of ATS abused in Asia and Pacific 
According to a 2006 report from the Asia and Pacific Amphetamine-
type Stimulants Information Centre (APAIC) (Unodc, 2009c), 
methamphetamine in pill form (‘yama’/’yaba’) is the primary ATS drug 
of abuse in China, Cambodia, Lao PDR, Thailand and Vietnam. On the 
other hand, crystal methamphetamine (‘ice’, street name for ’syabu’) is 
the main form of ATS abused in Malaysia, Brunei, Japan, the 
Philippines and Singapore. In Australia and Indonesia, the principal 
ATS drug of abuse is Ecstacy.  
While some countries showed a stable or increaseasing trend in the 
use of ATS, Malaysia reported a decreased abuse trend of crystalline 
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methamphetamine and Ecstacy from the year 2004 to 2006 (Unodc, 
2009c).   
Despite the seemingly declining trend of ATS abuse in Malaysia, the 
International Narcotics Control Strategy Report (INCSR) 2007(Bureau, 
2007) actually suggested that domestic abuse in Malaysia itself is 
increasing and that methamphetamine production from clandestine 
laboratories in Malaysia are getting bigger. 
This can be observed from the fact that, among others, one ‘superlab’ 
was seized in 2004 and another in 2006 in Kulim (Unodc, 2009c). In 
April 2007, the Narcotics Crime Investigations Department busted one 
large syabu producing laboratory in Johor, followed by another one in 
Klang, of which was believed to be the largest-ever syabu processing 
laboratory seized so far in Malaysia (Star, 2007).  
In the Asia and Pacific region, 64 clandestine drug laboratories 
producing methamphetamine were seized in 2006, a number that was 
a third higher compared with 2005 and almost four times of that seized 
in 2004 (Unodc, 2009c). In addition, more than 75% of the 
methamphetamine laboratory seizures during 2005 and 2006 occurred 
in China (Unodc, 2009c).  
1.8  Illicit drug market in Malaysia 
Although Malaysia is not a major source country of illicit drug market, 
Malaysian labs are increasing methamphetamine production and the 
country’s drug addiction rates are on the rise.  
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Drugs are also smuggled across Malaysian borders from different parts 
of the world (Unodc, 2009b). Heroin and marijuana are imported from 
the production areas of Golden Triangle area, while ketamine comes 
from India. These drugs are either consumed domestically or transit 
Malaysia to other several countries in the region. For example, Ecstasy 
from Amsterdam is flown into Kuala Lumpur International Airport (KLIA) 
for domestic use and distribution to Thailand, Singapore, and Australia. 
1.9  Legal framework towards illicit drug abuse and trafficking   
i). International framework 
Internationally there are several agreements and legal frameworks 
established towards illicit drug abuse and trafficking, including:(Unodc, 
2011)  
 United Nations Drug Control Conventions (1961, 1971, 1988) 
 Global Assessment Programme (1998) 
 ASEAN Plan of Action on Drug Abuse Control (1996) 
 ASEAN and China Cooperative Operations in Response to 
Dangerous Drugs (ACCORD) Plan of Action (2000) 
 Memorandum of Understanding (MOU) on Drug Control (1993) 
 Subregional Action Plan (2000) 
 Tokyo Conference on ATS (2000) 
 28th Meeting of Heads of National Drug Law Enforcement Agencies, 
Asia and the Pacific, in Bangkok (2004) 
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 Regional Government Responses 
Malaysia is a party to the 1988 United Nations Drug Control 
Convention, as well as a member of the ASEAN and ACCORD Plan of 
Actions. 
ii). Malaysia’s initiative and law enforcement against drug-
related offence  
One of the initiatives against drug abuse and trafficking of the 
Malaysian government is the launching of the ‘drug-free by 2015’ policy 
in 2003 (Nst, 2010). This long-term effort aims to reduce domestic drug 
use to negligible levels by 2015. 
In terms of legal framework, the Malaysian drug laws cover all aspects 
of drug-related offence, from prevention to rehabilitation. The five main 
drug laws enforced in Malaysia are (Pemadam, 2011):  
 Dangerous Drugs Act 1952 
 Poisons Act 1952 
 Drug Dependants (Treatment and Rehabilitation) Act 1983, 
Amendment 1998 
 Dangerous Drugs (Special Preventive Measures) Act 1985 
 Dangerous Drugs (Forfeiture of Property) Act 1988 
Malaysia strictly enforces its drug laws. Possession, use, and 
trafficking in illicit drugs in Malaysia are severe criminal offences. 
Malaysian legislation provides for a mandatory death penalty for 
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convicted drug traffickers, with the best known case being the 
execution of two Australians for heroin smuggling in 1986 (Tempo, 
1986). Other drug-related offenders can also expect heavy penalties 
such as long jail sentences and heavy fines.   
1.10  Drug-related offence arrestment and seizures in Malaysia 2009 
i).  Arrestment of drug offenders 
From January to December 2009, the Royal Malaysian Police (PDRM) 
and Royal Malaysian Custom (KDRM) have arrested 77,623 drug 
offenders under the Dangerous Drugs Act 1952 and Dangerous Drugs 
(Special Preventive Measures) Act 1985 (Adk, 2009). This figure is 
18.99% higher than that arrested for the same period of time in 2008 
(Table 1.1). 
Table 1.1: Comparison of the total arrestment of drug offenders under 
the Dangerous Drug Act 1952 between 2008 and 2009 
Type of offense Jan-Dec 2009 Jan-Dec 2008 Difference 
2009/2008 
Dangerous Act 1952 
Section 39B 3,045 2,580 18.02% 
Section 39A 5,538 4,870 13.72% 
Other sections 66,540 56,593 17.58% 
*ADB (LLPK) 
1985 
2,500 1,191 109.91% 
Total 77,623 65,234 18.99% 
*ADB (LLPK) 1985 = Dangerous Drug (Special Preventive Measures) Act 
1985 
Source: Agensi Antidadah Kebangsaan   
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ii). Drug seizures 
Meanwhile, different types of illicit drug have been seized by the three 
enforcing agents; PDRM, KDRM and the Pharmaceutical Services 
Division of the Malaysian Ministry of Health. Among the types of ATS 
seized, there was a drastic increase in the amount of Ecstacy powder 
and syabu, seized, while a marked drop in the amount seized for 
Ecstacy pills and Yaba pills (Table 1.2) (Adk, 2009). 
Table 1.2: Comparison of ATS seized between 2008 and 2009 
Drug type Jan-Dec 2009 Jan-Dec 2008 Difference 
2009/2008 
Ecstacy powder (kg) 708.52 8.6 8,136.60% 
Syabu (kg) 1,159.66 356.92 224.91% 
Ecstacy (pills) 75,515 80,778 -6.51% 
Yaba (pills) 107,952 281,343 -61.63% 
Source: Agensi Antidadah Kebangsaan   
Under the Dangerous Drugs (Forfeiture of Property) Act 1988, the 
PDRM has handled a total of 2,341 cases of property seizures in 2009. 
Based on the numbers recorded, there is an increase of 120 cases 
(5.4%) in 2009 compared with 2008 (Table 1.3) (Adk, 2009). 
Table 1.3: Comparison of property seized under Property Forfeiture Act 
1988 between 2008 and 2009 
Property seizure Jan-Dec 2009 Jan-Dec 2008 Difference 
2009/2008 
Total number of cases 2,341 2,221 5.40% 
Value of property 
confiscated 
38,200,000 70,300,000 84.03% 
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1.11  Demographic of drug users in Malaysia 2009 
According to the latest report from the Malaysian National Drug 
Information System (NADI) (Adk, 2009), in which statistics of drugs 
users in Malaysia were gathered from January to December 2009, 
there was an increase in the number of drug users detected. The 
number increased from 12,352 for the same period of time in 2008 to 
15,736 drug users in 2009 (a 27.40% increment).  
Among the number of cases identified, 7,123 were new users, 
indicating an increment of 19.94% compared to 5,939 for the same 
period of time in 2008. The number of repeat offenders detected were 
as many as 8,613, an increment of 34.31% compared with the same 
period of time in 2008 (6,413) (Table 1.4). 
Table 1.4: Comparison of drug users identified between 2008 and 2009 
Case status Jan-Dec 
2009 
Percentage Jan-Dec 
2008 
Difference 
2009/2008 
New user* 7,123  45.27%  5,939  19.94%  
Repeat 
user** 
8,613  54.73%  6,413  34.31%  
Total 15,736  100.00%  12,352  27.40%  
*Detected for the first time by NADI. 
**Previously detected by NADI. 
 
i). Comparison by state 
Amongst all the states, Penang recorded the highest number of 
detected drug users at 2,255, followed by Kedah (2,016), Kelantan 
(1,902), Selangor (1,864) and Kuala Lumpur (1,635). Compared to 
1 Introduction  
 
 22 
January-December 2008, all states recorded an increase in number of 
detected drug users except for Kuala Lumpur, Terengganu, Perak, 
Malacca and Sabah in 2009.   
ii).  Comparison by ethnicity 
Amongst drug users detected between January-December 2009, the 
majority were of Malay ethnics (13,705 or 87.09%), which is 0.16% of 
the total Malay population in Malaysia (8,826,000) (Table 1.5). 
 
Table 1.5: Comparison of drug users identified by ethnic between 2008 
and 2009 
Ethnic Jan-Dec 2009 Percentage Jan-Dec 
2008 
Difference 
2009/2008 
Foreigner 4  0.03%  12  -66.67%  
Sarawak pribumi 23  0.15%  17  35.29%  
Sabah pribumi 56  0.36%  150  -62.67%  
Indian 942  5.99%  1,090  -13.58%  
Chinese 951  6.04%  1,438  -33.87%  
Malay 13,705  87.09%  9,562  43.33%  
Others 55  0.35%  83  -33.73%  
Total 15,736  100.00%  12,352  27.40  
 
iii). Comparison by gender 
Of the 15,736 drug users detected in 2009, as many as 15,458 were 
male (98.23%) and 278 female (1.77%), reflecting an increment of 
28.01% and 0.72% in male and female users, respectively, compared 
with figure recorded for January-December  2008.  
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iv). Comparison by age group 
Data gathered over the 12 month periods also showed that youth 
population aged between 19-39 years old continue to be major drug 
users (11,949). Of all drug users identified, 332 (2.15%) are in fact 
teenagers (13-18 years old). The 25-29 year old users remain to be the 
biggest group of drug user (22.08%). Of particular note, there was an 
alarming 327% increase from 11 in 2008 to 47 in 2009 in users aged 
between 13-15 years old.   
v). Comparison by occupation 
The report also indicates that majority of the drug users are employed 
(15,123 or 96.10%). It was noted that general labourers constitute the 
biggest drug abuse population (7,280 or 46.26%), followed by 
employees in the industries of servicing (29.25%), construction 
(6.20%), technical (4.87%) and farming/fishing (4.82%).   
vi).  Comparison by level of education 
The majority of drug users (10,711 or 65.55%) received minimum Form 
3 secondary education, of which 4,197 (28.78%) attained 
SRP/LCE/PMR academic qualification. There was an increase in the 
number of drug users with STP/HSC/STPM and university degree 
qualification.   
vii).  Comparison by reasons of starting drug abuse 
As in the past years, the main reason of starting drug abuse is due to 
influence from friends (66.27%), for pleasure (12.47%) and out of 
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curiosity (11.37%). Other reasons include stress, pain relieve purpose, 
and inadvertent usage. 
viii).  Comparison by types of drug used 
Marijuanna abuse recorded the highest percentage (33.09%) over the 
12 months in 2009, while 1,298 or 8.24% were detected to take ATS, 
which includes Ecstacy pills, methamphetamine (syabu) and 
amphetamine (Table 1.6).  
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Table 1.6: Comparison of drug users identified by types of drug between 
2008 and 2009 
Drug type Jan-Dec 
2009 
Percentage Jan-Dec 
2008 
Difference 
2009/2008 
Opiates 
Heroin 
Morphine 
Codeine/cough 
syrup 
Opium 
 
5,047 
3,386 
50 
 
5 
 
32.07% 
21.52% 
0.32% 
 
0.03% 
 
4,974 
3,640 
70 
 
9 
 
1.47% 
-6.98% 
-28.57% 
 
-44.44% 
Marijuana 
Cannabis 
Psychotropic pills 
 
5,207 
39 
 
33.09% 
0.25% 
 
1,726 
145 
 
201.68% 
-73.10% 
ATS  
Ecstacy 
pills/MDMA 
Metamphetamine 
(syabu) 
Amphetamine 
 
83 
 
1,131 
84 
 
0.53% 
 
7.19% 
0.53% 
 
119 
 
1,443 
225 
 
-30.25% 
 
-21.62% 
-62.67% 
Inhalant 
Gum 
 
0 
 
0.00% 
 
1 
 
-100.00% 
Others 704 4.47% 0 0.00% 
 
Total 
 
15,736 
 
100.00% 
 
12,352 
 
27.40% 
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ix). Comparison by types of drug used by ethnic 
Amongst the Malay drug users, the three most common drugs used are 
heroin (29.94%), morphine (21.10%) and methamphetamine (7.07%). 
As for Chinese drug users, the three most common drugs used are 
heroin (45.32%), morphine (26.71%) and methamphetamine (10.83%).  
When a comparison is made between all ethnics, Malay drug users are 
the largest cannabis users (93.03%), followed by Indians (4.32%) and 
Chinese (2.17%). Similarly, the majority of ATS users are Malay, 
followed by Chinese and Indians (Table 1.7).   
Table 1.7: Comparison of ATS users identified by ethnic and types of 
drug abuse 
 
Drug 
type/ethnic 
  
 Ecstacy/MDMA 
  
 Methamphetamine 
 
Amphetamine  
  
Malay 66 79.52% 969 85.68% 75 89.29% 
Chinese 14 16.87% 103 9.11% 6 7.14% 
Indian 2 2.41% 27 2.39% 3 1.50% 
Sabah 0 0.00% 22 1.95% 0 0.00% 
Sarawak 1 1.20% 5 0.44% 0 0.00% 
Others 0 0.00% 5 0.44% 0 0.00% 
Foreigners 0 0.00% 0 0.00% 0 0.00% 
Total 83 100.00% 1,131 100.00% 84 100.00% 
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1.12  Problems associated with ATS or general drug abuse 
An increasing use of ATSs has been identified in the past decades and 
become an epidemic in many parts of the world.  
i). Social consequences 
The social consequences of drug abuse can be seen in several areas, 
with the most prominent impact on family, health, and crime. According 
to a 2004 research on the socio-economic impact of ATS in New 
Zealand (Wilkins et al., 2004), it was reported that about one third of 
those who had used an ATS drug in the last year reported experiencing 
harm in at least one area of their lives from the use of these drug types. 
About half of the frequent methamphetamine users reported harm in 
the areas of friendship and social life (55%), health (55%), and energy 
and vitality (53%). Work and work opportunities were also rated as 
seriously affected by frequent methamphetamine users. 
ii). Family and community 
ATS abuse is frequently associated with family and social problems. 
The disintegration of many families, for example, has been correlated 
more strongly with drug abuse than with poverty (Unodc, 1998a). On 
the other hand, the increasing use of heroin and psychotropic 
substances may be due in part to the breakdown of traditional family 
structures and values (Singhanetra-Renard, 1993). Young people are 
also more vulnerable than older people to the negative consequences 
of drug use, particularly in areas such as educational achievement and 
employment (Wilkins et al., 2004).  
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iii). Health 
Methamphetamine consumption is constantly linked to high-risk HIV 
behaviours (Semple et al., 2004, Reback et al., 2004, Urbina and 
Jones, 2004, Kurtz and Inciardi, 2003) and more recently, 
cardiovascular problems (Perez et al., 1999, Kaye et al., 2007, 
Droogmans et al., 2007, De Silva et al., 2007). The most serious 
problem, however, reported by frequent methamphetamine users was 
psychological rather than physical. About two-thirds of frequent 
methamphetamine users reported anxiety, mood swings, short temper, 
paranoia and depression, while 21% of them reported suicidal thoughts 
and 13% suicide attempts after using the drug (Wilkins et al., 2004).  
As a potent psychostimulant with a high dependence liability, 
methamphetamine abuse is closely associated with the risk of acute 
and chronic psychological disturbance, including psychosis (Who, 
1997).  
iv). Crime 
Frequent methamphetamine users were often involved in other illegal 
activities.   
In the 2004 report of the socio-economic impact of ATS in New 
Zealand (Wilkins et al., 2004), one third of the frequent 
methamphetamine users had sold methamphetamine, and about 40% 
had earned income from illegal activities in the last 6 months, with drug 
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dealing the most common type of illegal activity. Heavy drug users tend 
to resort to selling drug as a way to support their own consumption.   
More recently, amphetamine use has also been associated with 
increased crime and violence (e.g. feuds between trafficking gangs, 
robbery, homicide) (Kosten and Singha, 1999). Compared with other 
psychoactive drugs, chronic amphetamine use is more closely related 
to violent behaviour.   
Locally, in 2009 alone the Malaysian police have arrested 77,663 
people due to drug related offences, including those with positive urine 
test for ATS (Adk, 2009).  
v). Economic consequences 
On individual basis, the increasing trend in methamphetamine use 
raises particular concern because of its deleterious effects on 
individuals and related health costs. The health costs of a drug addict 
have been reported to be almost 80% higher than those of an average 
citizen (Unodc, 1998b).   
On a bigger scope, illicit drug use and trafficking also poses a 
significant impact on the economic sectors in consumer countries. 
Important and valuable resources are sacrificed, diverting from 
legitimate and more sustainable investments to drug production and 
consumption, which in turn impacts negatively on the productivity of the 
users (Unodc, 1998b).   
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Drug abuse also raises the GDP, the largest part of which is used for 
drug-related crime and law enforcement costs (Unodc, 1998b). For 
instance, the Malaysian government has to spend more than RM300 
million each year in its endeavour against illicit drug activities, half of 
which are used to set up rehabilitation centres (Utusan, 2006).  
As regards to finance, two significant consequences of illicit drug-
associated problem are money laundering and criminal investment 
(Unodc, 1998b).   
1.13  Medical complications of ATS abuse 
Amphetamines have mood-altering properties, which can occur in both 
short and long term use, and thus significant behavioural effects on the 
users.   
i). Short-term effects of ATS 
As mentioned, ATSs are addictive stimulants of the central nervous 
system (CNS). Use of ATS leads to various clinical effects: euphoria, 
intensifying emotions, altering self-esteem, and increasing alertness, 
aggression, and sexual appetite (Richards et al., 2009). 
While changes in mood, excitation, motor movements, sensory 
perception, and appetite are mediated more directly by central 
dopaminergic alterations, alterations in serotonin level are postulated to 
be the cause of amphetamine-related mood changes, psychotic 
behaviour and aggressiveness (Richards et al., 2009).  
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Therefore, immediately after taking methamphetamine, users 
experience a “rush” or “high” caused by the increased levels of 
dopamine and serotonin. The users’ sensation of pleasure and well-
being is intensified, and they reported of a sense of euphoria, 
heightened level of alertness and increased energy (Volkow et al., 
1999). Users also experience increased libido and enhanced sexual 
pleasure, which is why methamphetamine use is associated with high-
risk sexual behaviour (e.g. unprotected sexual intercourse, multiple sex 
partners) (Shoptaw, 2006, Mmwr, 2006). These drug effects may last 
up to 12 hours (Anonymous, 2004).  
As the drug effects wear off, the users come down from the “high” and 
start to experience symptoms such as anxiety, insomnia and paranoia 
(Gard, 2004). Some users may exhibit violent behaviour, while some 
experience hallucinations (Gard, 2004). Table 1.8 lists some of the 
signs indicating that a person might be using methamphetamine. 
Table 1.8: Signs indicating a person might be using methamphetamine         
 Decreased appetite 
 Anorexia 
 Episodes of sudden and violent behaviour 
 Paranoia, hallucinations 
 Insomnia 
 Compulsive cleaning and grooming 
 Confusion 
 Scratching 
 Tremors 
          (Gard, 2004) 
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Short-term methamphetamine use has also been reported to increase 
heart rate, blood pressure, temperature and rate of breathing, 
constriction of blood vessels, and cardiac arrhythmia (Maxwell, 2005).  
ii). Long-term effects of ATS 
Long-term abuse of ATS causes many negative health effects that may 
be difficult or impossible to reverse.  
First of all, distinctive changes occur in the physical appearance of 
long-term methamphetamine users, producing an aging effect 
(Winslow et al., 2007). These changes usually result from malnutrition, 
severe dental decay, poor hygiene and weight loss. Long-term users of 
methamphetamine often exhibit skin-picking behaviours, which can 
lead to abscesses (Lee et al., 2005). 
As a consequence of dopamine depletion due to chronic use of ATS, 
potentially irreversible neuronal changes can occur and that result in 
neurological and psychiatric symptoms (Volkow et al., 2001, Sekine et 
al., 2003). Neurotoxic effects of chronic ATS use include 
neurochemical alterations in areas of the brain associated with 
learning, thus leading to cognitive impairment and behavioural deficits 
(Maxwell, 2005). Long-term ATS users have also showed signs of 
memory loss that is similar to Alzheimer’s disease (Gard, 2004).  
And certainly, long-term abuse results in addiction, which is almost 
impossible for user to quit without medical treatment.  
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Another significant consequence of chronic (or high-dose) ATS abuse 
is the development of psychosis.  In particular, the Methamphetamine 
Treatment Project in California (Zweben et al., 2004) found participants 
had high levels of psychiatric symptoms, namely depression and 
attempted suicide, as well as anxiety and psychotic symptoms. They 
also reported high incidence of anger-control problem and violent 
behaviour, which corresponded with a high prevalence of assault and 
weapon charges. 
iii). Withdrawal syndrome   
Following cessation of chronic ATS use, users experience withdrawal 
syndrome, characterised by depression, psychomotor agitation, sleep 
disturbance (rebound REM with disturbing vivid dreams), and fatigue 
accompanied by dysphoria, irritability, anhedonia, anxiety, hyperphagia 
and intense drug craving (Kosten and Singha, 1999, Mcgregor et al., 
2005). In some respects it resembles an atypical depression.  
While the withdrawal was previously divided into ‘crash’, ‘withdraw’ and 
‘extinction’ - more recent studies suggest a more gradual improvement 
in mood and functioning over a 3-4 week period (Lago and Kosten, 
1994).  
In fact, a study by McGregor et al (Mcgregor et al., 2005) showed that 
methamphetamine withdrawal syndrome can be categorized into two 
phases: 
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 An acute phase lasting 7-10 days following cessation of dependent 
use, during which overall symptom severity declined in a linear 
pattern from a high initial peak. 
 A sub-acute phase lasting at least 2 weeks following the end of the 
acute phase during which most withdrawal symptoms remained 
relatively mild and stable. 
During the acute phase, it was noted that patients had increased 
sleeping and eating, depression-related symptoms and, less severely, 
anxiety and craving-related symptoms. 
Oversleeping was obvious during the acute phase, but was not 
followed by a period of insomnia during the sub-acute phase. Certainly, 
patients who had been using methamphetamine for a longer period of 
time had a more severe withdrawal course. 
1.14  Effects on other areas of health 
Besides impacting the central nervous systems, long-term use of ATSs 
has been associated with clinical toxicities on cardiovascular system 
and respiratory systems, poorer cognitive functioning and mental 
health, as well as other severe health problems.  
i). Cardiovascular system 
Methamphetamine users are at elevated risk of cardiac pathology. 
Cardiovascular symptoms, including chest pain, ischemia, myocardial 
infarction, tachycardia and palpitations (Richards et al., 2009), are 
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common in ATS abuse. Cases of stroke have also been reported with 
the use of ATS (Perez et al., 1999). 
ii). Respiratory system 
Like cocaine abusers, many ATS abuse patients present to emergency 
departments with respiratory symptoms (Albertson et al., 1995, Derlet 
et al., 1989). Respiratory signs commonly associated with ATS use 
include dyspnea and wheezing (Richards et al., 2009). Pulmonary 
hypertension has also long been reported in methamphetamine users 
(Arnett et al., 1976, Lewman, 1972). The variability of symptoms seems 
to depend on the type of ATS used, the dosage and route of 
administration. 
iii). Infectious diseases 
Intravenous methamphetamine use has been related to the risk of a 
number of sexually-transmitted and blood-borne infectious diseases, 
such as endocarditis (Cooper et al., 2007), viral hepatitis (Gonzales et 
al., 2006), and human immunodeficiency virus (HIV) disease (Colfax et 
al., 2004, Shoptaw et al., 2002). In HIV-infected patients, 
methamphetamine abuse can further lead to medical complications 
including hypertension, hyperthermia, rhabdomyolysis and stroke 
(Urbina and Jones, 2004). 
iv). Effects on pregnancy and foetus 
Methamphetamine use during pregnancy can be dangerous to both the 
mother and the foetus.  
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While methamphetamine abuse during pregnancy has been associated 
with maternal deaths (Catanzarite and Stein, 1995, Stewart and 
Meeker, 1997), which result in spontaneous abortion or teratogenesis 
to the foetus, methamphetamine exposure throughout gestation has 
been related with decreased growth in infants, even if they were 
exposed only for the first two trimesters (Smith et al., 2003). In one 
study (Oro and Dixon, 1987), it was found that infants exposed to 
methamphetamine throughout gestation were significantly smaller for 
gestational age compared with the unexposed group. In addition, 49% 
of them exhibited withdrawal signs, including abnormal sleep patterns, 
poor feeding, tremors and hypertonia. However, only 4% required 
medications. 
Other foetal effects associated with methamphetamine exposure 
include intrauterine growth retardation, prematurity, clefting, cardiac 
anomalies and death (Wouldes et al., 2004, Stewart and Meeker, 
1997). 
v). Effects on children and adolescents 
Limited evidence suggests that children may be at risk developmentally 
due to both the direct effects of prenatal drug exposure. Academic and 
mild physical delays were noted in a 14-year follow-up study of children 
born to women who abused amphetamines during pregnancy, though 
other potential confounders might be present (Cernerud et al., 1996). 
Children who are exposed to methamphetamine environmentally (e.g. 
methamphetamine laboratories) may experience headaches, nausea, 
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dizziness, dyspnea, chest pain, eye irritation and burns (Ndcp, 2007). 
Beyond clinical effects, these children are at risk for inadvertent 
poisoning, trauma, neglect, abuse and adverse psychological effects 
(Horton et al., 2003, Kolecki, 1998, Swetlow, 2003). 
vi). Other effects on health 
 Effects on skin 
The most common dermatological manifestations in patients who 
abuse amphetamine-related compounds are probably related to self-
induced skin picking, intravenous needles, or burns (Cadier and 
Clarke, 1993). 
 Hepatoxicity 
Hepatocellular damage has been reported after both acute and chronic 
amphetamine abuse (Kamijo et al., 2002, Henry et al., 1992, Jones et 
al., 1994).  
 Effects on gastrointestinal system 
Abuse of methamphetamine has been associated with the formation of 
giant gastrointestinal ulcers and ischemic colitis (Jones et al., 1994, 
Johnson and Berenson, 1991). 
 Impact on dental health 
Patients taking amphetamines are also at increased risk of gingival 
enlargement (Hasan and Ciancio, 2004), rampant caries, enamel 
erosion, xerostomia, bruxism and muscle trismus (Rhodus and Little, 
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2005).  Table 1.9 below summarizes the major signs and symptoms of 
ATS toxicity (Albertson et al., 1999). 
Table 1.9: Major signs and symptoms of ATS toxicity 
Cardiac 
Chest pain 
Myocardial infarction 
Palpitations 
Arrhythmia 
Cardiomyopathy 
Myocarditis 
Hypertension 
Sudden death 
Valve thickening 
Psychiatric 
Anxiety 
Depression 
Paranoia 
Delirium/hallucination 
Psychosis 
Suicide 
Aggressive behaviour 
Euphoria/hyperactivity 
Irritability  
Neurologic 
Headache 
Seizure 
Cerebral infarcts/stroke 
Cerebral vasculitis 
Mydriasis 
Cerebral haemorrhage 
Subarachnoid 
Intraventricular, Intracerebral 
Respiratory 
Pulmonary oedema 
Dyspnea 
Bronchitis 
Pulmonary hypertension 
Haemoptysis 
Pleuritic chest pain 
Asthma exacerbation 
Pulmonary granuloma 
Others 
Ulcers 
Hyperoyrexia 
Renal failure 
Ischaemic colitis 
Obstetric complications 
 
Anorexia/weight loss 
Rhabdomyolysis 
Nausea/vomiting 
Disseminated vasculitis 
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Chapter TWO:  Psychiatric Co-morbidity and Suicidality in 
Methamphetamine Dependence   
 
2.1   Abstract 
Introduction: In the past decade, psychiatric related disorders or 
sequelae in methamphetamine users started to receive more attention. 
It has been demonstrated that there is an increased rate of attempted 
suicide in this population. Previous studies suggested that one of the 
predictors for suicide attempts in methamphetamine users is 
psychiatric co-morbidity mainly depressive symptoms.  
Objectives: To determine the prevalence of suicidality and prevalence 
psychiatric co-morbidity in methamphetamine dependence patients.  
We also wanted to determine the association between psychiatric co-
morbidity and suicidality.   
Methodology:  
Design : This was a cross sectional study. 
Setting: The study was conducted at outpatient psychiatric clinic, 
Department of Psychological Medicine, University Malaya 
Medical Centre (UMMC), Kuala Lumpur and at Drug 
Rehabilitation Centre Papar, Sabah 
Patients: Study population were methamphetamine dependence 
and the eligibility criteria were patients aged more than 
18 and meeting the DSM-IV criteria for 
methamphetamine dependence. 
Measures: The Mini International Neuropsychiatric Interview 
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(M.I.N.I.) and a structured questionnaire to assess: (i) 
sociodemographic background (ii) psychiatric co-
morbidity in Axis I psychiatric disorders and (iii) drug use 
history. 
 
Results:      The subjects had high co-morbid rates for psychiatric 
illnesses. Of the 305 subjects, 54.4% of the subjects had at least one 
non-substance use axis I psychiatric disorder. The most frequently 
diagnosed co-morbidity was antisocial personality disorder (32.1%). 
The prevalence of suicidality was 12.1 %( 37/305). Major depressive 
disorder, panic disorder, current and lifetime psychotic disorder were 
associated with suicidality. After multiple logistic regression, the 
independent risk factors of suicidality were major depression (OR 7.3; 
95% C.I.: 3.0, 17.8) and lifetime psychotic disorder (OR 5.1; 95% C.I.: 
1.3, 20.3). 
Conclusion: The prevalence of psychiatric co-morbidity and suicidality 
is high in this population. We feel that identification and treatment of co-
morbid psychiatric illnesses in this population is of upmost importance.        
        
Keywords: Methamphetamine dependence, Psychiatric co-morbidity, 
Suicidality, Psychosis, Anti-social personality, Depression, 
Association study, Prevalence. 
 
2  Psychiatric Co-morbidity and Suicidality  
 
 41 
2.2   Introduction 
2.2.1. Psychiatry Co-morbidity 
The term ‘comorbidity’ was introduced in medicine by Feinstein to 
denote those cases in which a ‘distinct additional clinical entity’ 
occurred during the clinical course of a patient having an index 
disease(Feinstein, 1970). This term could indicate not only those cases 
in which a patient receives both a psychiatric and a general medical 
diagnosis (e.g. schizophrenia and diabets melllitus), but also those 
cases in which a patient receives two or more psychiatric diagnoses 
(e.g. major depression and substance dependence). The co-
occurrence of psychiatric disorder and substance dependence disorder 
is a common condition (Wilson, 2007). The presence of a psychiatric 
disorder increases the risk for the presence of substance dependence 
disorder and vice-versa (Swendsen et al., 2010). Much evidence 
suggest that when these disorders occur together, is associated with 
worse health outcomes, more complex clinical management, and 
increased health care costs (Wilson, 2007). 
To help explain this co-morbidity, we need to first recognize that 
substance dependence is a mental illness. It is a complex brain 
disease characterized by compulsive, at times uncontrollable drug 
craving, seeking, and uses despite devastating consequences 
(Leshner, 1999). Behaviors that stem from drug-induced changes in 
brain structure and function through complex neuroadaptive process. 
This process guides behaviour in maladaptive directions during which 
severe physical and social consequences engulf and disable the addict 
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(White, 2002). These changes occur in some of the same brain areas 
that are disrupted in other mental disorders, such as depression, 
anxiety, or schizophrenia. It is therefore not surprising that population 
surveys show a high rate of co-occurrence, or co-morbidity, between 
substance dependence and other mental illnesses (Regier et al., 
1990). It is often difficult to disentangle the overlapping symptoms of 
drug addiction and other mental illnesses, making diagnosis and 
treatment complex. Correct diagnosis is critical to ensuring appropriate 
and effective treatment. Ignorance of or failure to treat a co-morbid 
disorder can jeopardize a patient’s chance of recovery. 
2.2.2. Methamphetamine Dependence 
According to the definition in DSM-IV (Apa, 1994), dependence is 
measured by three or more of the following criteria, occurring at any 
time in the same 12 month period: 
1. Tolerance, as defined by either: 
(a) A need for markedly increased amounts of the substance to 
achieve intoxication or the desired effect; or 
(b) A markedly diminished effect with continued use of the same 
amount of the substance. 
2. Withdrawal, as manifested by either of the following: 
(a)  A characteristic withdrawal syndrome; or 
(b) The same or closely related substance is used to relieve or avoid 
withdrawal symptoms. 
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3. The substance is taken in larger amounts or for a longer period than 
intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or 
control substance use. 
5. A great deal of time is spent in activities necessary to obtain the 
substance, use the substance or recover from its effects. 
6. Important social, occupational or recreational activities are reduced 
or given up because of substance use. 
7. Substance use is continued despite knowledge of having a 
persistent or recurrent physical or psychological problem that is likely to 
have been caused or exacerbated by the substance. Degree and 
severity of dependence is primarily influenced by: 
(a) The type and potency of methamphetamine being used. The use of 
crystal methamphetamine (‘ice’ or ‘shabu’), which is usually more 
potent, may lead to dependence more quickly than 
methamphetamine base or powder; or 
(b) The mode of administration. Injecting methamphetamine may lead 
to higher levels of dependence than with other forms of 
administration such as snorting or ingesting. 
The widespread abuse of methamphetamine impacts society at various 
levels; from the individual, to the individual’s family and to their 
community. Methamphetamine dependence gives rise to serious 
behavioural, medical and psychiatric consequences, imposing an 
immense burden on the medical, public health and criminal justice 
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systems due to increased legal problems, violence, and high rates of 
HIV infection and hepatitis due to high risk sexual behaviour (Hando 
and Hall, 1994).   
2.2.3. Epidemiology of Methamphetamine dependence in Malaysia  
In Malaysia, within the first three months of 2010, the National Anti-
Drug Agency has identified 3,611 drug addicts, which is an increase of 
about 110% for the same period in the previous year. Among these 
identified addicts, 18% were dependent on amphetamine-type-
stimulants (ATS), which include amphetamine, methamphetamine and 
ecstacy pills. This represents a 117% increase in ATS addicts 
compared with the same period in the previous year.(Kdn, 2010) In the 
year 2008 there were 1,443 methamphetamine dependence subjects in 
Malaysia, while in the year 2009 there were 1,131 methamphetamine 
dependence subjects identified (Adk, 2009). 
2.2.4. Methamphetamine Dependence, Psychiatry Co-Morbidity 
and Suicidality  
Although there has been a marked worldwide increase in 
methamphetamine dependence, the psychiatric sequelae of 
methamphetamine dependence has not been well described. It is only 
in the past decade has psychiatric related disorders or sequelae in 
methamphetamine users started to receive more descriptive attention. 
The majority of methamphetamine users have been shown to suffer 
from a lifetime history of depression (Zweben et al., 2004, Hall et al., 
1996). Not surprisingly, it has been demonstrated that there is an 
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increase rate of attempted suicide in this population. One of the 
predictors for suicide attempts in methamphetamine users is 
depressive symptoms (Zweben et al., 2004). Studies have also shown 
suicide attempts were aggravated in patients with substance-use co-
morbidity when compared with those without (Glasner-Edwards et al., 
2008a). Besides mood symptoms, chronic or heavy methamphetamine 
users may exhibit psychotic symptoms that resemble paranoid 
schizophrenia (Glasner-Edwards et al., 2008a). However data on 
methamphetamine-related anxiety disorders on the other hand is still 
scarce and the association between anxiety symptoms and substance 
use remains controversial (Yen and Chong, 2006).  
In Malaysia, the prevalence of psychiatric sequelae of 
methamphetamine abuse as well as the association between the 
psychological effects of methamphetamine and suicidality is yet to be 
established. Having such data in hand will aid in formulating more cost-
effective treatments for methamphetamine dependent users and in the 
prevention of social problems, such as suicidal attempts.  
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2.2.5. RESEARCH QUESTION 
i). What was the prevalence of psychiatric co-morbidity among 
methamphetamine dependence patient?  
ii). Has psychiatric co-morbidity associated with suicidality among 
methamphetamine dependence patients?   
2.2.6. STUDY OBJECTIVES 
i). Primary Objective  
 To determine the prevalence of psychiatric co-morbidity among 
methamphetamine dependent Malaysians who seek treatment. 
 To determine the prevalence of suicidality in methamphetamine 
dependence patients.  
ii). Secondary objective 
To determine the association between psychiatric co-morbidity and 
suicidality among methamphetamine dependence patients.  
2.2.7. HYPOTHESIS 
There is association between psychiatric co-morbidity and suicidality 
among methamphetamine dependence patients.  
2.3  Methodology 
2.3.1. Study design  
This study was a hospital-based and drug rehabilitation-based cross 
sectional study.  
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2.3.2. Setting and study period 
The study was conducted at outpatient psychiatric clinic, Department of 
Psychological Medicine, University Malaya Medical Centre(UMMC), 
Kuala Lumpur and at Drug Rehabilitation Centre Papar, Sabah from 
June 2008 until June 2009. 
2.3.3. Study population 
Study population were methamphetamine dependence and the 
eligibility criteria were patients aged more than 18 and meeting the 
DSM-IV criteria for methamphetamine dependence. 
2.3.4. Sample size and sampling procedure 
Sample size was calculated using the computer software EPI-INFO. 
Universal sampling was used for the recruitment of the study subjects. 
i.) The power of the study was taken at 80% level.  
ii.) The significance level of the statistic tests done was at 95% 
Confidence Interval level and  was set at 0.05. The Null 
hypothesis was rejected when p < 0.05. 
iii.) The Odds Ratio was taken at 2.1 for the calculation. 
iv.) Expected frequency of disease in unexposed group (The 
proportion of the population with suicidality without 
depression - 55%)(Glasner-Edwards et al., 2008b).  
v.) The ratio of case to control was taken as 1 : 1. 
Total number of samples = 274 patients 
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2.3.5. Study variables 
Dependent variable 
Suicidality   
Independent variables 
Sociodemographic variables  
i). Age  
ii). Sex  
iii). Current employment status   
iv). Total family income 
v). Educational level 
vi). Marital status 
Psychiatric Co-morbidity in Axis I psychiatric disorders  
i). Mood disorders  
ii). Anxiety disorders  
iii). Psychotic disorder  
iv). Alcohol dependence  
v). Alcohol abuse  
vi). Poly-substance use 
vii). Antisocial personality disorder 
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viii). Present of any psychiatric co-morbidity 
Drug use history variables 
i). Age of first substance use  
ii). Duration of drug use   
iii). Amount of money spend on drug per month   
iv). Route of administration of methamphetamine   
v). Criminal record   
vi). Lifetime prevalence of substance use  
2.3.6. Operational definitions 
The operational definitions for variables and scale were described in 
detail in ANNEX “A”. 
2.3.7. Study instrument 
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a short 
structured diagnostic interview for DSM-IV or ICD-10 psychiatric 
disorders for the Major Axis I psychiatric disorder including suicidality 
(Sheehan et al., 1998b). It has been widely used in international clinical 
trials and epidemiological studies.(Joling et al., 2008, Van't Veer-
Tazelaar et al., 2009) The M.I.N.I. was available in local language 
(Sheehan et al., 1998a). 
2.3.8. Data collection methods 
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All patients with drug dependence were approached during the study 
period. Patients were briefed on the study and written consent was 
obtained. Only patients with urine toxicology screened positive for 
methamphetamine and within 30 days of last use of the 
methamphetamine were included in the study. A face-to-face interview 
was conducted using a structured questionnaire on drug use behaviour 
and the Mini International Neuropsychiatric Interview (M.I.N.I.). The 
interviews were conducted by a qualified psychiatrist. 
The structured questionnaire for drug use behaviour was used to 
assess severity of illicit drug addiction. This questionnaire consisted of 
three sections: (i) sociodemographic background (ii) psychiatric co-
morbidity in Axis I psychiatric disorders and (iii) drug use history  
2.3.9. Data Management 
The data were checked before ending each interview session and 
before compilation to ensure completeness. Raw data obtained were 
coded and entered into Statistical Package for Social Sciences (SPSS) 
Version 16.0. The data were summarized by running frequency 
distributions and simple descriptive statistics (means and standard 
deviations). Cleaning for double entry and outliers were done before 
the analysis.   
2.3.10. Data analysis 
i). Univariate analyses 
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Only one independent variable was analyzed at a time. It allowed the 
researcher to describe the characteristics of the study subjects. No 
comparisons were made at this point. For nominal independent 
variables, they were described in the form of frequencies and 
percentages. For continuous independent variables, they were 
summarized and described as means, standard deviations and 
median.  
ii). Bivariate analysis   
Pearson’s Chi-square test and Simple Logistic Regression were used 
to determine the possible association of significant variables to the 
occurrence of suicidality by determining the Odds ratio and 95% 
Confidence Interval. Continuous data were analyzed using the t-test. 
Skewed data was analysed using non parametric test. Subsequently 
the continuous variables were recategorised and further tested by 
Pearson’s Chi-square test and Simple Logistic Regression. An alpha 
level of significance 0.05 was set for all analyses. Significant risk 
factors in the bivariate analysis were partially adjusted with other 
significant variables to take care of interactions and confounding 
effects.    
iii). Multiple logistic regression 
After partial adjustment, all significant independent variables were 
further analyzed with enter, forward stepwise, backward stepwise 
methods of multiple logistic regression to determine which risk factors 
independently act as predictors of suicidality.  
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2.3.11. Pre-test 
A pre-test of the questionnaires was done on 5 patients who were 
attending the psychiatric clinic, UMMC. These respondents were 
excluded from the study. Some corrections were made after the pre-
test to facilitate patients’ understanding of the questionnaires. 
2.3.12. Ethical consideration 
Ethical approval was obtained from Medical Ethics Committee of 
UMMC. Before any interview, patients were informed regarding the 
nature and purpose of the study and the respondents were given the 
assurance that all information given will be treated with confidentiality. 
A written consent was obtained from the patients prior the interviews.  
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2.4  Results 
Demographics 
305 subjects were enrolled in this study and the prevalence of 
suicidality was 12.1%(37/305). Table 2.1 displayed the socio 
demographic characteristics of the study population. Majority of the 
study subjects was male, single and has fulltime job. There was no 
association between socio demographic variables and suicidality.  
Psychiatric Comorbidity 
The subjects had high comorbid rates for psychiatric illnesses. Of the 
305 subjects, 54.4% of the subjects had at least one non-substance 
use axis I psychiatric disorder. The most frequently diagnosed 
comorbidity was antisocial personality disorder (32.1%). Major 
depressive disorder, schizophrenia, panic disorder, current and lifetime 
psychotic disorder were associated with suicidality. For substance use 
axis l psychiatric disorder, poly-substance use has the highest 
prevalence (60.3%) and it was associated with suicidality (OR, 3.1; 
95%CI.: 1.3,7.4)(Table 2.2).  
Drug Use History 
Table 2.3 showed the results for methamphetamine use patterns and 
drug use history. Mean age at first methamphetamine use was 23.9 ± 
8.8 years and mean duration of methamphetamine use was 6.4 ± 4.9 
years. The most common route of administration of methamphetamine 
was smoking (68.2%). In addition to methamphetamine, the most 
frequently used illicit drug was cannabis. Cigarette smoking and 
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alcohol consumption were also very common among the study 
subjects. 
After multiple logistic regression, the independent risk factors of 
suicidality were major depression (OR 7.3; 95% C.I.: 3.0, 17.8) and 
lifetime psychotic disorder (OR 5.1;95% C.I.: 1.3, 20.3)(Table 2.4). 
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Table 2.1: Association between Demographic Characteristics and 
Suicidality among Methamphetamine Dependence 
Variables Suicidality No 
suicidality 
Total 
n=305 
OR(95%CI) 
Age (years),  
mean + SD 
 
Gender 
    ‡Male  n (%) 
    Female n (%) 
 
Education 
30.3+ 8.0 
 
 
 
37(12.3) 
1(33.3) 
32.2+9.2 
 
 
 
265(87.7) 
2(66.7) 
30.5 + 8.2 
 
 
 
302 
3 
-1.9(-4.8,0.9)* 
 
 
 
 
3.6(0.3,40.5) 
    Primary n (%)  
    Secondary n (%)  
    ‡Tertiary n (%)  
 
3(5.8) 
33(14.9) 
2(6.5 ) 
  
49(94.2) 
189(85.1) 
29(93.5 ) 
 
52 
222 
31 
0.9(0.1,5.6) 
2.5(0.6,11.1) 
 
 
Employment     
    ‡Fulltime n (%)  
    Part-time n (%)  
31(13.0 ) 
3(7.7) 
208(87.0 ) 
36(92.3) 
239 
39 
 
0.6(0.2,1.9 ) 
    Student n (%)  
    Unemployed n (%) 
2(5.3 ) 
2(9.5) 
4(66.7) 
19(90.5) 
6 
21 
3.4(0.6,19.1) 
0.7(0.2,3.2) 
     
         
Total Income  (RM), 
mean + SD  
n=38 
2460.5+3037.9 
n=264 
2216+6365.8 
n=302 
2247.4 + 6045.5 
 
-283.8(-2311.2, 
1823.6)* ¶ 
 
 
Marital Status 
   ‡ Married n (%)  
    Single n (%)  
    Divorced  
& widow n (%)  
      
 
 
13(12.3 ) 
23(13.3 ) 
1(3.8) 
 
 
 
93(87.7) 
150(86.7) 
25(96.2) 
 
 
 
106 
 173 
26 
  
 
 
 
 
 
1.1(0.5,2.3) 
0.3(0.04,2.3) 
 
      
*mean difference(95% CI of Difference) 
‡reference group 
¶Mann-Whitney U Test 
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Table 2.2:  Association between Axis I Psychiatric Disorders and 
Suicidality among Methamphetamine Dependence 
Psychiatric Co-morbidity Suicidality 
n (%) 
No 
suicidality 
n (%) 
Total 
n=305(%) 
OR(95%CI) 
Mood Disorders 
    Major depressive disorder* 
 
23 (42.6) 
 
31 (57.4) 
 
54 (17.7) 
 
12.5(5.8-26.9) 
    Bipolar Disorder (Mania) 9(18.0) 41(82.0) 50 (16.4) 
 
1.7(0.7-4.0) 
Anxiety Disorders     
    Generalized Anxiety disorder 
    Obsessive compulsive disorder 
1(50.0) 
0(0) 
1(50.0) 
3(100) 
2 (0.7) 
3 (1.0) 
7.4(0.4-121.1) 
0.9(0.9- 1.0) 
    Panic disorder* 5(35.7) 9(64.3) 14 (4.6) 4.4(1.4-14.1) 
    Social phobia 2( 22.2) 7(77.8) 9 (3.0) 2.1(0.4-10.6) 
         
Psychotic disorder 
     
   
 
 
    Schizophrenia* 5(55.5) 4(44.5) 9(3.0) 10.3(2.6-40.3) 
     
    Current* 15(30.6) 34(69.4) 49 (16.1) 4.6(2.2-9.9) 
    Lifetime* 34(22.2) 119(77.8) 153 (50.2) 14.1(4.2-47.3) 
         
Alcohol dependence 14(17.7) 65(82.3) 79 (25.9) 1.9(0.9-3.9) 
Alcohol abuse 
Poly-substance use* 
9(15.3) 
30(16.3) 
50(84.7) 
154(83.7) 
59 (19.3) 
184 (60.3) 
1.4(0.6-3.1) 
3.1(1.3-7.4) 
         
Antisocial personality disorder 17(17.2) 82(82.8) 98 (32.1) 1.9(0.9-3.8) 
     
Any psychiatric co-morbidity* 
 
35(21.1) 131(78.9) 166(54.4) 
   
18.3(4.3-77.6) 
      
     
*statistically significant p<0.05 
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Table 2.3:     Association between Drug Use History and Suicidality 
among  Methamphetamine Dependence 
Variables Suicidality No suicidality Total 
 
mean difference 
(95% CI of difference) 
Age of first substance use  
Year (mean + SD) 
    Methamphetamine n=304 
    Alcohol    n=192 
    Cannabis n=104 
    Nicotine  n=293 
    Heroin     n=35 
 
Duration of drug use  
Year (mean + SD) 
    Methamphetamine* 
    Alcohol 
    Cannabis 
    Nicotine 
    Heroin 
     
Amount of money spend on 
drugs,RM** (mean + SD) 
    Methamphetamine* 
    Alcohol 
    Cannabis 
    Nicotine 
    Heroin* 
     
Route of administration of 
methamphetamine 
   ‡Oral        n(%)  
    Nasal       n(%)  
    Smoking  n(%)  
    Injection n(%) 
 
 
24.11+7.95 
18.81+7.75 
17.57+4.62 
15.77+5.46 
21.00+4.90 
 
 
 
7.86+4.98 
11.16+24.52 
2.70+4.87 
14.73+8.93 
2.68+6.36 
 
 
 
1585.14+1574.58 
270.81+614.58 
73.24+180.09 
138.65+111.53 
289.19+682.64 
 
 
 
1(5.6) 
7(9.2) 
28(13.5) 
1(33.3) 
 
 
23.84+8.90 
19.13+5.79 
18.86+5.21 
16.15+5.42 
23.63+5.02 
 
 
 
6.24+4.92 
5.24+6.72 
2.45+5.08 
12.17+7.28 
1.15+4.18 
 
 
 
883.37+1611.69 
187.37+408.85 
74.87+261.44 
154.89+384.85 
56.20+266.05 
 
 
 
17(94.4) 
69(90.8) 
179(86.5) 
2(66.7) 
 
 
23.88 + 8.78 
19.09 + 6.08 
18.68 + 5.13 
16.10 + 5.42 
23.03 + 5.05 
 
 
 
6.44 + 4.94 
5.96 +10.71 
2.48 +5.04 
12.48 + 7.52 
1.34 + 4.51 
 
 
 
968.78 + 1621.03 
197.52 + 438.59 
74.67 + 252.70 
152.91 + 362.70 
84.65 + 351.42 
 
 
 
18 (5.9) 
76(25.0) 
207(68.2) 
3 (0.9) 
 
 
 
-0.27(-3.30,2.78)¶ 
0.32(-2.18,2.82) 
1.28(-1.64,4.21) ¶ 
0.38(-1.55,2.30) 
2.63(-1.46,6.72) 
 
 
 
-1.62(-3.32,0.08) ¶ 
-5.92(-9.57,-2.28) ¶ 
-0.25(-2.00,1.49) 
-2.56(-5.15,0.03) 
-1.53(-3.08,0.03) 
 
 
 
-701.77(-1256.61,-146.92) ¶ 
-83.44(-234.80,69.92) ¶ 
1.66(-85.75,89.00) ¶ 
16.24(-109.15,141.63) ¶ 
-232.99(-351.62,-114.35) ¶ 
 
 
 
 
1.7(0.2,14.9)§ 
2.7(0.3,20.7) §  
8.5(0.4,195.5) § 
     
Criminal record   
    Illegal activity n(%)  
    Conviction       n(%) 
 
18(12.6) 
20(13.3) 
 
125(87.4) 
130(86.7) 
 
143 (47.0)  
150 (49.3) 
 
1.1(0.5,2.1) § 
1.2(0.6,2.5) § 
     
Lifetime prevalence of 
substance use 
    Alcohol     n(%) 
    Cannabis  n(%) 
    Nicotine    n(%) 
    Heroin       n(%) 
   Glue          n(%) 
    Ketamine  n(%) 
   
 
 192 (62.9) 
104 (34.1) 
293 (96.1) 
35 (11.5) 
25 (8.2) 
7 (2.3) 
 
         
    *statistically significant  
**Ringgit Malaysia 
 
‡reference group              ¶Mann-Whitney U Test 
§ Odds Ratio(95%CI) 
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Table 2.4:   Independent Predictors for Suicidality among 
Methamphetamine Dependence Patient  
 
Psychiatric co-
morbidity 
Odds ratio     95% CI 
 
Major depression                               7.3 3.0,17.8 
      
Psychotic disorder   
     lifetime                             5.1 1.3,20.3 
   
               Adjusted with age, sex and marital status 
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2.5  Discussion 
Our study demonstrated that methamphetamine dependence in 
Malaysians who seek treatment have high psychiatric comorbidity, with 
antisocial personality disorder being the most prevalently diagnosed 
comorbidity. Psychiatric comorbidities that were significantly associated 
to suicidality in the treatment-seeking methamphetamine users were 
depression, schizophrenia, panic disorder, and current and lifetime 
psychotic disorder.  
The observations from our study supported findings of earlier studies 
that methamphetamine-dependent individuals are at greater risk of 
experiencing particular psychiatric symptoms (Kalechstein et al., 2000, 
Yen and Chong, 2006, Chen et al., 2003), and are more likely to 
experience depressive symptoms and suicidal ideation than the non-
methamphetamine dependent individuals. The observation still holds 
even after adjusting for socio-demographic variables and dependence 
on other substances  (Kalechstein et al., 2000). 
What remains uncertain at this point of time is whether psychiatric 
morbidity predisposes an individual to abuse drug, or drug use resulted 
in the psychiatric manifestations. A study by Yen and Chong (Yen and 
Chong, 2006) proposed that the psychiatric manifestations in 
methamphetamine users are very likely a result of stimulant use that 
has exceeded a certain threshold. Their study results are accordant to 
the findings of earlier studies, suggesting that the occurrence of 
psychiatric manifestations in methamphetamine-using individuals is not 
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correlated to lifetime-use duration or the amount consumed, but is 
more associated with increasing use of the stimulant. 
Methamphetamine and Suicidality 
Suicidality, or suicidal ideation, implicates an apparent risk for eventual 
suicide completion. The prevalence of methamphetamine-associated 
suicidality in our study was 12.1%, which is close to that reported in a 
study of adolescent methamphetamine users in Taiwan (Yen and 
Shieh, 2005). 
In that study, a substantially higher percentage of adolescent 
methamphetamine users with suicidal ideation were diagnosed with 
depressive disorder, which is consistent with the findings of previous 
studies describing the association between depressive disorder and 
suicidal behaviour (Zweben et al., 2004). That study also found that 
adolescent methamphetamine users with suicidal ideation were more 
likely to have a family history of substance abuse as compared with 
those without suicidal ideation. However, the family history of the 
methamphetamine dependents was not investigated in our study.  
In order to identify the potential factors that precipitate the decision to 
commit suicide Callor (Callor et al., 2005), conducted a study by 
examining medical examiner records of suicide completers. The study 
found that alcohol and methamphetamine were the most common 
substances detected in either blood or urine, or in both blood and urine 
of the youth suicide completers, whom at that point of time were not 
diagnosed for mental illness or not being non-compliant with 
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psychotropic medications. Similarly, in the Methamphetamine 
Treatment Project (Glasner-Edwards et al., 2008b), it was found that 
psychiatric characteristics of methamphetamine users are strongly 
associated with substance abuse. 
From these findings of our study and studies of other researchers, it is 
recommended that when treating methamphetamine-dependent 
individuals, a careful assessment of psychiatric history is warranted. In 
order to formulate an effective suicide prevention strategy, it is 
absolutely necessary to identify the risk factors for suicidal behaviour 
associated with methamphetamine abuse. 
Methamphetamine and Depression 
Out study shows that major depression (54% of total subjects) is a 
statistically significant independent risk factor for suicidality in 
methamphetamine-dependent users. Indeed, many studies have found 
a strong relationship between substance abuse and depression 
(Christie et al., 1988, Deykin et al., 1986, Kandel and Davies, 1986). 
For instance, Kalechstein et al (Kalechstein et al., 2000) reported that 
57.1% of methamphetamine-dependent prison and jail inmates 
experienced depressive symptoms within the year prior to their study 
intake. 
The prevalence of depression among methamphetamine users has 
been known to be higher than the general population, with the majority 
of methamphetamine users reporting a lifetime history of depression 
(Zweben et al., 2004, Hall et al., 1996). In addition, depressive 
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symptoms are also a major component of the withdrawal syndrome in 
the cessation of methamphetamine use (Markou and Kenny, 2002, 
Mcgregor et al., 2005). Depressive symptoms can appear during 
immediate withdrawal and during the initial weeks and even months of 
abstinence following methamphetamine cessation (Rawson et al., 
2002a). 
It remains unclear as to whether depressive symptoms preceded onset 
of drug use or methamphetamine used gave rise to depressive 
symptoms. This area of uncertainty underscores the need for further 
investigation. However, there are data (Peck et al., 2005) to indicate 
that individuals felt depressed due to recent methamphetamine use, 
and less depressed if they had recently abstained. More importantly, 
the findings provide strong support for the potential of behavioural drug 
abuse treatments in attaining long-term reductions in depression and 
methamphetamine use in methamphetamine-dependent users. 
Methamphetamine and Psychotic Disorder 
In our study, 16.1% of subjects experienced current psychotic disorder 
while 50.2% have had lifetime psychotic disorder. This lifetime rate is 
higher compared with that reported in a study involving treatment-
seeking methamphetamine-dependent gay and bisexual men, where 
26.5% of them had lifetime histories of substance-induced psychotic 
disorders (Shoptaw et al., 2003). 
It is known that chronic or heavy methamphetamine use may induce 
psychotic symptoms that resemble paranoid schizophrenia. Such 
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symptoms include delusions, ideas of reference, and auditory 
hallucinations (Glasner-Edwards et al., 2008a). 
It is generally recognised that methamphetamine users with additional 
risk factors for psychotic illness, such as familial loading, may be at 
greater risk to develop psychotic symptoms. However, some 
individuals may experience symptoms for a considerably prolonged 
period, even in the absence of prior history of psychotic illness. Those 
symptoms could be an exacerbation of symptoms of an underlying 
psychotic illness (Curran et al., 2004), or newly induced during 
intoxication and drug withdrawal (Zweben et al., 2004).  
The psychosis-inducing potential of methamphetamine is not 
unanticipated, considering that it is a more potent derivative of 
amphetamine, also a stimulant that is well-known to amphetamine-
induced psychosis following chronic use (Chen et al., 2003).  
An earlier study by Chen et al (Chen et al., 2003) reported that among 
methamphetamine users, those with psychosis were more vulnerable 
to other psychiatric morbidities, which include major depressive 
disorder and anti-social personality disorder, when compared with 
those without psychosis. Our observation is in line with their findings, 
that is, methamphetamine-dependent individuals are highly associated 
with psychiatric co-morbidity. Therefore, careful screening and 
assessment of psychosis in methamphetamine-dependent users is 
essential in guiding effective treatment for this at-risk group. 
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Methamphetamine and Panic Disorder 
Panic disorder was the prominent anxiety disorder reported in our 
subjects (4.6%). Data on methamphetamine-related panic disorder is 
scarce and the association between anxiety symptoms and substance 
use remains controversial (Yen and Chong, 2006). 
One of the earlier reports linking methamphetamine and panic disorder 
was a case study of a young woman who had a relapse and worsening 
of panic disorder following a single injection of methamphetamine, 
despite after a long period of remission (Iwanami et al., 1997). More 
recent data comes from the Methamphetamine Treatment Evaluation 
Study (MATES) (Cogger S, 2008), which is the first longitudinal 
treatment cohort study of methamphetamine-dependent users in 
Australia. Preliminary results from MATES showed that 31% of their 
sample subjects met the DSM-IV criteria for panic disorder (with or 
without Agoraphobia) in the past year.  
Limitation and Errors 
i). Adequacy of Sample Size  
The required sample size was 274, when the calculated study sample 
was based on 80% power of the study and odds ratio 2.1 of bivariate 
association. The actual study has inflated the sample size to 305, in 
order to consider other important confounders would not have been 
missed during the development of the full model.      
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ii). Representative and Generalisation 
The findings of this study could only generalize with caution because 
the study population was from the outpatient clinic located in a hospital 
in Kuala Lumpur and from one drug rehabilitation centre in Sabah. The 
study population differs from the patients in the community because of 
the treatment seeking behavior. Furthermore, there was ethnicity 
diversity in Sabah compared to other state in Malaysia. To make 
generalized inferences of the findings of this study to the 
methamphetamine dependence patients in community would be 
inappropriate because the setting in this study had introduced selection 
bias. 
For a better generalization of the findings, it would be ideal to conduct 
a community survey. Unfortunately, such a study is not feasible to 
conduct due to the legal implication. The identified subjects would 
provide information bias, because they had offended the law and the 
possibility being charged to the court.  
All identified patients were willing to be interviewed and consented to 
participate in this study.  
iii). Instruments of the study 
All the scales have been used widely in this country however until now, 
there has been  no paper being published regarding the validation of 
the scales in the local population.  
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In view of the assessment of suicidality was through face-to-face 
interviewed using M.I.N.I., some of the patients might not have 
admitted that they ever had suicidality. This may introduce 
misclassification bias, between the presence and absentce of 
suicidality among the methamphetamine dependent patient.    
iv). Conduct of study   
Information bias was one of the limitations especially when information 
was obtained via a face-to- face interview. The validity on history of 
drug use could be questioned, especially since some of the information 
could not be verified. Some of the information might occur long time 
ago and the possibility of recall bias could happen.     
In some circumstances when a translator was needed, the translator 
may have misunderstood the questions even though further 
explanations were given and this led to the respondents providing the 
wrong answer.           
v). Comparing findings with other studies 
Comparison of the findings of this study to other studies may be 
inaccurate, although other studies examined the same variables, but 
the inclusion and exclusion criteria used to identify subjects or sampled 
population could differ, or study could be conducted with different study 
design.  
Some similar confounder that has been examined by other studies, but 
slightly at different aspect was relationship. In this study, divorce has 
been identified as factor associated with suicidality, but in another 
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study, separation was highly associated with suicidality especially 
among youth (Wyder et al., 2009). Other study has found women living 
with spouse and children as protective factor from suicide (Poudel-
Tandukar et al., 2010).  
Some of the variables that have been included in other studies for the 
association of suicidality but not in this study were school performance 
as risk of suicide (Bjorkenstam et al., 2010), acute stress reaction 
(Gradus et al., 2010), genetic factor (Pregelj et al., 2011), gun 
ownership (Kim et al., 2011), environmental factors e.g. altitude (Kim et 
al., 2011), temperature (Kim et al., 2010b)  and ambient particulate 
matter (Kim et al., 2010a). Financial difficulties (Judd et al., 2010) that 
lead to debt or due to gambling (Wong et al., 2010) could be one of the 
reason for suicidality. 
2.6  Conclusions  
In conclusion, the prevalence of psychiatric comorbidity and suicidality 
is high in this population. We feel that identification and treatment of 
comorbid psychiatric illnesses in this population is of utmost 
importance, due to several reasons. Firstly, it is unethical not to screen 
and treat for psychiatric illnesses in this population, and untreated 
psychiatric illness cause unnecessary suffering. Failure to identify 
comorbid psychiatric illnesses here means an opportunity for treatment 
is lost in a population that is otherwise difficult to reach in the 
community. In the community, the drug user is said to be embedded in 
a web of psychological distortions and maladaptive behaviour that 
hinder compliance and entry into treatment. Denial, projection, 
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minimization, avoidance and omnipotence on the side of the drug user, 
and the negative effect they elicit and the counter transference on the 
side of the therapist may all hinder treatment in the community (Woody 
et al., 1983). Secondly, identification and treatment of psychiatric 
illnesses must be addressed as the central role in relapse prevention of 
substance use. Comorbid psychiatric illnesses, particularly depression, 
are often associated with high rates of continued substance usage after 
treatment (Brewer et al., 1998, Brooner et al., 1997).  
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Chapter THREE:  Prevalence and Association of Methamphetamine 
Induced-Psychosis 
 
3.1  Abstract 
Introduction: The use of methamphetamine in high dose produces a 
wide range of symptoms, including irritability, physical aggression, 
hyperawareness and psychomotor agitation. When used repeatedly 
and chronic, this stimulant can cause the most widely known side 
effect, which is drug-induced psychosis. It displays symptoms similar to 
those of paranoid schizophrenia, which is characterised by 
hallucinations, delusions and thought disorders. 
Objectives: To determine the prevalence of methamphetamine induce 
psychosis and to determine the association between psychiatric co-
morbidity and methamphetamine-induced psychosis. 
Methodology:  
Design : This was a cross sectional study. 
Setting: The study was conducted at outpatient psychiatric 
clinic, Department of Psychological Medicine, 
University Malaya Medical Centre (UMMC), Kuala 
Lumpur and at Drug Rehabilitation Centre Papar, 
Sabah. 
Patients: Study population were methamphetamine dependent 
and the eligibility criteria were patients aged more than 
3  Methamphetamine Induced-Psychosis  
 
 70 
18 and meeting the DSM-IV criteria for 
methamphetamine dependence. Those who had 
psychotic symptoms prior to methamphetamine 
dependence and those with a history of schizophrenia 
or other psychotic disorder were excluded. 
Measures: The Mini International Neuropsychiatric Interview 
(M.I.N.I.) and a structured questionnaire to assess: (i) 
sociodemographic background (ii) psychiatric co-
morbidity in Axis I psychiatric disorders and (iii) drug 
use history. 
           
Results:       The subjects had high rates for methamphetamine-
induced psychosis. Of the 292 subjects, 47.9% of the subjects had at 
least one episode of psychotic symptoms after they were dependent on 
methamphetamine. About 13.0% of the patients were still having 
psychotic symptoms at the time of assessment. Persecutory delusion 
was the most common lifetime psychotic symptoms found in 101 
participants (72.1%). Auditory hallucinations were the most common 
current psychotic symptoms found in 31 participants (81.6%). After 
multiple logistic regression, the independent risk factors of psychosis 
were bipolar disorder (OR 4.7; 95% C.I.: 1.4, 16.6), antisocial 
personality disorder (OR 3.7; 95% C.I.: 1.4, 9.8), higher amount of 
stimulant used and higher family income. 
Conclusion: These findings substantiate the fact that 
methamphetamine users are highly associated with psychosis, 
3  Methamphetamine Induced-Psychosis  
 
 71 
including those without known history of schizophrenia or other 
psychotic disorders. 
Keywords: Methamphetamine dependence, Psychiatric co-morbidity, 
Psychosis, Prevalence, Association study. 
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3.2  Introduction 
Methamphetamine is a derivative of amphetamine, with similar but 
more pronounced psychotropic properties (Nida, 1998). The use of 
methamphetamine produces a wide range of symptoms, including 
irritability, physical aggression, hyperawareness and psychomotor 
agitation.  
When used in high dose or repeatedly, this stimulant can cause drug-
induced psychosis that display symptoms similar to those of paranoid 
schizophrenia, which is characterised by hallucinations, delusions and 
thought disorders. 
Methamphetamine-induced psychosis is one of the most widely known 
side effects associated with high-dose or chronic methamphetamine 
use (Griffith et al., 1972, Hall et al., 1996). In the Pacific region, 
especially Japan and Taiwan, psychosis as a result of 
methamphetamine abuse is common (Suwaki H. et al., 2007, Chou et 
al., 1999). In fact, earlier studies have reported that frequent 
methamphetamine use increases the risk of psychosis significantly, 
regardless of whether primary psychotic disorders, such as 
schizophrenia, are present in the patient (Mcketin et al., 2006b, Chen 
et al., 2003). 
Other studies have also observed greater incidences of suicide 
attempts, hospitalisations and greater psychiatric symptom severity in 
patients with substance use comorbidity compared with those without 
substance use disorders (Drake et al., 1996, Swofford et al., 1996).  
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In general, psychotic symptoms induced by substance use resolve 
within hours or days after withdrawal from the drug (transient type), but 
they may be significantly prolonged (persistent type) in some 
individuals, despite the absence of a known prior history of psychotic 
illness (Hall et al., 1996, Iwanami et al., 1994). 
A drug-induced psychosis can be distinguished from primary psychotic 
disorders by the length of time the symptoms persist. In drug-induced 
psychosis, symptoms usually resolve after the drug is discontinued. If 
symptoms do not resolve within 2 weeks after cessation of substance 
use, a primary psychiatric disorder should be suspected (Larson, 
2008).  
In addition to the potential for methamphetamine use to induce 
psychosis, users with additional risk factors for psychotic illness (e.g. 
familial loading) may be particularly at greater risk of developing 
psychotic symptoms (Chen et al., 2005). Those with psychotic 
disorders are also more likely to have other substance use disorders 
(Regier et al., 1990). 
An Australian study (Mcketin et al., 2006b) have found that dependent 
methamphetamine users to be three times more likely to experience 
psychotic symptoms than their non-dependent counterparts, even after 
adjusting for history of schizophrenia and other psychotic disorders. 
This clearly shows that dependent methamphetamine users are a 
particularly high-risk group for psychosis.  
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Despite the known risk for both drug-induced and drug-independent 
psychoses in methamphetamine users, there are limited number of 
studies on the prevalence of psychotic disorders and other associated 
factors in this population.  
Methamphetamine abuse and its psychiatric sequelae are increasingly 
rampant in Malaysia. In Malaysia, within the first three months of 2010, 
the National Anti-Drug Agency has identified 3,611 drug addicts, which 
is an increase of about 110% for the same period in the previous year. 
Among these identified addicts, 18% were dependent on 
amphetamine-type-stimulants (ATS), which include amphetamine, 
methamphetamine and ecstacy pills. This represents a 117% increase 
in ATS addicts compared with the same period in the previous year 
(Kdn, 2010).  
Before effective strategy and treatment plan can be devised to curb this 
public health and social burden of the country, an understanding of the 
demographic and characteristics of methamphetamine users is 
warranted. Therefore, the aims of this study were to investigate the 
prevalence of psychosis among methamphetamine-dependent patients 
and to investigate the associated factors. 
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3.2.1. RESEARCH QUESTION 
What factors associated with methamphetamine-induced psychosis?   
3.2.2. STUDY OBJECTIVES 
i). Primary Objective  
To determine the prevalence of methamphetamine-induced psychosis. 
ii). Secondary objective 
To determine the association between psychiatric co-morbidity and 
methamphetamine-induced psychosis 
3.2.3. HYPOTHESIS 
There is association between psychiatric co-morbidity and 
methamphetamine-induced psychosis.  
3.3  Methodology 
3.3.1. Study design  
This study was a hospital-based and drug rehabilitation-based cross 
sectional study.  
3.3.2. Setting and study period 
The study was conducted at outpatient psychiatric clinic, Department of 
Psychological Medicine, University Malaya Medical Centre(UMMC), 
Kuala Lumpur and at Drug Rehabilitation Centre Papar, Sabah from 
June 2008 until June 2009. 
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3.3.3. Study population 
Study population were methamphetamine dependence and the 
eligibility criteria were patients aged more than 18 and meeting the 
DSM-IV criteria for methamphetamine dependence. Those who had 
psychotic symptoms prior to methamphetamine dependence and those 
with history of schizophrenia or other psychotic disorders were 
excluded. 
3.3.4. Sample size and sampling procedure 
Sample size was calculated using the computer software EPI-INFO. 
Universal sampling was used for the recruitment of the study subjects. 
i.) The power of the study was taken at 80% level.  
ii.) The significance level of the statistic tests done was at 95% 
Confidence Interval level and  was set at 0.05. The Null 
hypothesis was rejected when p < 0.05. 
iii.) The odds Ratio was taken at 2.0 for the calculation. 
iv.) Expected frequency of disease in unexposed group (The 
proportion of the population with psychosis without 
psychiatric comorbidity - 21%) (Mcketin et al., 2006b)   
v.) The ratio of case to control was taken as 1 : 1. 
Total number of samples = 290 patients 
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3.3.5. Study variables 
Dependent variable 
Methamphetamine induce psychosis    
Independent variables 
Sociodemographic variables  
i). Age  
ii). Sex  
iii). Current employment status   
iv). Total family income 
v). Educational level 
vi). Marital status 
vii). Past medical history 
Psychiatric Co-morbidity in Axis I psychiatric disorders  
i). Mood disorders  
ii). Anxiety disorders  
iii). Suicidality  
iv). Alcohol dependence  
v). Alcohol abuse  
vi). Poly-substance use 
vii). Antisocial personality disorder 
viii). Present of any psychiatric co-morbidity 
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Drug use history variables 
i). Age of first substance use  
ii). Duration of drug use   
iii). Amount of money spend on drug per month   
iv). Route of administration of methamphetamine   
v). Criminal record   
vi). Lifetime prevalence of substance use  
3.3.6. Operational definitions 
The operational definitions for variables and scale were described in detail 
in ANNEX “A”. 
3.3.7. Study instrument 
The M.I.N.I. is a short structured diagnostic interview for DSM-IV or 
ICD-10 psychiatric disorders for the Major Axis I psychiatric disorder 
(Sheehan et al., 1998b). It has been widely used in international clinical 
trials and epidemiological studies (Joling et al., 2008, Van't Veer-
Tazelaar et al., 2009). The MINI was available in local language 
(Sheehan et al., 1998a). 
3.3.8. Data collection methods 
All patients with drug dependence were approached during the study 
period. Patients were briefed on the study and written consent was 
obtained. Only patients with urine toxicology screened positive for 
methamphetamine and within 30 days of last use of the 
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methamphetamine were included in the study. A face-to-face interview 
was conducted using a structured questionnaire on drug use behaviour 
and the Mini International Neuropsychiatric Interview (M.I.N.I.). The 
interviews were conducted by a qualified psychiatrist. 
The structured questionnaire for drug use behaviour was used to 
assess severity of illicit drug addiction. This questionnaire consisted of 
three sections: (i)  sociodemographic background (ii) psychiatric co-
morbidity in Axis I psychiatric disorders and (iii) drug use history  
3.3.9. Data Management 
The data were checked before ending each interview session and 
before compilation to ensure completeness. Raw data obtained were 
coded and entered into Statistical Package for Social Sciences (SPSS) 
Version 16.0. The data were summarized by running frequency 
distributions and simple descriptive statistics (means and standard 
deviations). Cleaning for double entry and outliers were done before 
the analysis.   
3.3.10. Data analysis 
i). Univariate analyses 
Only one independent variable was analyzed at a time. It allowed the 
researcher to describe the characteristics of the study subjects. No 
comparisons were made at this point. For nominal independent 
variables, they were described in the form of frequencies and 
percentages. For continuous independent variables, they were 
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summarized and described as means, standard deviations and 
median.  
ii). Bivariate analysis   
Pearson’s Chi-square test and Simple Logistic Regression were used 
to determine the possible association of significant variables to the 
occurrence of methamphetamine induced psychosis by determining the 
Odds ratio and 95% Confidence Interval. Continuous data were 
analyzed using the t-test. Skewed data was analysed using non 
parametric test. Subsequently the continuous variables were re-
categorised and further tested by Pearson’s Chi-square test and 
Simple Logistic Regression. An alpha level of significance 0.05 was set 
for all analyses. Significant risk factors in the bivariate analysis were 
partially adjusted with other significant variables to take care of 
interactions and confounding effects.    
iii). Multiple logistic regression 
After partial adjustment, all significant independent variables were 
further analyzed with enter, forward stepwise, backward stepwise 
methods of multiple logistic regression to determine which risk factors 
independently act as predictors of methamphetamine induced 
psychosis.  
3.3.11. Pre-test 
A pre-test of the questionnaires was done on 5 patients who were 
attending the psychiatric clinic, UMMC. These respondents were 
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excluded from the study. Some corrections were made after the pre-
test to facilitate patients’ understanding of the questionnaires. 
3.3.12. Ethical consideration 
Ethical approval was obtained from Medical Ethics Committee of 
UMMC. Before any interview, patients were informed regarding the 
nature and purpose of the study and the respondents were given the 
assurance that all information given will be treated with confidentiality. 
A written consent was obtained from the patients prior the interviews.  
3  Methamphetamine Induced-Psychosis  
 
 82 
3.4  Results  
Demographics 
Two hundred ninety two subjects were enrolled in this study. Of the 
292 subjects, 140 (47.9%) of the subjects had at least one episode of 
psychotic symptoms after they were dependent on methamphetamine. 
38 (13.0%) of the patients were still having psychotic symptoms at the 
time of assessment. Table 3.1 displayed the socio demographic 
characteristics of the study population. Participants had a mean age of 
30.5 + 8.2 years. Majority of the study subjects was male (98.9%). 
Participants with psychotic symptoms were 2 times more likely to be 
single (OR 1.9; 95% C.I.: 1.2, 3.1) and 3 times more likely to be 
unemployed (OR 3.3; 95% C.I.: 1.2, 9.4). There was statistically 
significant association between total income and psychosis. Those who 
had psychotic symptoms had higher income than those without 
psychotic symptoms (Table 3.1).  
Psychotic Symptoms 
Table 3.2 showed the prevalence rates of lifetime and current psychotic 
symptoms elicited by the use of MINI among the methamphetamine 
induce psychosis. Persecutory delusion (72.1%) was the most common 
symptom found during lifetime among the participants followed by 
strange or unusual belief (69.3%) and auditory hallucinations (60.7%). 
For those who still having current psychotic symptoms, auditory 
hallucinations was the most common (81.6%), followed by persecutory 
delusions (76.3%) and delusions of reference (71.7%) (Table 3.2). 
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Psychiatric Comorbidity 
Table 3.3 compared the participants with psychosis and without 
psychosis regarding diagnostic comorbidity. Those in the psychosis 
group were more likely to have a diagnosis of panic disorder (92.3% vs 
7.7%), bipolar mania (87% vs 13%), antisocial personality disorder 
(81.9% vs 18.1%), major depressive disorder (77.6% vs 22.4%) and 
alcohol dependence (62.3% vs 37.7%). Not surprisingly, the 
substance-induced psychotic group had higher rates of poly-substance 
use (62.8% vs 37.2%).  
Drug Use History 
Table 3.4 showed the results for methamphetamine use patterns and 
drug use history. The occurrence of psychotic symptoms was 
significantly associated with mean duration of methamphetamine use. 
Those who had psychosis used methamphetamine over longer 
duration (7.6 ± 5.1 years) compared to those who do not have 
psychotic symptoms (5.3 + 4.5 years). The amount of money spent per 
month to buy methamphetamine was also statistically significantly 
higher among those who experienced psychotic symptoms compared 
to those who do not have psychotic symptoms. The mean amount 
spend for those who had psychotic symptoms were RM 1,560.60 + 
2,063.30 per month, while those who do not have psychotic symptoms 
only spend RM 376.90 + 557.40. 
After multiple logistic regression, the independent risk factors of 
psychosis were mania (OR 4.7; 95% C.I.: 1.4, 16.6), antisocial 
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personality disorder (OR 3.7; 95% C.I.: 1.4, 9.8), higher amount of 
stimulant use and higher family income (Table 3.5). 
3  Methamphetamine Induced-Psychosis  
 
 85 
 
 
Table 3.1:   Association between Demographic Characteristics and 
Psychosis among Methamphetamine Dependence Patients 
Variables Psychosis No Psychosis Total 
n=292 
OR(95%CI) 
Age (years), mean + SD 
 
Gender 
‡Male  n (%) 
Female n (%) 
 
Education 
30.5 + 8.4 
 
 
137 (47.4) 
3 (100) 
30.5 + 7.9 
 
 
152 (52.6) 
0 (0) 
30.5 + 8.2 
 
 
289 
3 
*-0.2 (-2.1, 1.6) 
 
 
 
 
Primary n (%) 
Secondary n (%) 
‡Tertiary n (%) 
 
20 (40.0) 
102 (48.3) 
18 (58.1) 
30 (60.0) 
109 (51.7) 
13 (41.9) 
50 
211 
31 
0.7 (0.3, 1.5) 
0.5 (0.2, 1.4) 
Employment     
‡Fulltime n (%) 
Part-time n (%) 
 108 (47.0) 
12 (33.3) 
 122 (53.0) 
24 (66.7) 
230 
36 
 
0.6 (0.3, 1.3) 
Student n (%) 
Unemployed n (%)** 
5 (83.3) 
15 (75.0) 
1 (16.7) 
5 (25.0) 
6 
20 
5.2 (0.6, 45.2) 
3.3 (1.2, 9.4) 
     
         
Total Income  (RM), 
mean + SD 
n = 138 
2950.7 + 
8424.8 
n = 151 
1544.1 + 
1169.1 
n=290 
2247.4 + 
6045.5 
 
* ¶ -1406.5 (-2768.7,  
-44.4) 
 
 
Marital Status 
‡ Married n (%) 
Single n (%)** 
Divorced & widow n (%) 
 
 
 
38 (36.9) 
87 (55.5) 
15 (57.7) 
 
 
65 (63.1) 
76 (44.5) 
11 (42.3) 
 
 
103 
 163 
26 
  
 
 
 
1.9 (1.2, 3.1) 
2.0 (0.8, 4.9) 
 
         
** statistically significant 
*mean difference(95% CI of Difference) 
‡reference group 
¶Mann-Whitney U Test 
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Table 3.2:   Clinical Symptom Profiles of Patients with Methamphetamine 
Psychosis (Elicited By the Use of MINI) 
   
Psychotic Symptoms Lifetime (%) Current (%) 
 
Any psychotic symptoms  
 
Persecutory delusions 
 
Strange or Unusual Beliefs 
 
Auditory hallucinations 
 
Thought Insertion 
 
Thought reading 
 
Delusions of references 
 
Visual hallucinations 
 
Disorganized speech 
 
Negative psychotic symptoms 
 
Disorganized behaviour 
 
  
140 (100) 
 
101 (72.1) 
 
97 (69.3) 
 
85 (60.7) 
 
78 (55.7) 
 
63 (45.0) 
 
46 (32.8) 
 
22 (15.7) 
 
38 (100) 
 
29 (76.3) 
 
21 (55.3) 
 
31 (81.6) 
 
24 (63.1) 
 
17 (44.7) 
 
27 (71.1) 
 
11 (28.9) 
 
8 (21.1) 
 
6 (15.8) 
 
2 (5.3) 
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 Table 3.3: Association between Axis I Psychiatric Disorders and 
Psychosis among Methamphetamine Dependence Patients  
Psychiatric Co-morbidity Psychosis 
n (%) 
No 
Psychosis 
n (%) 
Total 
n=292 
(%) 
OR(95%CI) 
 
Mood Disorders 
    Major depressive disorder* 
 
 
38 (77.6) 
 
 
11 (22.4) 
 
 
49 (16.7) 
 
 
4.8 (2.3, 9.8) 
    Bipolar Disorder (Mania)* 40 (87.0) 6 (13.0) 46 (15.7) 
 
  9.7 (3.9, 23.8) 
 
 
Anxiety Disorders     
    Generalized Anxiety disorder 
    Obsessive compulsive disorder 
0 (0) 
2 (66.7) 
2 (100) 
1 (33.3) 
2 (0.7) 
3 (1.0) 
 
   2 (0.2, 22.2) 
    Panic disorder* 12 (92.3) 1 (7.7) 13 (4.5) 14.3 (1.8, 111.2) 
    Social phobia 5 (55.6) 4 (44.4) 9 (3.0) 1.4 (0.3, 5.2) 
     
 
    
Suicidality* 28 (90.3) 3 (9.7) 31 (10.6) 12.4 (3.7, 41.9) 
 
 
    
Alcohol dependence* 48 (62.3) 29 (37.7) 77 (26.3) 2.2 (1.3, 3.7) 
Alcohol abuse 
Poly-substance use* 
33 (61.1) 
108 
(62.8) 
21 (38.9) 
64 (37.2) 
54 (18.5) 
172 
(58.9) 
1.9 (1.0, 3.5) 
4.6 (2.8, 7.7) 
     
 
    
Antisocial personality disorder* 77 (81.9) 17 (18.1) 94 (32.2) 9.7 (5.3, 17.7) 
 
 
    
Any psychiatric co-morbidity* 
 
 
115 
(75.2) 
   38 
(24.8) 
 
153(52.4) 
   
13.8 (7.8, 24.3) 
     
*statistically significant  
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Table 3.4:   Association between Drug Use History and Psychosis among 
Methamphetamine Dependence Patients  
Variables Psychosis No Psychosis Total 
 
mean difference 
(95% CI of difference) 
Age of first substance use  
Year (mean + SD) 
Methamphetamine n=292 
    Alcohol    n=180 
    Cannabis n=95 
    Nicotine  n=272 
    Heroin     n=35 
 
Duration of drug use  
Year (mean + SD) 
    Methamphetamine* 
    Alcohol 
    Cannabis* 
    Nicotine 
    Heroin* 
     
Amount of money spend 
on drugs,RM** (mean + SD) 
    Methamphetamine* 
    Alcohol 
    Cannabis* 
    Nicotine 
    Heroin* 
     
Route of administration 
of methamphetamine 
   ‡Oral        n(%)  
    Nasal       n(%)  
    Smoking  n(%)  
    Injection n(%) 
 
 
22.9 + 8.2 
18.5 + 5.6 
18.6 + 5.0 
15.6 + 4.9 
22.4 + 4.8 
 
 
 
7.6 + 5.1 
6.8 +13.6 
3.9 + 6.0 
12.6 + 7.9 
2.0 + 5.6 
 
 
 
1560.6 + 2063.3 
225.1 + 507.5 
123.3 + 336.3 
184.2 + 494.8 
184.2 +494.8 
 
 
 
10 (55.6) 
37 (50.6) 
89(45.4) 
2 (66.7) 
 
 
24.8 + 9.2 
19.7 + 6.5 
18.8 + 5.6 
16.5 + 5.7 
25.2 + 5.5 
 
 
 
5.3 + 4.5 
5.0 +6.5 
0.9 + 3.2 
12.3 + 7.1 
0.6 + 2.8 
 
 
 
376.9 +557.4 
169.9 +356.2 
25.9 +101.3 
121.5 + 130.7 
121.5 + 130.7 
 
 
 
8 (44.4) 
36 (49.3) 
107 (54.6) 
1 (33.3) 
 
 
23.8 + 8.8 
19.1 + 5.9 
18.6 + 5.2 
16.1 + 5.4 
23.0 + 5.0 
 
 
 
6.4 + 4.9 
5.9 +10.7 
2.3 +4.9 
12.4 + 7.5 
1.4 + 4.6 
 
 
 
986.8 + 1650.0 
198.3 + 440.4 
72.5 + 252.2 
154.0 + 369.4 
81.6 + 340.6 
 
 
 
18 (5.9) 
73(25.0) 
196(67.1) 
3 (1) 
 
 
1.9 (-0.1, 3.9) ¶ 
1.2 (-0.5, 2.9) 
0.2 (-2.1, 2.6) ¶ 
0.9 (-0.3, 2.2) 
2.8 (-1.2, 6.9) 
 
 
 
   -2.3 (-3.4, -1.2) ¶ 
-1.8 (-4.2, 0.6) ¶ 
-2.9 (-4.0, -1.8) 
-0.3 (-2.0, 1.3) 
-1.4 (-2.4, -0.4) 
 
 
 
-1183.6 (-1524.7, -842.4) ¶ 
-55.2 (-154.2, 43.7) ¶ 
-97.3 (-153.4 , -41.3) ¶ 
-62.6 (-144.3, 19.0) ¶ 
-102.5 (-181.3, -23.8) ¶ 
 
 
 
 
0.9 (0.3, 2.6) § 
0.7 (0.2, 1.9) § 
1.6 (0.1, 20.9) § 
Criminal record   
    Illegal activity n(%)  
    Conviction       n(%) 
 
69 (51.1) 
77 (52.7) 
 
66 (48.9) 
69 (47.3) 
 
135 (46.2)  
146 (50.0) 
 
1.2 (0.8, 2.0) § 
1.5 (0.9, 2.3) § 
     
Lifetime prevalence of 
substance use 
    Alcohol     n(%) 
    Cannabis  n(%) 
    Nicotine   n(%) 
    Heroin      n(%) 
    Glue          n(%) 
    Ketamine n(%) 
 
   
 
180 (61.6) 
95 (32.5) 
272 (93.1) 
35 (11.9) 
20 (6.8) 
7 (2.4) 
 
*Statistically Significant              §Odds Ratio(95%CI)   
‡Reference Group                      **Ringgit Malaysia 
¶Mann-Whitney U Test  
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Table 3.5:   Independent Predictors for Psychosis Among 
Methamphetamine Dependence Patients 
                           
  Odds Ratio 
    
 95% CI 
 
 
Bipolar Mania 
 
                              
  4.7 
                                                          
 
   1.4, 16.6 
Antisocial Personality 
 
  3.7             1.4, 9.8 
Amount of Stimulant Used 
 
1.0             1.0, 1.2 
 
Higher Family Income 
 
 1.0             1.0, 1.1 
   
                   Adjusted with age and sex 
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3.5  Discussion 
This is the first study in Malaysia to examine the prevalence of 
methamphetamine induced psychosis among methamphetamine 
dependent from hospital-based and drug rehabilitation-based 
populations.  
In comparison with other studies, the prevalence rate of current or past 
psychotic disorders found in this investigation is substantially higher 
than those reported in other settings. The Methamphetamine 
Treatment Project (Glasner-Edwards et al., 2008a) reported a 12.9% 
prevalence rate of current or past psychotic disorders among 
treatment-seeking, methamphetamine-dependent adults, while a study 
involving methamphetamine-dependent gay and bisexual men seeking 
outpatient drug abuse treatment noted 26.5% of prevalence. (Shoptaw 
et al., 2003) A study of inpatients admitted for substance dependence 
in Sweden showed that 31.5% of methamphetamine abusers met 
criteria for psychotic diagnoses. (Dalmau et al., 1999)   
However in a cross-country study including Australia, Japan, 
Philippines and Thailand where psychotic symptoms in 
methamphetamine psychotic in-patients were evaluated using the Mini-
International Neuropsychiatric Interview found high prevalence rate of 
lifetime and current psychotic symptoms (Srisurapanont et al., 2003). 
74.4% out of 130 participants were having persecutory delusions 
followed by auditory hallucinations, strange and unusual beliefs and 
thought reading during their lifetime. They also found that 44.6% of the 
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participants were having current psychotic symptoms of auditory 
hallucination. 
The clinical symptoms profiles of patients with methamphetamine 
psychosis were almost similar between our study and other studies 
(Srisurapanont et al., 2003, Chen et al., 2003). In all the studies, the 
main psychotic symptoms were persecutory delusions and auditory 
hallucinations.  
A study in Taiwan (Chen et al., 2003) showed that when compared with 
methamphetamine users without psychosis, methamphetamine users 
with psychosis were younger when they first used methamphetamine, 
used larger amounts of the drug, had educational levels of high school 
or lower. The majority of their subjects were single, divorced, separated 
or widowed.  The demographic characteristics of our study subjects 
were similar to those reported in their study, where the majority of our 
patients were young adults, male, single, and most of them received up 
to secondary education only. In addition, we further found that 
psychosis among methamphetamine dependent users was 3 times 
more prevalent in those who were unemployed (OR 3.3) and 2 times 
more common in those who were single (OR 1.9). 
The majority of our study subjects were male in both psychosis and no-
psychosis groups reflects the fact that substance use and substance 
use disorders are more common among men, both in the general 
population and in the population with severe mental illness. 
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In our study, methamphetamine-dependent users who had psychosis 
were generally, though not statistically significantly, younger when they 
first used the substance, as compared with methamphetamine-
dependent users who did not develop psychosis (22.9 years vs 24.8 
years). Those who developed psychotic disorders, however, were 
statistically significantly using methamphetamine over a longer period 
of time (7.6 years) compared to those who are not psychotic (5.3 
years). Psychosis was also associated with longer duration of using 
cannabis and longer duration of using heroin. 
This makes it reasonable to assume that methamphetamine users who 
started using the drug at a younger age tend to use the drug for a 
longer time and at higher risk of developing psychotic illnesses. This 
may imply a dose-response relationship in the development of 
methamphetamine induced psychosis. This relationship was previously 
observed in association between cannabis and psychosis (Linszen et 
al., 1994). 
Those who had psychosis tend to make higher total family income than 
those were not psychotic (RM2,950.7 vs RM1,544.1), may explain why 
methamphetamine-dependent subjects with psychosis spent 
significantly higher amounts of money on the stimulant drug than their 
non-psychotic counterparts (RM1,560.6 vs RM376.9). The psychosis 
group also spent significantly more money on cannabis and heroin. 
Methamphetamine users not only are a high-risk population for drug-
induced psychosis, but are also at risk of suffering from other 
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psychiatric co-morbidities. Our study demonstrated that 
methamphetamine-dependent subjects with psychotic symptoms had 
significantly higher prevalence than the non-psychotic 
methamphetamine users in several of the Axis I psychiatric disorders 
assessed: bipolar mania (87% vs 13%; OR 9.7), major depression 
(77.6% vs 22.4%; OR 4.8), panic disorder (92.3% vs 7.7%; OR 14.3), 
anti-social personality disorder (81.9% vs 18.1%; OR 9.7) and alcohol 
dependence (62.3% vs 37.7%; OR 2.2).  
Substance use in patients with bipolar disorder is common. The 
National Epidemiological Catchment Area Study (ECA) found a 56% 
lifetime prevalence of substance abuse or dependence among persons 
with bipolar disorder (Regier et al., 1990).  Estroff et all (1985) found 
that the reported lifetime prevalence of amphetamine abuse in bipolar 
disorder subject was 38.8% (Estroff et al., 1985).  Although the 
frequency of this co-occurrence is well-documented, the reasons for 
this association are not clear. There are several potential hypotheses 
for why substance use and bipolar disorders co-occur: (a) substance 
abuse occurs as a symptom of bipolar disorder; (b) substance abuse is 
an attempt by bipolar patients to self-medicate symptoms; (c) 
substance abuse causes bipolar disorder; and (d) substance use and 
bipolar disorders share a common risk factor (Strakowski and Delbello, 
2000).  
Some of our findings concur with the results found in a study by Chen 
et al (Chen et al., 2003), where their methamphetamine-induced 
psychosis patients had significantly higher prevalence of major 
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depression (OR 7.4), alcohol dependence (OR 3.4), and antisocial 
personality disorder (OR 3.3), when compared with their non-psychotic 
counterparts.  
The risk of suicidality was also considerably elevated in 
methamphetamine users with psychosis than those without psychosis 
(OR 12.4) in our study. Comparable findings were reported in a study 
by Caton and colleagues (Caton et al., 2005), where individuals with 
substance-induced psychosis had higher rates of suicidal idea in the 
previous year. Their study also found that substance-induced 
psychosis subjects had higher rates of polysubstance use (alcohol, 
cocaine, heroin, hallucinogen and polydrug). As shown in our study, 
alcohol dependence, alcohol abuse and lifetime history of 
polysubstance use were significantly associated with psychotic 
symptoms among methamphetamine-dependent subjects. The most 
frequently used illicit drug besides methamphetamine in this study was 
cannabis and heroin. 
Studies have shown that combined abuse of methamphetamine and 
alcohol can aggravate mental disorders (Yamamura et al., 1991, Chen 
et al., 2003) because concomitant use of these substances increases 
toxicity in methamphetamine users, thereby increasing the risk of 
methamphetamine psychosis. Interaction of amphetamine and alcohol 
has been reported to increase toxicity in humans and animals 
(Yamamura et al., 1991, Yamamura et al., 1992). These observations 
support the significant association between alcohol dependence and 
methamphetamine psychosis observed in this study. 
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After performing multiple logistic regression analysis to eliminate the 
confounding effect, the independent predictors for psychosis found in 
this study were bipolar mania, major depression, antisocial personality, 
single marital status, spent significantly larger amount of money to buy 
methamphetamine, and having a higher total family income. 
The demographic data and clinical characteristics of 
methamphetamine-induced psychosis individuals as well as the key 
predictors derived from this study will provide important insights into 
substance-induced psychosis, and will impart a clearer understanding 
of the relationship of substance use and substance use disorders to 
psychotic illnesses. We also believe that this information will be of 
great help to the relevant authorities to formulate effective treatment 
and management of severe and persistent mental illnesses that co-
occur with substance use. 
Limitation and Errors 
i). Adequacy of Sample Size  
The required sample size was 290, when the calculated study sample 
was based on 80% power of the study and odds ratio 2.0 of bivariate 
association. The actual study subjects were 292 and have maintained 
the power of study.                                               
ii). Representative and Generalisation 
The findings of this study could only generalize with caution because 
the study population was from the outpatient clinic located in a hospital 
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in Kuala Lumpur and from one drug rehabilitation centre in Sabah. The 
study population differs from the patients in the community because of 
the treatment seeking behavior. Furthermore, there was ethnicity 
diversity in Sabah compare to other state in Malaysia. To make 
generalized inferences of the findings of this study to the 
methamphetamine dependence patients in community would be 
inappropriate because the setting in this study had introduced selection 
bias. 
For a better generalization of the findings, it would be ideal to conduct 
a community survey. Unfortunately, such a study is not feasible to 
conduct due to the legal implication.  
All identified patients willing to be interviewed and consented to 
participate in this   study.  
iii). Instruments of the study 
All the scales have been used widely in this country however until now, 
there was no paper being published regarding the validation of the 
scales in the local population.  
iv). Conduct of study   
Information bias was one of the limitations especially when information 
was obtained via a face-to- face interview. The validity on history of 
drug use could be questioned, especially some of the information could 
not be verified. Some of the information might occur long time ago and 
the possibility of recall bias could happen.     
3  Methamphetamine Induced-Psychosis  
 
 97 
In some circumstances when a translator was needed, the translator 
may have misunderstood the questions even though further 
explanations were given and this led to the respondents providing the 
wrong answer.           
v). Comparing Findings With Other Studies 
Comparison of the findings of this study to other studies may be 
inaccurate, although other studies examined the same variables, but 
the inclusion and exclusion criteria used to identify subjects or sampled 
population could differ, or study could be conducted with difference 
study design.  
Some of the variables that have been included in other studies for the 
association of methamphetamine induce psychosis but not in this study 
were the form of methamphetamine (Dore and Sweeting, 2006), 
genetic factor (Nakamura et al., 2006), children behaviour-attention 
deficit hyperactivity disorder (Salo et al., 2008), family history of 
psychiatric illness (Salo et al., 2008, Chen et al., 2005) and 
neurotransmitter activity (Yui et al., 2004).  
3.6  Conclusions 
The prevalence of psychosis among methamphetamine dependent 
subjects was found to be alarmingly high in this study. Independent risk 
factors for psychosis were determined; methamphetamine dependent 
who i) have bipolar mania, ii) have anti-social personality, iii) use higher 
amount of methamphetamine, or iv) have higher total family income, 
are at greater risks to develop psychotic symptoms. These findings 
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substantiate the fact that methamphetamine users are a high-risk 
population for psychosis, including those without known history of 
schizophrenia or other psychotic disorders. 
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Chapter FOUR:  Association of Brain-Derived Neurotrophic Factor 
(Val66Met) Genetic Polymorphism with Male 
Methamphetamine Dependence in Malaysia 
 
4.1  Abstract 
Introduction: Brain-derived neurotrophic factor (BDNF), a member of 
the neurotrophic factor family, is widely expressed in the adult 
mammalian brain and plays an important role in the long-term survival, 
differentiation, and outgrowth of neurons. Previous studies suggested 
that the BDNF gene may be involved in the mechanisms underlying 
substance dependence. 
Objectives: This study investigated (i) the association of the BDNF 
gene Val66Met polymorphism with methamphetamine dependence (ii) 
the association of the BDNF gene Val66Met polymorphism with the 
occurrence of psychosis among methamphetamine dependence patients 
in a Malaysian male population with different ethnicities. 
Methodology:  
Design : This was a case-control study. 
Setting: Cases were recruited from Department of Psychological 
Medicine, University Malaya Medical Centre (UMMC), 
Kuala Lumpur, Drug Rehabilitation Centre Papar, Sabah 
and Prison at Kota Kinabalu, Sabah. Controls were healthy 
volunteers from University of Malaya Medical Centre 
(UMMC) and Luyang Health Clinic, Sabah. 
Patients: The subjects included all male patients aged more than 18 
who fulfilled the Diagnostic and Statistical Manual of 
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Mental Disorders, fourth edition (DSM-IV; American 
Psychiatric Association, 1994) criteria for 
methamphetamine dependence.  
Cases were defined as male patients with 
methamphetamine dependence and confirmed by a 
positive urine test for methamphetamine.  
Controls were defined as healthy male subjects who 
volunteers to participant in this study.  
Measures: The Mini International Neuropsychiatric Interview (M.I.N.I.) 
and a structured questionnaire to assess 
sociodemographic background. The BDNF Val66Met 
polymorphism was genotyped by polymerase chain 
reaction-based methods with forward and reverse primers 
(PCR-RFLP).  
Results: 186 male methamphetamine-dependent subjects and in 154 
male controls of four different ethnicities, namely, Malay, Chinese, 
Kadazan-Dusun, and Bajau were recruited in this study. Our results 
showed that the distribution of the BDNF Val66Met genotype in 
Chinese subjects with methamphetamine dependence (OR=2.6, 
p=0.015) and methamphetamine psychosis (OR=0.2, p=0.034) were 
significant compared with controls. The frequency of the 66Val allele in 
methamphetamine-dependent subjects was higher than that in the 
control group, suggesting that the 66Val carriers are more susceptible 
to methamphetamine dependence. However, 66Val allele frequency in 
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other ethnicities was not significantly different from the controls. The 
results of the study also showed that in the Chinese methamphetamine 
dependent subjects, there was a difference in allele frequency when 
comparing those who developed psychosis and those who did not. 
Conclusion: Our findings suggest that the BDNF Val66Met 
polymorphism may contribute to methamphetamine dependence and 
psychosis in the Chinese population but not in other Malaysian 
ethnicities. 
 
 
Keywords: Brain-derived neurotrophic factor, Methamphetamine dependence, 
Psychosis, Association study, Single nucleotide polymorphism 
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4.2   Introduction 
Risk Factors for Methamphetamine Dependence  
Methamphetamine abuse can lead to drug dependence when taken 
often enough and in large enough quantities. However, individuals are 
differentially vulnerable to methamphetamine dependence. The 
probability of continuing drug use varies from individual to individual, 
and the difference is very likely due to both biological and psychosocial 
factors.   
Drug dependence or addiction is a developmental disease that begins 
in childhood and adolescence. Observations in the past suggested that 
both genetic and environmental conditions play an important role in 
predisposing individuals to their drug-taking behaviour (George R.U. et 
al., 2000) from the initiation of drug use, to regular drug use, addiction 
and relapse.    
Note that not all individuals at risk of drug abuse will start using drugs 
or become addicted (George R.U. et al., 2000). Furthermore, a risk 
factor for one person may not be for another. Similarly, the absence of 
risk factors provides no assurance that a person will not become a drug 
user. 
Genetic Factors   
Over the past decades, familial and population genetic studies (Mirin et 
al., 1991, Rounsaville et al., 1991, Luthar and Rounsaville, 1993) have 
revealed possible genetic bases for some of the inter-individual 
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differences in vulnerability to substance abuse and addiction risk. Twin 
(Pickens et al., 1995, Johnson et al., 1996, Miles et al., 2001) and 
adoption (Cadoret et al., 1986, Cadoret et al., 1996) studies have also 
determined that both genetic and environmental influences are 
involved in drug use or dependence. Genetic factors and combined 
genetic-environmental interactions have been estimated to be account 
for 40% to 60% of the variability in addiction risk (Kendler et al., 1994, 
Tsuang et al., 1998, Kendler et al., 2000).  
How Gene Contribute To Dependence Vulnerability  
The susceptible single nucleotide polymorphisms in some genes may 
contribute to addiction vulnerability in several ways, including changing 
the structure or function of specific proteins. A mutant protein causes 
structural or functional changes of specific brain circuits during 
development phase or in adulthood (Nestler, 2000). These altered 
brain circuits may change an individual’s responsiveness to initial drug 
exposure, or alter the adaptations that occur in the brain after repeated 
drug exposure. 
In addition, allelic variants of specific genes could also (George R.U. et 
al., 2000):  
 Mediate differential drug reinforcing properties. 
 Alter drug pharmacodynamics or pharmacokinetics. 
 Influence "sensation-seeking" personality attributes that may 
facilitate exposure to drugs. 
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 Exacerbate Drug Toxicities.   
Genes in Methamphetamine Dependence Risk 
The heritability for psychostimulants has been estimated to be around 
66% (Tsuang et al., 1998, Kendler et al., 2000, Tsuang et al., 1996). 
Genes important in the mesolimbic/mesocortical dopaminergic 
pathways are known to be strong candidate genes contributing to inter-
individual differences in substance abuse vulnerability (George R.U. et 
al., 2000).  
Many of the genetic studies in methamphetamine addiction risk have 
concentrated on the contribution of genes encoding proteins of the 
dopamine system, such as the dopamine receptor genes (e.g. DRD1, 
DRD2), dopamine transporter gene (DAT1), and dopamine beta-
hydroxylase gene (DBH) (Rutter, 2006) Dopamine is thought to be 
essential to the brain’s response to drugs like opiates and 
psychostimulants.  
For example, Chen and colleagues(Chen et al., 2004a) examined the 
DRD2, DRD3 and DRD4 gene variants in 851 methamphetamine 
subjects with and without psychosis (416 methamphetamine abusers 
and 435 controls). They found that the 7-repeat (exon III) DRD4 
polymorphism occurred more frequently in the methamphetamine 
abusers than in controls (2% vs 0.6%).  
In a follow-up study conducted by Li et al (Li et al., 2004), a modest 
interaction among the high-activity allele of catechol-O-
methyltransferase (COMT) and DRD4 genotypes was noted among the 
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methamphetamine abusers. COMT is an enzyme involved in the 
metabolism of dopamine, adrenalines and noradrenalines. Their 
observations further demonstrated that genetic variations in the 
dopamine system may exert an additive effect on the risk of becoming 
a methamphetamine abuser. 
Other candidate genes that may be related to drug addiction to 
methamphetamine include genes that are pharmacokinetically related 
to the drug, such as cytochrome P450 (CYP) gene family (Yamada et 
al., 2005, Sellers and Tyndale, 2000), trace amine receptor 4 (TRAR4) 
gene (Parker and Cubeddu, 1986, Borowsky et al., 2001, Baud et al., 
1985), fatty acid amide hydrolase (FAAH) gene,(Sipe et al., 2002, 
Flanagan et al., 2006) serotonin transporter gene (Murphy et al., 2004), 
and superoxide dismutase 2 (SOD2) (Nakamura et al., 2006). 
BDNF 
Brain-derived neurotrophic factor (BDNF), a member of the nerve 
growth factor-related family of neutrophins, is widely expressed in the 
adult mammalian brain. Evidence indicates that BDNF may be involved 
in the mechanisms underlying substance abuse (Hofer et al., 1990). 
BDNF plays an important role in the neurodevelopment of 
dopaminergic (DA)-related systems. This protein interacts with the 
meso-limbic DA systems that are involved in the therapeutic response 
to substance abuse, and it subsequently promotes and maintains 
dopamine D3 receptor (DRD3) expression (Krebs et al., 2000). 
Methamphetamine is a drug that easily induces drug conditioning and 
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elevated BDNF mRNA. BDNF expression has been found to increase 
acutely after drug abuse, leading to subsequent long-lasting elevation 
of DRD3 in the nucleus accumbens, which may facilitate response to 
drug-associated stimuli and finally induce addictive disorders (Le Foll et 
al., 2005).  
Recent studies have demonstrated that the BDNF gene is associated 
with vulnerability to drug abuse (Itoh et al., 2005). Furthermore, 
Flanagin et al. (Flanagin et al., 2006) reported that BDNF has been 
implicated in the behavioural response to psychomotor stimulants and 
that it potentiates neurotransmitters, which are strongly linked to 
addiction. They suggested that this gene is a logical candidate gene for 
the study of addiction. Data derived from animal studies have 
demonstrated that BDNF modulates dopaminergic and serotonergic 
functions that are strongly linked to substance abuse (Dluzen et al., 
1999). BDNF, located on chromosome 11p13, contains a common and 
functional single nucleotide polymorphism, rs6265 (Val66Met), at 
codon 66. This G196A polymorphism results in a valine (Val) to 
methionine (Met) substitution in the prodomain, which affects 
intracellular trafficking and activity- dependent secretion of BDNF (Li et 
al., 2005). A previous study reported that the valine (196G) allele is 
more commonly methamphetamine dependent and suggested that the 
GG genotype is a risk factor for substance abuse, related to late onset 
of substance abuse(Cheng et al., 2005). According to Haile et al.(Haile 
et al., 2009), this BDNF polymorphism is not only linked to 
methamphetamine dependence, but also to the development of 
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methamphetamine psychosis. A study on the human BDNF gene has 
demonstrated that the Val66Met BDNF gene polymorphism is 
associated with methamphetamine dependence in methamphetamine-
dependent Taiwanese subjects, suggesting that homozygous carriers 
of the 196G allele are more susceptible to methamphetamine abuse 
(Cheng et al., 2005). This finding suggested that the Val66Met BDNF 
polymorphism may confer risk for substance abuse.  
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4.2.1. RESEARCH QUESTION 
i). Is Val66Met brain-derived neurotrophic factor (BDNF) 
polymorphism associated with risk of methamphetamine 
dependence in male patients? 
ii). Is Val66Met BDNF polymorphism associated with the occurrence 
of psychosis among methamphetamine-dependent male patients? 
4.2.2. STUDY OBJECTIVES 
 General Objective  
To determine whether genetic polymorphism is a risk factor for 
methamphetamine dependence in male patients.  
 Specific Objectives  
i). To determine the association between Val66Met BDNF 
polymorphism and methamphetamine dependence in male 
patients of different ethnicities.  
ii). To determine the association between Val66Met BDNF 
polymorphism and the occurrence of psychosis among different 
ethnicities of methamphetamine-dependent male patients.  
4.2.3. HYPOTHESIS 
i). There is an association between Val66Met BDNF polymorphism 
and methamphetamine dependence male patients in different 
ethnicity.  
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ii). There is an association between Val66Met BDNF polymorphism 
and the occurrence of psychosis among different ethnicity of 
methamphetamine dependence male patients.   
4.3  Methodology 
4.3.1. Study design  
This study was a case-control study. 
4.3.2. Study Period 
The study period was from June 2007 until June 2011. Data was 
collected from June 2008 until June 2009. 
4.3.3. Location of Study 
Cases 
i). Inpatient and outpatient of Department of Psychological 
Medicine at University Malaya Medical Centre (UMMC)   
ii). Drug Rehabilitation Centre in Papar, Sabah that specializes in 
the treatment  methamphetamine-dependent patients.  
iii). Prison in Kota Kinabalu, Sabah 
Controls 
i). Healthy volunteers at University of Malaya Medical Centre 
ii). Healthy volunteers at Luyang Health Clinic, Sabah  
4.3.4. Study population 
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The subjects included all male patients aged more than 18 who fulfilled 
the Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV; American Psychiatric Association, 1994) criteria for 
methamphetamine dependence.  
i). Definition of Cases and Controls for Methamphetamine 
dependence 
Cases: Cases were defined as male patients with methamphetamine 
dependence and was confirmed by a positive urine test for 
methamphetamine during recruitment.  
Controls: Controls were defined as healthy male subjects who 
volunteered to participant in this study. They were medically healthy 
with no history of chronic medical or surgical illness, had no previous 
history of psychiatric illness, and did not fulfil the DSM-IV criteria for 
amphetamine and methamphetamine dependence.   
ii). Definition of Cases and Controls for the Occurrence of 
Psychosis among Methamphetamine Dependence Patients  
Cases: Cases were identified by qualified psychiatrists that confirmed 
the presence of psychosis. The male subjects were considered to have 
psychosis if they have persecutory delusions and delusions of 
reference or present with auditory, visual hallucinations or tactile 
hallucinations. 
Controls: Controls were defined as healthy male subjects who 
volunteers to participant in this study. They had no previous history of 
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psychiatric illness and were not dependence for amphetamine and 
methamphetamine.   
4.3.5. Exclusion Criteria 
Patients who had the following characteristics were excluded from this 
study: 
i). Patients with mixed or unclear ethnicity.  
ii). Patients with past history of psychiatric illness.  
iii). Patients with other substance dependence and abuse.  
4.3.6. Sample Size  
The sample size was calculated using an online programme, namely 
Power of Association With Errors (PAWE)(Gordon et al., 2002, Gordon 
et al., 2003) for genetic case-control association studies. Universal 
sampling was used for the recruitment of the study subjects. 
i). Error Model: Gordon Heath Liu Ott 
ii). Ԑ1 =  0.05   , Ԑ2  =0.05 
iii). Generate the genotype frequencies: Genetic model free method 
iv). Genetic model free method assuming Hardy Weinberg 
Equilibrium 
Case 1 allele frequency    =0.667 (G) 
Control 1 allele frequency =0.433 (G) 
v). The power of the study was taken at 80% level.  
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vi). The significance level of the statistic tests done was at 95% 
Confidence Interval level and  was set at 0.05. The Null 
hypothesis was rejected when p < 0.05. 
vii). The ratio of case to control was taken as 1:1. 
Total number of samples (Data with Error):  
 
Minimal sample size for allelic test  =      Cases 44 : Controls 44 
Minimal sample size for genotypic test =      Cases 56 : Controls 56 
  
4.3.7. Study variables 
Dependent variable 
i). Methamphetamine dependence 
ii). The occurrence of psychosis among methamphetamine 
dependence    
Independent variables 
Sociodemographic variables  
i). Ethnicity 
 Malay 
 Chinese 
 Kadazan-Dusun 
 Bajau   
ii). Age 
iii). Age of onset for methamphetamine dependence  
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Brain-Derived Neurotrophic Factor (BDNF) Val66Met 
Polymorphism  
i). Genotype 
 G/G 
 G/A 
 A/A  
ii). Allele  
 A 
 G  
4.3.8. Study instrument 
The Mini International Neuropsychiatric Interview (M.I.N.I.) is a short 
structured diagnostic interview for DSM-IV or ICD-10 psychiatric 
disorders for the Major Axis I psychiatric disorder.(Sheehan et al., 
1998b) It has been widely used in international clinical trials and 
epidemiological studies (Joling et al., 2008, Van't Veer-Tazelaar et al., 
2009). The MINI was available in local language (Sheehan et al., 
1998a). 
4.3.9. Data collection methods 
For cases, all male patients with drug dependence were approached 
during the study period. Patients were briefed on the study and written 
consent was obtained. Only patients with urine toxicology screened 
positive for methamphetamine and within 30 days of last use of the 
4    BDNF and Methamphetamine Dependence  
 
 114 
methamphetamine were included in the study. A face-to-face 
interviewed was conducted using a structured questionnaire to obtain 
sociodemographic data for cases and controls. The cases were 
accessed for the occurrence of psychosis by a qualified psychiatrist 
using the Mini International Neuropsychiatric Interview (M.I.N.I.). Three 
millilitres of blood was collected from each subject by a standard 
method in an EDTA tube. 
4.3.10. DNA Preparation and Analysis 
DNA was extracted from leucocytes by using the QIAmp Blood Kit 
(Qiagen, Germany). For those who were reluctant to provide blood 
samples, buccal swab tissues were obtained by the QIAmp Mini Kit 
(Qiagen, Germany). Genotyping of the Val66Met genetic polymorphism 
of the BDNF gene (G196A; rs6265) was performed by using 
polymerase chain reaction (PCR)-based methods with forward and 
reverse primers (forward, 5′-ACTCTGGAGAGCGTGAAT-3′; reverse, 
5′-ATACTGTCACACACGCTC-3′, respectively). The PCR reaction was 
performed under the following conditions: 95 °C for 5 min; then 35 
denaturing cycles of 30 s each at 95 °C, 30 s of annealing at the 
appropriate temperature, and 30 s each at 72 °C for extension, and 
final elongation at 72 °C for 10min. PCR was carried out by using PCR 
Master Mix (Fermentas International Inc, Canada). Following that, the 
restriction fragment length polymorphism (RFLP) method was 
conducted with restriction enzyme NlaIII (New England Biolabs, USA). 
The PCR product was digested by NlaIII and the mixture was 
incubated at 37 °C in a dry-block heater overnight. The temperature 
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was then increased to 65 °C for 20 min to terminate the activity of the 
enzyme. After the DNA was digested by restriction enzyme, products 
were loaded on 2.5% (w/v) agarose gel stained with GelRed (Biotium, 
USA) and then electrophoresed. The gel was viewed under UV light to 
observe restriction patterns. The size and distribution of the band was 
used to determine the genotype of the DNA sample. The PCR products 
were chosen randomly for validation by DNA sequencing. 
4.3.11. Data Management 
The data were checked before ending each interview session and 
before compilation to ensure completeness. Raw data and DNA results 
were coded and entered into Statistical Package for Social Sciences 
(SPSS) Version 16.0. The data were summarized by running frequency 
distributions and simple descriptive statistics (means and standard 
deviations). Cleaning for double entry and outliers were done before 
the analysis.   
4.3.12. Data analysis 
i). Univariate analyses 
Only one independent variable was analyzed at a time. It allowed the 
researcher to describe the characteristics of the study subjects e.g. 
cases and controls and their distributions. No comparisons were made 
at this point. For nominal independent variables, they were described in 
the form of frequencies and percentages. For continuous independent 
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variables, they were summarized and described as means, standard 
deviations and median.  
ii). Bivariate analysis   
Pearson’s Chi-square test and the Fisher's exact test were used to 
determine the possible association of ethnicity and Val66Met BDNF 
polymorphism e.g. BDNF 196G/G genotype, the 196G/A heterozygote, 
and the 196A/A genotype to methamphetamine dependence as first 
outcome, or to the occurrence of psychosis among methamphetamine 
dependence as second outcome. Odds ratio and 95% Confidence 
Interval were used to determine the association of inter-group 
comparisons of genotype and allele frequency differences. Continuous 
data (e.g. age) were analyzed using the t-test. An alpha level of 
significance 0.05 was set for all analyses.  
4.3.13. Ethical consideration 
Ethical approval was obtained from Medical Ethics Committee of 
UMMC. Before any interview, patients were informed regarding the 
nature and purpose of the study and the respondents were given the 
assurance that all information given will be treated with confidentiality. 
A written consent was obtained from the patients prior the interviews.  
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4.4  Results 
A total of 186 subjects (n=186) and 154 controls (n=154) comprising 
Malay, Chinese, Kadazan-Dusun and Bajau ethnicities were recruited 
in this study. The demographic distribution for the methamphetamine-
dependent and control subjects are summarised in Table 4.1. The 
overall mean age for the male control subjects was 33.0 ± 12.2 years 
old while the mean age for the male methamphetamine-dependent 
subjects was 31.0 ± 8.2 years old. The recorded ages for the 
methamphetamine-dependent and control subjects were the ages 
when they were recruited. After stratifying the subjects according to the 
different ethnic groups, only the age was statistically significant 
difference for the male Malay, Chinese and Kadazan-Dusun between 
cases and control.  
Results from RFLP indicated that three variants exist in the digestion 
product: homozygous 66Val (GG), heterozygous (GA), and 
homozygous 66Met (AA) (Fig. 4.1). The presence of 168-bp and 75-bp 
bands indicated the existence of the A (66Met) allele; the presence of a 
243-bp band indicated the existence of the G (66Val) allele; and the 
presence of 75-bp, 168-bp, and 243-bp bands indicated the existence 
of the AG (66Met/66Val) heterozygote. The 100-bp ladder was used as 
a DNA marker. The products of the RFLP were randomly selected to 
perform direct DNA sequencing for validation. The frequencies of 
genotypes and alleles for controls and methamphetamine-dependent 
subjects are shown in Table 4.2 and 4.3. The genotype distribution in 
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both controls and methamphetamine-dependent subjects fulfilled the 
Hardy–Weinberg equilibrium. 
For the Malaysian Chinese population, the differences in the genotype 
frequency (p=0.016) and allele frequency (p=0.015) between male 
controls and male methamphetamine-dependent subjects were found 
to be significant (Table 4.2 and 4.3). The frequency of carrying the G 
allele in methamphetamine-dependent subjects was significantly higher 
(p=0.015, odds ratio: 2.6, 95% CI 1.26–5.43) than in the controls. 
Comparison of the 66Val/66Val genotype with 66Val/66Met plus the 
66Met/66Met genotype, revealed that the homozygous carriers of 
66Val allele has 4.6 times more risk of being dependent on 
methamphetamine (p=0.018, odds ratio: 4.6, 95% CI 1.42–15.14). 
Furthermore, comparison between 66Val/66Val with 66Met/66Met 
showed a significantly increased odds ratio (p=0.021, odds ratio: 10.0, 
95% CI 1.62–60.91) than in the controls (Table 4.4). However, for the 
overall data (Table 4.5) and the data of other races, no significant 
difference was observed. 
The frequencies of genotypes and alleles for methamphetamine-
dependent subjects with and without psychosis are shown in Table 4.6 
and 4.7. With regard to the occurrence of methamphetamine 
psychosis, no significant difference in either genotype frequency 
(p=0.850) or allele frequency (p=0.889) was seen when comparing 
methamphetamine-dependent subjects who experience psychosis with 
those who do not. However, examination of the data according to the 
ethnicities revealed that there was a significant difference in allele 
4    BDNF and Methamphetamine Dependence  
 
 119 
frequency in the Chinese methamphetamine-dependent subjects 
(p=0.034) (Table 4.7). The frequency of carrying the A allele in Chinese 
methamphetamine-dependent subjects with psychosis was higher than 
in the methamphetamine-dependent subjects without psychosis. 
Comparison of the 66Val allele frequency with 66Met allele frequency 
revealed a significant difference in odds ratio (OR: 0.2, 95% CI 0.07–
0.86, p=0.034) (Table 4.8). The results showed no significant difference 
in genotype and allele frequency between methamphetamine-
dependent subjects with and without psychosis among the other races 
studied (Table 4.9).  
The effect of the BDNF Val66Met genetic polymorphism on the age of 
onset of methamphetamine abuse was also analyzed in 187 
methamphetamine-dependent subjects. The mean age of onset for the 
methamphetamine dependent groups was 24.8±9.0 years old for 
BDNF 66Val/66Val (n=57), 23.2±9.4 years old for BDNF 66Val/66Met 
(n=99), and 23.4±5.9 years old for BDNF 66Met/66Met (n=31). For the 
age of onset among the Chinese dependent group, the mean age was 
30.3±8.5 years old for BDNF 66Val/66Val (n=10), 32.1±11.4 years old 
for BDNF 66Val/66Met (n=12), and 24.0±11.3 years old for BDNF 
66Met/66Met (n=2). The age of onset of the methamphetamine-
dependent subjects neither in overall dependent subjects (p=0.539) nor 
in Chinese (p=0.593), Malay (p=0.822), Kadazan-Dusun (p=0.762) and 
Bajau (p=0.371) dependent subjects was not significant. 
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Figure 4.1   Gel photo of 2.5% (w/v) agarose gel electrophoresis for 
detection of BDNF Val66Met polymorphism 
 
 
 
Table 4.1:   Demographic data for the male methamphetamine-dependent 
and the male control subjects 
 
 
 
 
Characteristics 
Malay  
(n = 110) 
Chinese  
(n = 89) 
Kadazan-Dusun  
(n = 80) 
Bajau 
 (n = 81) 
Total 
(n = 340) 
Case 
(59) 
Control      
(51) 
Case    
(24) 
Control    
(45) 
Case      
(50) 
Control   
(30) 
Case    
(53) 
Control   
(28) 
Case 
(186) 
Control 
(154) 
 
Age (years) 
 mean (SD) 
 
 
31(7.8) 
 
36(10.6) 
++ 
 
40(9.6) 
 
30(9.4) 
++ 
 
29(6.6) 
 
33(11) 
++ 
 
28(6.4) 
 
31(16.7) 
 
31(8.2) 
 
33(12.2) 
 
Onset age of meth 
dependence (years), 
mean (SD) 
 
                       
 
25(9.1) 
                    
 
31(10.1) 
  
                      
 
22(7.6) 
                      
 
21(7.1) 
                      
 
24(8.8) 
 
Meth dependence  
                    
     With psychosis,  
     N (%) 
28(47.5)   11(45.8) 
  
14(28.0)   15(28.3)   68(36.6)   
     
 Without psychosis, 
     N (%) 
 
 
31(52.5) 
   
13(54.2) 
  
 
36(72.0) 
   
38(71.7) 
   
118(63.4) 
  
                               
++ t-test: statistical significant 
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Table 4.2:   Genotype frequencies of the BDNF Val66Met polymorphism 
in male controls and male methamphetamine-dependent subjects. 
 
      
Ethnicity Participant  
Genotype  
n (frequency)   
  G/G G/A A/A p 
Malay Case subject 20(0.34) 33(0.56) 6(0.10) 0.37 
 Control 16(0.31) 25(0.49) 10(0.20)  
Chinese Case subject 10(0.42) 12(0.50) 2(0.08) 0.01* 
 Control 6(0.13) 27(0.60) 12(0.27)  
Kadazan-Dusun Case subject 13(0.26) 28(0.56) 9(0.18) 0.83 
 Control 6(0.20) 18(0.60) 6(0.20)  
Bajau Case subject 13(0.24) 26(0.50) 14(0.26) 0.86 
 Control 8(0.29) 14(0.50) 6(0.21)  
Total Case subject 56(0.30) 99(0.53) 31(0.17) 0.26 
 Control 36(0.23) 84(0.55) 34(0.22)  
* statistically significant 
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Table 4.3:   Allelic frequencies of the BDNF Val66Met polymorphism in 
male  controls and male methamphetamine-dependent subjects 
* statistically significant 
 
 
 
 
 
 
 
      
Ethnicity Participant  Allele frequency   
  G A p OR (CI 95%) 
Malay Case subject 0.62 0.38 0.45 1.3 (0.75-2.20 ) 
 Control 0.56 0.44   
Chinese Case subject 0.67 0.33 0.01* 2.6(1.26-5.43)* 
 Control 0.43 0.57   
Kadazan-Dusun Case subject 0.54 0.46 0.74 1.2(0.62-2.23) 
 Control 0.50 0.50   
Bajau Case subject 0.49 0.51 0.70 0.8(0.44-1.60) 
 Control 0.54 0.46   
Total Case subject 0.57 0.43 0.13 1.3(0.94-1.73) 
  Control 0.51 0.49   
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Table 4.4:   The odds ratio with comparison between allele and genotype 
frequencies of the BDNF Val66Met polymorphism in Chinese controls 
and Chinese methamphetamine-dependent subjects.   
Genotype p Odds ratio 95% confidence interval 
G vs A 0.01 * 2.6 1.26 – 5.43 
GG vs AA 0.02 * 10.0 1.60 – 60.90 
GG vs (GA + AA) 0.01 * 4.6 1.42 – 15.14 
(GG + GA) vs AA       0.07 3.9 0.88 – 28.11 
* Statistically Significant  
 
 
Table 4.5:   The odds ratio with comparison between allele and genotype 
frequencies of the BDNF Val66Met polymorphism in controls and 
methamphetamine-dependent subjects.   
Genotype p Odds ratio 95% confidence interval 
G vs A 0.11 1.2 0.94 – 1.73 
GG vs AA 0.10 1.7 0.89 – 3.25 
GG vs (GA + AA) 0.16 1.4 0.86 – 2.31 
(GG + GA) vs AA 0.21 1.4 0.82 – 2.44 
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Table 4.6:   Genotype frequencies of the BDNF Val66Met polymorphism 
in male methamphetamine-dependent subjects with and without 
psychosis.   
 Ethnicity Participant  Genotype   
   G/G G/A A/A p 
Malay Psychosis 10(0.36) 15(0.54) 3(0.10) 0.94 
 No psychosis 10(0.32) 18(0.58) 3(0.10)  
Chinese Psychosis 2(0.18) 7(0.64) 2(0.18) 0.055 
 No psychosis 8(0.62) 5(0.38) 0(0.00)  
Kadazan-Dusun Psychosis 3(0.21) 8(0.57) 3(0.21) 0.87 
 No psychosis 10(0.28) 20(0.55) 6(0.17)  
Bajau Psychosis 4(0.27) 8(0.53) 3(0.20) 0.80 
 No psychosis 9(0.24) 18(0.47) 11(0.29)  
Total Psychosis 19(0.28) 38(0.56) 11(0.16) 0.85 
  No psychosis 37(0.31) 61(0.52) 20(0.17)  
 
4    BDNF and Methamphetamine Dependence  
 
 125 
 
 
Table 4.7:   Allelic frequencies of the BDNF Val66Met polymorphism in 
male methamphetamine-dependent subjects with and without psychosis.   
# Fisher’s exact test 
*statistically  significant 
 
 
 
 
 
Ethnicity Participant  Allele frequency   
  G A p OR (CI 95%) 
Malay Psychosis 0.63 0.37 0.96 1.1 (0.50-2.22 ) 
 No psychosis 0.61 0.39   
Chinese Psychosis 0.50 0.50 0.03#* 0.2(0.07-0.86) 
 No psychosis 0.81 0.19   
Kadazan-Dusun Psychosis 0.50 0.50 0.66# 0.8(0.33-1.92) 
 No psychosis 0.56 0.44   
Bajau Psychosis 0.53 0.47 0.73 1.3(0.54-2.96) 
 No psychosis 0.47 0.53   
Total Psychosis 0.56 0.44 0.89 0.9(0.62-1.45) 
  No psychosis 0.57 0.43   
4    BDNF and Methamphetamine Dependence  
 
 126 
 
 
Table 4.8:   The odds ratio with comparison between allele and genotype 
frequencies of the BDNF Val66Met polymorphism in methamphetamine-
dependent subjects with psychosis and methamphetamine-dependent 
subjects without psychosis. 
Genotype p Odds ratio 95% confidence interval 
G vs A 0.89 0.9 0.62 – 1.45 
GG vs AA 0.88 0.9 0.37 – 2.40 
GG vs (GA + AA) 0.63 0.8 0.43 – 1.63 
(GG + GA) vs AA 0.90 1.1 0.47 – 2.44 
 
 
Table 4.9:   The odds ratio with comparison between allele and genotype 
frequencies of the BDNF Val66Met polymorphism in Chinese 
methamphetamine-dependent subjects with psychosis and 
methamphetamine-dependent subjects without psychosis. 
Genotype p Odds ratio 95% confidence interval 
G vs A 0.03 * 0.2 0.07 – 0.86 
GG vs AA 0.03 * 0.01 0.0 – 0.85 
GG vs (GA + AA) 0.04 * 0.2 0.01 – 0.95 
(GG + GA) vs AA 0.12 0.01 0.0 – 1.76 
* Statistically Significant  
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4.5  Discussion 
Studies on single nucleotide polymorphisms and its association with 
methamphetamine dependence have not been previously carried out in 
Malaysia. This field of study is still a relatively new and interesting field 
to explore in Malaysia.  
The results of this study did not find an association between 
BDNFVal66Met genotype or allele frequency and methamphetamine 
dependence in the overall Malaysian subjects studied. This finding was 
similar to a recent study among 189 methamphetamine abusers from a 
Japanese population (79.4% male and 20.6% female), BDNF Val66Met 
polymorphism was not associated with methamphetamine abuse (Itoh 
et al., 2005). In our study, although this association was not significant 
overall, the data for the Chinese subgroup suggested that the BDNF 
Val66Met polymorphism contributes to methamphetamine dependence 
vulnerability in this ethnicity. The risk for methamphetamine 
dependence in the Chinese subgroup with the 66Val 169G allele was 
2.6,whereas with the 66Val homozygous 196G, it was 4.6, suggesting 
that this allele may contribute to methamphetamine dependence in the 
male Chinese population. Although the results of this study showed 
that the 66Val allele for the Chinese subpopulation is a risk factor for 
methamphetamine dependence, the age of onset for 
methamphetamine abuse from either the overall data or the Chinese 
dependent subjects within the three genotypes was not significant, 
inconsistent with the results of Cheng et al (Cheng et al., 2005). They 
reported a significant difference in the age of onset for 
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methamphetamine abuse across the three genotype groups (p=0.048), 
perhaps because of involvement of independent genes with a different 
penetrance level of different susceptibility loci in the pathogenesis of 
substance dependence. In this study, the 66Met allele was less 
common in the Chinese methamphetamine-dependent groups than it 
was in the control group. However, the 66Val/66Val genotype is more 
common in methamphetamine-dependent groups, and this finding is 
also compatible with the observation from previous studies which was 
in Han Chinese population that the Met allele is the dominant allele of 
the BDNF Val66Met polymorphism (Cheng et al., 2005, Chen et al., 
2004b).  Furthermore, the odds ratio of being methamphetamine 
dependent between 66Val/66Val and 66Val/66Met plus the 
66Met/66Met genotype (OR=4.2) in this study also revealed that the 
Met allele is the dominant allele of the BDNF Val66Met polymorphism. 
This finding may indicate that the Chinese population in Malaysia and 
the Han Chinese have a common origin. The 66Val allelic frequency in 
our study for the Malaysian Chinese subgroup was 46.4%, comparable 
with previous findings that showed that the frequency of this allele in 
normal African-American, European-American, and Chinese people 
was 13.6%, 33.6%, and 46.7%, respectively. This result suggests that 
this allele is dominant in the Chinese and European-American 
population (Cheng et al., 2005, Liu et al., 2005). 
Our overall data and stratified analyses by ethnicity showed that the 
BDNF Val66Met polymorphism was not associated with 
methamphetamine psychosis among the methamphetamine abusers, 
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suggesting that this polymorphism does not cause susceptibility to 
psychosis in male Malaysian methamphetamine-dependent subjects. 
This finding is in line with the study of Itoh et al. (Itoh et al., 2005) that 
showed that the BDNF gene was not associated with 
methamphetamine psychosis in a Japanese population. Results of this 
study however, showed a significant difference in allele frequency 
between those who developed psychosis and those who do not in the 
Chinese methamphetamine-dependent subjects. In contrast with the 
methamphetamine dependence, the risk for methamphetamine 
psychosis with the 66Val 196G allele was 0.2, while with 66Met 196A 
allele was 4.2 in Chinese methamphetamine-dependent subjects, 
whereas the methamphetamine dependence with the 66Val 196G 
allele was 2.6, suggesting that this 66Val allele is more likely to 
contribute to methamphetamine dependence in the male Chinese 
population but not for the methamphetamine psychosis. Moreover, 
66Met allele may contribute to methamphetamine psychosis but not to 
methamphetamine dependence. This may be due to variation in 
definitions of psychosis that is being used in the present study 
compared to the ones that are being used in other studies, and it may, 
in part, be due to the small sample size of the methamphetamine 
psychosis in the present study. Hall et al. (Hall et al., 2003) in an 
animal study showed that heterozygous BDNF-knockout mice 
displayed cocaine-conditioned place preferences and reduced 
locomotion during habituation after cocaine injections. He reported that, 
compared with 66Met carriers, 66Val/66Val carriers may have higher 
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levels of central BDNF, which increases the euphoric effect following 
methamphetamine administration and renders them more vulnerable to 
methamphetamine abuse. Our findings were similar to those of Hall et 
al. (Hall et al., 2003) in that more case subjects than control subjects 
had the 66 Val variant. There may be several explanations for the 
contrasting finding between the present study and that of Cheng et al 
(Cheng et al., 2005). It is possible that our finding is a false positive 
which is contributed by the impact of stratification on our results. 
However, this is not very likely because we do have a relatively 
homogenous group, especially in gender and the type of drug used, all 
our subjects being males (Table 4.3) who were on methamphetamine 
only. 
Limitation and Errors 
i). Adequacy of sample size  
The required minimal sample size for allelic test was 44 cases and 44 
controls, whereas minimal sample size for genotypic test was 56 cases 
and 56 controls. The calculated study sample was based on 80% 
power of the study for the stratification of ethnic. For this study, only 
Malay has maintained the power of study for allelic and genotypic test. 
As for Kadazan-Dusun and Bajau the study subjects was relatively 
small size, the number of control was 50% lesser than cases, and 
therefore the potential association cannot be determined.     
ii). Comparing findings with other studies 
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Other studies might not find the similar findings, either the studies have 
very different ethnic backgrounds or the sample size was small.  
4.6  Conclusions 
In conclusion, our results showed a significant difference in the allelic 
and genotype frequencies in the Malaysian Chinese population for both 
methamphetamine dependence and psychosis. Our findings suggest 
that the 66Val/66Val genotype of the BDNF Val66Met polymorphism is 
a risk factor for methamphetamine dependence. Besides that, the 
BDNF 66Met allele may contribute to a vulnerability to 
methamphetamine psychosis in the Chinese population. However our 
study failed to show any association between BDNF Val66Met 
polymorphism with occurrence of methamphetamine dependence, and 
with risk of psychosis in the other ethnic populations and total 
Malaysian population studied. Further study with a larger sample size 
may provide more evidence to confirm the genetic influence of BDNF in 
methamphetamine dependence. 
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Chapter FIVE:  Efficacy and Safety of Aripiprazole in the 
Treatment of Methamphetamine-Induced 
Psychosis: An Open Label Prospective Study 
 
 
 
5.1  Abstract 
Introduction: Methamphetamine-induced psychosis is one of the most 
widely known side effects associated with high-dose or chronic 
methamphetamine use. It has been reported that methamphetamine 
dependent users were three times more likely to experience psychotic 
symptoms than non-regular methamphetamine users. There is a great 
need for the treatment of methamphetamine-induced psychosis. 
Objectives:  The objective of this study was to explore the therapeutic 
effects and tolerability of aripiprazole in the occurrence of psychosis 
among methamphetamine-dependent patients.  
Methodology:  
Design: This was an open label single arm prospective study. 
Setting: Patients were recruited from the inpatient psychiatric 
wards and outpatient psychiatric clinic in University 
Malaya Medical Centre(UMMC), Kuala Lumpur.    
Patients: The study population included male or female with a 
current Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV) diagnosis of methamphetamine 
dependence. The patients must be having acute 
5 Aripiprazole and Methamphetamine-Induced Psychosis 
 
 133 
psychotic symptoms due to methamphetamine and the 
Clinical Global Impression severity (CGI-S) score must 
be > 4. Patient must be treatment naive and was not on 
any psychotrophics. 
Intervention: Eligible patients were treated with the initial dose of 5-10 
mg aripiprazole. From day 2 to day 14, aripiprazole was 
flexible dosed (5-15mg/day) at the discretion of the 
treating psychiatrist.   
Measures: The primary outcome measure was the Positive and 
Negative Syndrome Scale (PANSS) and Clinical Global 
Impression scale- Severity of Illness (CGI-S). Other 
scales included the Amphetamine Withdrawal 
Questionnaire scale (AWQ), Brief Substance Craving 
Scale (BSCS), Barnes Akathasia Scale (BAS), Simpson 
Angus Scale (SAS), Abnormal Involuntary Movement 
Scale (AIMS) and Hospital Anxiety Depression Scale 
(HADS).Mixed-effects model repeated-measures 
analysis was utilized to examine changes in outcome 
measures over time with the treatment aripiprazole. 
RESULTS:       A total of 49 patients were enrolled and started on 
aripiprazole. In all, 41 patients (83.7%) completed the study. At 
baseline the mean PANSS total score was 79.2 + 13.7 and the mean 
CGI-S score was 4.3 + 0.5. There was a statistically significant decline 
in the mean PANSS-total and CGI-S score over the course of the 
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study. The mean reduction was 27.6 ± 21.4 point (p < 0.05, 95% CI [- 
34.8, -20.4] from baseline at day 14 for total PANSS score and 2.0 ± 
1.2 point (p < 0.05, 95% CI [-2.4, -1.6) for CGI-S. At day 14 the mean 
PANSS total score was 51.6 ± 14.7 and the mean CGI-S score was 
2.3 ± 1.0. Aripiprazole was generally well tolerated during the study. 
Adverse events were reported in 10 (20.4%) patients. The reported 
adverse events were akathisia, insomnia, agitation, sedation and 
depression. 2 (4.1%) patients discontinued from the study due to 
akathisia. Most adverse events were mild to moderate in intensity. 
There was no serious adverse event during the study period. No 
statistically significant changes were noted with respect to BARS, SAS 
and AIMS.  
CONCLUSIONS:   This 2-week, open-label study shows that 
aripiprazole given once-daily improved the psychotic symptoms 
associated with methamphetamine dependence. The treatment was 
generally well tolerated with mild to moderate adverse events. In this 
study aripiprazole was an efficacious and safe option for the treatment 
of methamphetamine induce psychosis. 
Keywords: Methamphetamine dependence, Methamphetamine induce 
psychosis, Aripiprazole, Open label study, Safety, Efficacy, 
Psychosis 
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5.2  Introduction 
Methamphetamine can trigger psychotic symptoms in individuals with 
no past history of psychosis (Leduc and Mittleman, 1995). Culminating 
evidence has indicated that chronic use of methamphetamine 
gradually leads to the development of a psychotic state resembling 
paranoid schizophrenia (Sato, 1992, Iwanami et al., 1994). It has been 
reported that methamphetamine dependent users were three times 
more likely to experience psychotic symptoms than non-regular 
methamphetamine users (Mcketin et al., 2006b).   
Duration of methamphetamine induced psychosis  
Although methamphetamine induced psychiatric disorders are typically 
self-limited and usually abate on their own, treatment is still needed in 
cases of emergency situations (i.e. acute episodes of 
methamphetamine induced psychosis), as well as to prevent 
recurrence in long-term.  Recurrence of psychotic symptoms can occur 
due to continued use of methamphetamine or other drug use and also 
due to psychosocial stressors (Yui et al., 1997, Yui et al., 2000).  
In some cases psychosis may persist and around 5 -15% of users who 
developed methamphetamine psychosis fails to recover completely 
(Hofmann, 1983). When the psychotic symptoms persist and interfere 
with the patient’s social and occupational functioning, treatment should 
be targeted to psychiatric symptoms present (Larson, 2008).  
 
5 Aripiprazole and Methamphetamine-Induced Psychosis 
 
 136 
Medical management of methamphetamine psychosis 
Psychotic symptoms occur most often during intoxication; therefore, 
treatment of methamphetamine psychosis should focus on controlling 
medical and psychiatric symptoms while eliminating the offending 
substance (Larson, 2008).  
Medical therapy of methamphetamine induced psychosis involves 
stabilizing and minimizing the symptoms of psychosis (e.g. agitation). 
Firstly, methamphetamine need to be removed from the body (Larson, 
2008). To achieve this, charcoal, for example, can be used to eliminate 
methamphetamine from the gastrointestinal and circulatory systems. 
In emergency situation, clinicians normally select a high-potency 
antipsychotic (e.g. haloperidol) for administration, as antipsychotics 
help control psychotic symptoms and provide rapid tranquilization of 
the agitated patients (Larson, 2008). Table 5.1 below lists other types 
of treatment that can be rendered during an acute episode of 
methamphetamine-induced psychosis. 
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Table 5.1:  Treatment of acute methamphetamine induced psychosis  
Benzodiazepines 
(Lorazepam, 
Chlordiazepoxide) 
 Primarily used to sedate agitated patients 
 Available in oral, intravenous injection 
and intramuscular injection forms, 
allowing the drug to be used in 
emergency situations 
Opiate antagonists 
(Naloxone) 
 Inhibit the action of opiates  
Beta-blockers 
(Propanolol) 
 Useful in patients who are agitated, 
anxious, and hyper-arousable due to 
methamphetamine use 
 Temporarily used until methamphetamine 
is eliminated from the patient’s body 
system 
 In prolonged anxiety, non-addictive beta-
blockers may be helpful 
Expectorants 
(Ammonium chloride) 
 Mainly used to acidify the urine and 
increase methamphetamine excretion 
when intoxication from 
methamphetamines resulted in 
psychiatric and medical complications 
 Available in PO form; patient must be 
able to swallow or receive a nasogastric 
tube 
Adsorbents(Activated 
charcoal suspension) 
 Given through a nasogastric tube into the 
stomach 
 Absorb intentionally and accidentally 
ingested substances to prevent further 
absorption into the systemic circulation 
(Larson, 2008) 
Clinical evidence on treatment of methamphetamine psychosis 
To date, there is little empirical evidence on which to base treatment 
approaches to methamphetamine induced psychosis. Most published 
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treatment consists of case reports and small open label studies 
(Srisurapanont et al., 2001b). There is currently no approved 
medication by the Food and Drug Administration (FDA) or the 
Malaysian Drug Authority to be used in the treatment of 
methamphetamine induce psychosis. 
Two early studies showed that agitation and some psychotic symptoms 
may subside within an hour after an antipsychotic injection in 
methamphetamine users. The first study (Angrist et al., 1974) showed 
that haloperidol intramuscular administration significantly reduced the 
symptoms of excitement and paranoid ideation within an hour. The 
second study (Richards et al., 1998) demonstrated that droperidol (a 
butyrophenon) could sedate agitated methamphetamine users 
significantly faster than lorazepam after intravenous administration.  
Other than that, case studies of methamphetamine psychosis have 
reported good responses to olanzapine (Misra et al., 2000), risperidone 
(Misra and Kofoed, 1997) and quetiapine (Dore and Sweeting, 2006).   
Current research evidence available suggests that the most commonly 
used agents for the acute treatment of methamphetamine-induced 
psychosis are benzodiazepines and antipsychotics (Mcketin et al., 
2006b). In Australia, the most commonly prescribed antipsychotic was 
olanzapine, while in Thailand and the Philippines it was haloperidol 
(Mcketin et al., 2006a).    
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Aripiprazole in the treatment of methamphetamine induced 
psychosis   
Aripiprazole, the sixth atypical antipsychotic medication, was first 
approved by the Food and Drug Administration (FDA) in 2002 for the 
treatment of schizophrenia. Available as tablets for oral administration, 
aripiprazole is also indicated for the treatment of acute manic episodes 
associated with bipolar 1 disorder since 2004.   
Pharmacology of aripiprazole 
Unlike other atypical antipsychotics (e.g. olanzapine, quetiapine, 
risperidone) that act as antagonist at D2 dopamine receptors(Kapur, 
2004, Strange, 2001), aripiprazole appears to mediate its antipsychotic 
effects primarily by partial agonism at D2 receptors (Burris et al., 2002, 
Grunder et al., 2003, Yokoi et al., 2002), which are responsible for 
dopaminergic activity modulation. 
A partial agonist has a lower intrinsic activity at the receptors than a full 
agonist (i.e. the naturally occurring neurotransmitters), allowing it to act 
either as a functional agonist or a functional antagonist, depending on 
the surrounding levels of the intrinsic full agonist (Lieberman, 2004).  
In the absence of a full agonist, a partial agonist shows functional 
agonist activity – binding to the receptor to produce a response. In the 
presence of a full agonist, on the other hand, a partial agonist shows 
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functional antagonist activity – receptor binding reduces the response 
generated by the full agonist.  
This partial agonist effect stabilizes dopamine receptors while allowing 
a modulation of function, rather than blocking them exclusively (Stahl, 
2001). Therefore, partial agonists are also known as dopamine system 
stabilizers, which constitute a new class of antipsychotic agents 
without leading to apparent motor side effects (Stahl, 2001). 
It is the partial dopamine agonist effect of this drug that aripiprazole 
has been tested for its effects in reducing cocaine cravings in 
schizophrenic cocaine-dependent subjects (Beresford et al., 2005). It 
was hypothesized that aripiprazole acts either through lowering 
dopamine over-activity or through increasing dopamine under-activity, 
or through some combination of both. 
In addition, aripiprazole also functions as a partial agonist at the 
serotonin 5-HT1A receptors and, like the other atypical antipsychotics, 
displays an antagonist profile at the serotonin 5-HT2A receptors 
(Torrent, 2003). Aripiprazole has moderate affinity for histamine H1 
receptors and alpha1-adrenergic receptors, and no appreciable affinity 
for cholinergic muscarinic receptors (Torrent, 2003). Actions at 
receptors other than D2, 5-HT1A, and 5-HT2A may explain some of the 
other clinical effects of aripiprazole. For instance, the orthostatic 
hypotension observed with aripiprazole may be attributed to its 
antagonist activity at adrenergic alpha1 receptors (Torrent, 2003).
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Clinical pharmacokinetics of aripiprazole(Torrent, 2003)  
Aripiprazole activity is most likely due to the parent drug, aripiprazole, 
and to a lesser extent, to its major metabolite, dehydro-aripiprazole, 
which is also known to have affinities for D2 receptors. Dehydro-
aripiprazole represents 40% of its parent drug exposure in plasma.  
Steady-state plasma concentrations are achieved within 14 days of 
dosing for both aripiprazole and dehydro-aripiprazole. Both parent drug 
and active metabolite have elimination half-lives of 75 hours and 95 
hours, respectively. At steady state, the pharmacokinetics of 
aripiprazole is dose-proportional. 
Aripiprazole is well absorbed. Its maximum plasma concentration 
(CMax) is achieved within 3-5 hours after oral dosing, with an absolute 
oral bioavailability of 87%. Absorption of this drug is not affected by 
food. 
Aripiprazole undergoes extensive hepatic metabolism involving the 
cytochrome P450 isozymes CYP3A4 and CYP2D6. Aripiprazole is 
usually excreted in trace amount (<1%) in the urine, while about 18% 
of the oral dose is recovered unchanged in the feces.  
Co-administration of aripiprazole with medications that may inhibit (e.g. 
paroxetine, fluoxetine) or induce (e.g. carbamazepine) the metabolic 
enzymes may lead to an increase or a decrease of plasma 
concentrations of aripiprazole, respectively.  
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Aripiprazole in the treatment of psychiatric disorders   
The effects of aripiprazole in psychiatric disorders have been mainly 
investigated in schizophrenia. In schizophrenia, excessive dopamine 
activity is thought to cause positive symptoms, while reduced 
dopamine activity leads to negative symptoms and cognitive 
impairment. A partial agonist will act as a functional antagonist in the 
mesolimbic dopamine pathway where dopamine activity is excessive, 
but show functional agonist activity in the mesocortical pathway where 
dopamine activity is low (Lieberman, 2004). 
In addition, a partial agonist is likely to avoid complete blockade of the 
nigrostriatal or tuberoinfundibular pathways, which are associated with 
extra-pyramidal symptoms (EPS) and elevated prolactin levels, 
respectively (Lieberman, 2004).  
Clinical trials with aripiprazole have demonstrated the value of partial 
agonist treatment approach. Aripiprazole has been shown to produce 
significant improvements in positive and negative symptoms in short- 
and long-term studies of patients with schizophrenia or schizoaffective 
disorder (Lieberman, 2004).  
In both short- and long-term studies, aripiprazole treatment was well 
tolerated, showing a low liability for EPS and hyperprolactinemia, a 
lack of QTc prolongation, and minimal weight gain or sedation 
(Lieberman, 2004). 
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More recently, aripiprazole was shown to be useful in treating 
psychosis associated with Parkinson’s Disease (Keck et al., 2007) and 
preventing relapse in bipolar 1 disorder (Lopez-Meza et al., 2005), as 
well as an effective and safe adjunctive therapy to standard anti-
depressant treatment in patients with major depressive disorder 
(Marcus et al., 2008). 
The proven efficacy of aripiprazole in a number of psychiatric disorders 
thus provides a rationale for investigating this drug in the treatment of 
methamphetamine induced psychosis.   
Tolerability and safety of aripiprazole (Torrent, 2003) 
The most common adverse events associated with aripiprazole 
therapy include:   
 Insomnia, restlessness; 
 Headache, dizziness, akathisia, somnolence or sedation, tremor; 
 Blurred vision; 
 Tachycardia; 
 Orthostatic hypotension;   
 Nausea, vomiting, constipation, dyspepsia. 
Other adverse effects known to be associated with antipsychotic 
therapy have also been reported during treatment with aripiprazole, 
including (Torrent, 2003): 
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 Neuroleptic syndrome; 
 Tardive dyskinesia; 
 Seizure; 
 Cerebrovascular events and increased mortality in elderly 
demented patients; 
 Hyperglycemia and diabetes mellitus. 
Rare adverse events associated with aripiprazole are such as allergic 
reactions and a potentially fatal symptom complex known as 
neuroleptic malignant syndrome (NMS) (Torrent, 2003). Patients who 
develop NMS may have, among the symptoms, high fevers, muscle 
rigidity, rapid heart rate, excessive sweating and heart arrhythmias.   
Nevertheless, when compared with other typical antipsychotics for 
treating schizophrenia and schizophrenia-like psychoses, the latest 
Cochrane review (Bhattacharjee and El-Sayeh, 2008) revealed that 
aripiprazole, despite producing similar efficacy as typical antipsychotic 
drugs, presents significant advantages in terms of tolerability.  
There were fewer occurrences of extra-pyramidal symptom, and 
particularly akathisia, fewer incidences of hyperprolactinemia and 
raised fasting blood glucose, and lesser risk of sinus tachycardia and 
blurred vision in patients treated with aripiprazole compared with those 
who received typical antipsychotic therapy (Bhattacharjee and El-
Sayeh, 2008).  
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This favorable adverse effects profile of aripiprazole may help enhance 
its effectiveness in treatment compliance.  
While evidence clearly suggests aripiprazole to be a well-tolerated 
treatment in patients with psychiatric disorders, there is still little known 
about its tolerability in methamphetamine dependent subjects. 
Therefore, studies of the safety and efficacy of aripiprazole in this 
group of individuals are urgently warranted to determine its role in the 
treatment methamphetamine induced psychosis. 
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5.3   Systematic review on the efficacy and safety of aripiprazole 
in the treatment of methamphetamine-induced psychosis.  
5.3.1. Methods 
5.3.2. Search strategy  
This systematic review included literature published between January 
2000 and March 2011.  An electronic search on the following 
databases was carried out:  PUBMED, Web of Science, OVID Medline 
(R), the Cochrane Central Register of Controlled Trials and the 
Cochrane Database of Systematic Review, using the search terms: 
Systematic review 1 
(a) Methamphetamine or Methamfetamine 
(b) Aripiprazole  
(c) Drug-induced psychosis or psychoses  
Systematic review 2 
(a) Amphetamine  
(b) Aripiprazole  
(c) Drug-induced psychosis or psychoses  
Where Medical Subject Headings (MeSH) terms were available, they 
were exploded and combined. Reference lists from retrieved papers 
were also searched. 
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5.3.3. Type of studies  
Only publication in English for experimental studies (e.g. randomized 
clinical trials and quasi-randomized studies) and systematic review 
were included if: 
(a) Participants were treated with aripiprazole 
(b) Psychosis or changes in psychosis were measured in a 
standardised manner. 
5.3.4. Types of participant 
Male or female patients, of any age or ethnic origin, who has 
methamphetamine or amphetamine dependence and 
methamphetamine or amphetamine-induced psychosis. 
5.3.5. Types of intervention 
The treatment group was aripiprazole. 
5.3.6. Types of outcome measures  
The changes in psychosis, retention rate of the study, treatment 
response rate.  
5.3.7. Data extraction 
Information was extracted on data source such as participants, 
interventions, results and outcome.   
 
5.3.8. Results 
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A total of 2 experimental studies for methamphetamine-
inducedpsychosis and 1 experimental study for amphetamine-induce 
psychosis were identified by the search and cross-referencing 
strategies.  
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Figure 5.1   Flow chart showing the article-identification process for 
methamphetamine-induced psychosis   
 
 
 
 
  
 
 
 
 
Figure 5.2   Flow chart showing the article-identification process for 
amphetamine-induced psychosis    
 
 
 
 
  
 
 
 
 
Papers not meeting inclusion criteria 
based on abstract =2 (animal study)  
 
 
Final number of paper 
included in the study = 0 
Total number of potential 
relevant papers = 2 
Papers not meeting inclusion criteria 
based on abstract =1 (animal study)  
 
 
Final number of paper 
included in the study = 0 
Total number of potential 
relevant papers = 1 
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5.3.9. RESEARCH QUESTION 
What is the efficacy and safety of aripiprazole in the treatment of 
methamphetamine-induced psychosis patients?   
5.3.10. STUDY OBJECTIVES 
Primary Objective  
To determine the efficacy of aripiprazole in the treatment of 
methamphetamine-induced psychosis patients.  
Secondary objectives 
i). To determine the efficacy of aripiprazole using PANSS subscales in 
the treatment of methamphetamine-induced psychosis patients.  
ii). To determine the efficacy of aripiprazole in improving the 
methamphetamine withdrawal and craving symptoms among 
patients with methamphetamine-induced psychosis.  
iii). To determine the efficacy of aripiprazole in improving the 
depressive and anxiety symptoms among patients with 
methamphetamine-induced psychosis.  
Tertiary Objective 
i). To determine the safety of aripiprazole in the treatment of 
methamphetamine-induced psychosis patients. 
ii). To describe the adverse events of aripiprazole in the treatment of 
methamphetamine-induced psychosis patients.   
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5.3.11. HYPOTHESES 
Hypothesis for primary objective:   
i). Aripiprazole-treated patients will show a significant reduction in the 
means total Positive and Negative Symptoms Scale (PANSS) score 
between baseline and day 4. 
ii). Aripiprazole-treated patients will show a significant reduction in the 
means total Positive and Negative Symptoms Scale (PANSS) score 
between baseline and day 7. 
iii). Aripiprazole-treated patients will show a significant reduction in the 
means total Positive and Negative Symptoms Scale (PANSS) score 
between baseline and day 14. 
iv). Aripiprazole-treated patients will show a significant reduction in the 
means total Positive and Negative Symptoms Scale (PANSS) score 
between baseline and day 4, 7 and 14. 
Hypothesis for secondary objective:  
i). Aripiprazole-treated patients will show a significant reduction in the 
means positive symptoms PANSS subscale score between 
baseline and day 4. 
ii). Aripiprazole-treated patients will show a significant reduction in the 
means positive symptoms PANSS subscale score between 
baseline and day 7.  
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iii). Aripiprazole-treated patients will show a significant reduction in the 
means positive symptoms PANSS subscale score between 
baseline and day 14. 
iv). Aripiprazole-treated patients will show a significant reduction in the 
means negative symptoms PANSS subscale score between 
baseline and day 4. 
v). Aripiprazole-treated patients will show a significant reduction in the 
means negative symptoms PANSS subscale score between 
baseline and 7. 
vi). Aripiprazole-treated patients will show a significantly reduction in the 
means negative symptoms PANSS subscale score between baseline 
and day 14. 
vii). Aripiprazole-treated patients will show a significant reduction in the 
means general psychopathological PANSS subscale score 
between baseline and day 4. 
viii). Aripiprazole-treated patients will show a significant reduction in 
the means general psychopathological PANSS subscale score 
between baseline and day 7. 
ix). Aripiprazole-treated patients will show a significantly reduction in 
the means general psychopathological PANSS subscale score 
between baseline and day 14. 
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x). Aripiprazole-treated patients will show a significant reduction in the 
means Clinical Global Impression – Severity of Illness (CGI-S) 
scale score between baseline and day 4. 
xi). Aripiprazole-treated patients will show a significant reduction in the 
means Clinical Global Impression – Severity of Illness (CGI-S) 
scale score between baseline and day 7. 
xii). Aripiprazole-treated patients will show a significant reduction in the 
means Clinical Global Impression – Severity of Illness (CGI-S) 
scale score between baseline and day 14. 
xiii). Aripiprazole-treated patients will show a significant reduction in 
the means Clinical Global Impression – Severity of Illness (CGI-S) 
scale score between baseline and day 4, 7 and 14. 
xiv). Aripiprazole-treated subjects will show a significantly greater 
reduction in Amphetamine Withdrawal Questionnaire (AWQ) means 
score between baseline and day 4.  
xv). Aripiprazole-treated subjects will show a significantly greater 
reduction in Amphetamine Withdrawal Questionnaire (AWQ) means 
score between baseline and day 7.  
xvi). Aripiprazole-treated subjects will show a significantly greater 
reduction in Amphetamine Withdrawal Questionnaire (AWQ) means 
score between baseline and day 14.  
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xvii). Aripiprazole-treated subjects will show a significantly greater 
reduction in Amphetamine Withdrawal Questionnaire (AWQ) means 
score between baseline and day 4, 7 and 14.  
xviii). Aripiprazole-treated subjects will show a significantly greater 
reduction in Brief Substance Craving Scale (BSCS) means score 
between baseline and day 4. 
xix). Aripiprazole-treated subjects will show a significantly greater 
reduction in Brief Substance Craving Scale (BSCS) means score 
between baseline and day 7. 
xx). Aripiprazole-treated subjects will show a significantly greater 
reduction in Brief Substance Craving Scale (BSCS) means score 
between baseline and day 14. 
xxi). Aripiprazole-treated subjects will show a significantly greater 
reduction in Brief Substance Craving Scale (BSCS) means score 
between baseline and day 4, 7 and 14. 
xxii). Aripiprazole-treated subjects will show a significantly greater 
reduction in Hospital Anxiety Depression Scale (HADS) means 
scores between baseline and day 14. 
Hypothesis for tertiary objective:  
Aripiprazole-treated patients will not show a significant increase in 
Barnes Akathasia Scale (BAS), Simpson Angus Scale (SAS) and 
Abnormal Involuntary Movement Scale (AIMS) scores between 
baseline and day 4, 7 and 14.  
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5.4  Methodology 
5.4.1. Study Design 
           This study was an open-label single arm prospective study.   
5.4.2. Study Period 
The study period was from July 2007 until June 2011. Data was 
collected from September 2008 to December 2010.  
5.4.3. Location of Study 
This study was conducted at the inpatient psychiatric wards and 
outpatient psychiatric clinic in University Malaya Medical Centre 
(UMMC).  
5.4.4. Study Population 
The study population included males or females with a current 
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) 
diagnosis of methamphetamine dependence.  
5.4.5. Inclusion Criteria  
i). Male or female, aged 18 – 65 years.  
ii). Patient with moderate to severe psychosis with CGI-S  ≥ 4.   
iii). Severity score of at least 4 on at least one of the Positive and 
Negative Symptoms Scale (PANSS)-items: P1 – Delusions, P3 - 
Hallucinatory behaviour, P4 – Excitement, P6 – 
Suspiciousness/persecution, or G9 – Unusual thought content. 
5 Aripiprazole and Methamphetamine-Induced Psychosis 
 
 156 
iv). Duration of psychosis for more than 2 weeks.   
v). Must have been using methamphetamine at least once a week for 
the past three months at enrollment. 
vi). Urine positive for methamphetamine and within 30 days of last use 
of the methamphetamine. 
vii). Patient must be treatment naῖve, was not on any psychotrophics. 
viii). Patient must not have current dependence with other substances 
such as alcohol, cocaine, opiates and marijuana. However, the past 
history abusing of these drugs was allowed for this study. 
ix). Present without any current intoxification effects of 
methamphetamine to provide written informed consent at the time 
of the baseline session and to comply with study procedures. 
x). Using a barrier (diaphragm or condom) with spermicide, 
intrauterine device (IUD), or complete abstinence as a method of 
birth control (if a woman of child-bearing capacity).  
xi). Patient was not suicidal or homicidal. 
5.4.6. Exclusion Criteria 
i). Serious medical illnesses that potentially progress to life-
threatening medical illness which may compromise patient safety or 
study conduct. 
ii). Known hypersensitivity or allergy to Aripiprazole. 
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iii). Documented history of schizophrenia, bipolar, organic brain 
disease, dementia, or any diseases that require other 
antipsychotics.  
iv). Unstable diabetes mellitus 
v). An absolute neutrophil count (ANC) of of ≤ 1.5 x 109 per liter;  
vi). Abnormal ECG. 
vii). Clinically significant abnormal laboratory values. 
viii). Female who is positive on a urine pregnancy test or lactating. 
5.4.7. Sample size estimation 
Based on previous study (Leucht et al., 2006), the minimum sample 
size required for this study was calculated by using the PS software.  
i). The power of the study is taken at 80% level for paired t-test of 
PANSS score.  
ii). The significance level of the statistic tests done was at 95% 
Confidence Interval level and  was set at 0.05. The Null 
hypothesis was rejected when p < 0.05. 
iii). Δ – the difference in the mean of matched pairs is 10 for PANSS score. 
iv). Σ – the standard deviation of difference in the response of 
matched pairs is 20. 
Therefore the sample size obtained for this study as follow: 
Total number of subjects = 33 patients 
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5.4.8. Study Variables 
The study variables that were considered for analysis in this 
study population were as follows: 
(Operational definitions and scale in ANNEX A) 
5.4.9. Primary Study Endpoints  
The efficacy of aripiprazole in the treatment of methamphetamine 
induce psychosis:  
i). The means scores of total PANSS rating scale   
Patients were assessed between baseline and day 4, 7 and 14.   
5.4.10. Secondary Study Endpoint 
i). The means scores of positive symptoms PANSS subscale 
ii). The means scores of negative symptoms PANSS subscale  
iii).  The means scores of general psychopathological PANSS subscale 
iv). The means scores of CGI-S rating scale 
v). The means scores of Amphetamine Withdrawal Questionnaire 
(AWQ) scale.  
vi). The means scores of Brief Substance Craving Scale (BSCS) scale.  
vii). The means scores of Hospital Anxiety Depression Scale (HADS) 
scale.(only day 14) 
Patients were assessed between baseline and day 4, 7 and 14.    
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5.4.11. Tertiary Study Endpoint  
The safety of aripiprazole in methamphetamine induce psychosis: 
i). The means scores of BAS rating scale  
ii). The means scores of SAS rating scale  
iii). The means scores of AIMS rating scale  
iv). To describe all adverse events reported by patients during the 
study. 
Patients were assessed between baseline and day 4, 7 and 14.     
5.4.12. Descriptive Variables 
Sociodemographic and Baseline Characteristics 
i). Age  
ii). Sex  
iii). Race 
iv). Marital status 
v). Educational level 
vi). Employment pattern   
vii). Duration of full time employment 
viii). Total family income 
ix). Methamphetamine use history 
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x). History of medical/surgical illness 
5.4.13. Study Instruments 
i). MINI International Neuropsychiatric Interview (M.I.N.I.) 
(Sheehan et al., 1998b) 
This was a face-to-face structured interview for the Major Axis I 
psychiatric disorder in DSM-IV and ICD-10. The M.I.N.I. is a short 
structured diagnostic interview for DSM-IV or ICD-10 psychiatric 
disorders for the Major Axis I psychiatric disorder including suicidality. 
It has been widely used in international clinical trials and 
epidemiological studies (Joling et al., 2008, Van't Veer-Tazelaar et al., 
2009). The MINI was available in local language (Sheehan et al., 
1998a). 
ii). Amphetamine Withdrawal Questionnaire (AWQ) (James et 
al., 2004) 
A short, reliable and valid questionnaire for the evaluation of 
amphetamine withdrawal symptom. Items of the AWQ were based on 
the fourth edition of the Diagnostic and Statistical Manual for Mental 
Disorders (DSM-IV) and a comprehensive review. A field trial for 
assessing the reliability, validity and factor structure was conducted in 
outpatients and inpatients with amphetamine withdrawal. The AWQ 
internal consistency was satisfactory with a Cronbach’s alpha of 0.77. 
For test-retest reliability, a Spearman rank order correlation coefficient 
of the AWQ total score was 0.79. The AWQ total score for criterion 
5 Aripiprazole and Methamphetamine-Induced Psychosis 
 
 161 
validity was moderately correlated with the other two accepted 
measures. Principal component analysis, eigenvalue-one test and a 
varimax rotation performed to elicit the factors of AWQ yielded a three-
factor model of AWQ: namely hyperarousal, reversed vegetative and 
anxiety factors.   
iii). Brief Substance Craving Scale (BSCS) (Somoza E, 1999a)  
The BSCS uses Likert scales, ranging from 0 to 4, to assess 
methamphetamine craving on 3 dimensions of craving: intensity, 
length, and frequency. A composite score is derived from the total of 
these items. 
iv). Positive and Negative Symptoms Scale (PANSS) (Kay et al., 
1987) 
The Positive and Negative Syndrome Scale(PANSS) is a medical 
scale used for measuring symptom severity of patients with 
schizophrenia. It refers to the two types of symptoms in schizophrenia, 
as defined by the American Psychiatric Association: positive 
symptoms, which refer to an excess or distortion of normal functions 
(e.g. hallucinations and delusions), and negative symptoms, which 
represent a diminution or loss of normal functions. A face-to-face 
interview of the scale will capture three components: positive scale (7 
items), negative scale (7 items) and general psychopathology scale(16 
items). 
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v). Abnormal Involuntary Movement Scale (AIMS) (Rush, 2000) 
The Abnormal Involuntary Movement Scale (AIMS) is a rating scale 
that was originally designed in Italian language in the 1980s (Burti et 
al., 1981), to measure involuntary movements known as tardive 
dyskinesia (TD). TD is a disorder that sometimes develops as a side 
effect of long-term treatment with neuroleptic (antipsychotic) 
medications. The AIMS test is used not only to detect tardive 
dyskinesia but also to follow the severity of a patient’s TD over time. It 
is a valuable tool for clinicians who are monitoring the effects of long-
term treatment with neuroleptic medications and also for researchers 
studying the effects of these drugs. The AIMS test was originally 
developed for administration by trained clinicians. 
Description  
The entire test can be completed in about 10 minutes. The AIMS test 
has a total of twelve items rating involuntary movements of various 
areas of the patient’s body. These items are rated on a five-point scale 
of severity from 0–4. The scale is rated from 0 (none), 1 (minimal), 2 
(mild), 3 (moderate), 4 (severe). Two of the 12 items refer to dental 
care. The patient must be calmed and sitting in a firm chair that doesn’t 
have arms, and the patient cannot have anything in his or her mouth. 
The clinician asked the patient about the condition of his or her teeth 
and dentures, or if he or she was having any pain or discomfort from 
dentures.  
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The remaining 10 items refer to body movements themselves. In this 
section of the test, the clinician or rater asked the patient about body 
movements. The rater also looked at the patient in order to note any 
unusual movements first-hand. The patient was asked if he or she had 
noticed any unusual movements of the mouth, face, hands or feet. If 
the patient said yes, the clinician then asked if the movements annoy 
the patient or interfere with daily activities. Next, the patient was 
observed for any movements while sitting in the chair with feet flat on 
the floor, knees separated slightly with the hands on the knees. The 
patient was asked to open his or her mouth and stick out the tongue 
twice while the rater watched. The patient was then asked to tap his or 
her thumb with each finger very rapidly for 10–15 seconds, the right 
hand first and then the left hand. Again the rater observed the patient’s 
face and legs for any abnormal movements.  
After the face and hands had been tested, the patient was then asked 
to flex (bend) and extend one arm at a time. The patient was then 
asked to stand up so that the rater can observe the entire body for 
movements. Next, the patient was asked to extend both arms in front 
of the body with the palms facing downward. The trunk, legs and 
mouth were again observed for signs of TD. The patient then walked a 
few paces, while his or her gait and hands were observed by the rater 
twice. 
A rating of 2 or higher on the AIMS scale, however, is evidence of 
tardive dyskinesia. If the patient has mild TD in two areas or moderate 
movements in one area, then he or she should be given a diagnosis of 
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TD. The AIMS test is considered extremely reliable when it is given by 
experienced raters. 
vi). Barnes Akathasia Scale (BARS) (Barnes, 1989)  
The Barnes Akathisia Scale (commonly known as BAS or BARS) is a 
rating scale that is administered by physicians to assess the severity of 
drug-induced akathisia. The Barnes Akathisia Scale is the most widely 
used rating scale for akathisia. This scale includes objective and 
subjective items such as the level of the patient’s restlessness. It 
comprises items for rating the observable, restless movements which 
characterise the condition, the subjective awareness of restlessness, 
and any distress associated with the akathisia. In addition, there is an 
item for rating global severity. A standard examination procedure is 
recommended. The inter-rater reliability for the scale items (Cohen’s 
kappa) ranged from 0.738 to 0.955. 
Akathisia is a syndrome of motor restlessness, principally seen in 
association with antipsychotic medication. It is characterized by a 
subjective experience of mental unease and the urge to move, and 
manifests physically as particular patterns of restless movement. 
vii). Simpson Angus Scale (SAS) (Simpson and Angus, 1970)  
Simpson-Angus Scale (SAS) is a 10-item rating scale that has been 
used widely for assessment of Neuroleptic-Induced Parkinson in both 
clinical practice and research settings. It consists of one item 
measuring gait (hypokinesia), six items measuring rigidity and three 
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items measuring glabella tap, tremor and salivation, respectively. Items 
are rated for severity on a 0-4 scale, with definitions given for each 
anchor point. It is an established rating scale. SAS is a reliable and a 
valid instrument. It performs well and similarly to DSM-IV in Neuroleptic 
Induce Parkinsonism case detection (Janno et al., 2005). 
viii). Clinical Global Impression Scale – Severity of Illness (CGI-S)   
The Clinical Global Impression rating scales are commonly used 
measures of symptom severity, treatment response and the efficacy of 
treatments in treatment studies of patients with mental disorders(Guy, 
1976). Many researchers, while recognizing the validity of the scale, 
consider it to be subjective as it requires the user of the scale to 
compare the subjects to typical patients in the clinician experience 
(Huber et al., 2008, Haro et al., 2003). 
The Clinical Global Impression – Severity scale (CGI-S) is a 7-point 
scale that requires the clinician to rate the severity of the patient’s 
illness at the time of assessment, relative to the clinician’s past 
experience with patients who have the same diagnosis. Considering 
total clinical experience, a patient is assessed on severity of mental 
illness at the time of rating 1=normal, not at all ill; 2, borderline 
mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; 
or 7, extremely ill. 
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ix). Hospital Anxiety Depression Scale (HADS)  
The Hospital Anxiety and Depression Scale (HADS) was developed by 
Zigmond and Snaith (Zigmond and Snaith, 1983) in 1983. Its purpose 
is to provide clinicians with an acceptable, reliable, valid and easy to 
use practical tool for identifying and quantifying depression and 
anxiety. The role of the scale is dimensional rather than categorical; it 
is best used not to make diagnoses of psychiatric disorders, but for 
identifying general hospital patients who need further psychiatric 
evaluation and assistance(Herrmann, 1997). 
The HADS is a self-report rating scale of 14 items on a 4-point Likert 
scale (range 0–3). It is designed to measure anxiety and depression (7 
items for each subscale). The total score is the sum of the 14 items, 
and for each subscale the score is the sum of the respective seven 
items (ranging from 0–21). It is worth noting that items referring to 
depression symptoms that describe somatic aspects of depression 
(e.g. insomnia and weight loss) are not included in the scale. 
The HADS has been translated and widely used in more than 25 
countries since its original development. Herrmann, in an extended 
review, reported that the HADS has demonstrated reliability and 
validity when used to assess medical patients (Herrmann, 1997). 
Bjelland reached similar conclusions in his review 5 years 
later(Bjelland et al., 2002). The HADS has been used in the general 
population(Mykletun et al., 2001), on general hospital patients 
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(Johnston et al., 2000), in cancer care settings (Moorey et al., 1991), 
and even in HIV patients (Savard et al., 1998). 
x). Structured Questionnaires 
The patient baseline characteristics were obtained by using a 
structured questionnaire. The information such as demographic data, 
history of methamphetamine use, past medical and surgical history 
were recorded in case record form (CRF).    
5.4.14. Study Drug  
5.4.14.1 Intervention 
Aripiprazole is a psychotropic drug. It is a light yellow colored, round, 
flat,  evelled edged, uncoated tablets that contain 10mg of 
aripiprazole.  
5.4.14.2 Concomitant Therapy  
The concomitant medications such as benzodiazepine and benzhexol 
were allowed for this study.  
Commitment therapy that was not permitted during the study was:  
i). Carbamazepine  
i). Ketoconazole  
ii). Quinidine  
iii). Fluoxetine  
iv). Paroxetine 
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5.4.14.3 Receiving, Storage, Dispensing and Return 
i). Receipt of Drug Supplies 
Study drug (intervention) was supplied in bulk shipments by a 
pharmaceutical company. An inventory was performed after accepting 
the drug shipment. The study coordinator counted and verified that the 
shipment contained all the items mentioned in the supply. The 
investigator would notify the pharmaceutical company of any damage 
of the study drug.  
ii). Storage 
Stock study drug was stored in a locked cabinet in the research centre 
with climate control maintaining the temperatures within a range of 
20°C to 25°C. Only the study coordinator and principal investigator 
have accessed to the study drug.  
iii). Dispensing of Study Drug 
The principal investigator or study coordinator would dispense the 
appropriate amount of study drug, according to the number of day of 
follow up. Subject compliance monitoring was conducted by doing pill 
counts at every study visit for all patients. 
iv). Return of Study Drug 
At the completion of the study, the final reconciliation of drug shipped, 
drug consumed and drug remaining was done. After appropriate 
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accounting the pharmaceutical company was informed, the unused 
study drug was returned to the pharmaceutical company.    
5.4.15. Conduct of study 
i). Pre-test 
A pre-test of the structured questionnaires was done on 10 patients 
who were attending the substances dependence clinic at UMMC. 
Some corrections were made to facilitate patients’ understanding of the 
questionnaires. 
ii). Training of study coordinator 
The study coordinator was trained regarding the screening, recruitment 
and interviewing of the study patient for the baseline characteristics. 
She was also trained about the procedure in handling the study drug.          
iii). Subject recruitment and screening 
All inpatient and outpatient with psychotic symptom due to substance 
dependence were approached during this study. Some of the patients 
were recruited from the response of this study newspaper 
advertisement, and articles written up by principal investigator in 
newspaper pertaining to methamphetamine-induced psychosis. A Mini 
International Neuropsychiatric Inventory (M.I.N.I.) was administered to 
obtain DSM-IV diagnosis of methamphetamine dependence and to rule 
out Major Axis I psychiatric disorders. Urine toxicology was done and 
only patients with urine positive for methamphetamine during 
screening were included in this study. 
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The patients were briefed on this study and written consent was 
obtained. Prior to the consent, patient was provided with a detailed 
information about aripiprazole, the rationale for why it was being 
studied, frequency of dosing, and length of treatment, potential 
benefits, side effects and risks, safeguards and emergency 
procedures. The collections of all laboratory specimens were described 
in detail, as the number and frequency of the research interviews and 
self-assessments. Patients were assured that their participation was 
voluntary and that withdrawal from the study would not jeopardize 
current or future treatment.  
 All medications taken by the patient for the 30 days prior to screening 
was documented. A face-to-face interview was conducted to collect 
primary data by using a structured questionnaire. Some secondary 
data pertaining to medical and surgical history were obtained from 
patient’s case note. A complete physical examination was done 
including vital signs and weight and ECG was performed. The principal 
investigator confirmed and signed off on the inclusion and exclusion 
criteria on a case report form (CRF) prior to the patient formally 
recruited in the study or given study medication. 
iv). Baseline visit 
The patients were further evaluated with Positive and Negative 
Symptoms Scale (PANSS), Clinical Global Impression Scale– Severity 
of Illness (CGI-S), Amphetamine Withdrawal Questionnaire (AWQ), 
Brief Substance Craving Scale(BSCA), Abnormal Involuntary 
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Movement Scale(AIMS), Barnes Akathasia Scale(BAS), Simpson 
Angus Scale(SAS) and Hospital Anxiety Depression Scale(HADS). A 
urine pregnancy test was conducted for female patients with 
childbearing capability. 
v). Treatment 
Eligible patients enrolled on Day 1 were treated with aripiprazole for 14 
days. Aripiprazole was administered orally, once daily. The initial dose 
was given when the patient entered treatment; morning doses were 
preferred to give maximum drug concentration during daytime. 
The initial dose was 5-10 mg. From Day 2 to Day 14, the dose of 
aripiprazole could be adjusted at 5 mg/day, 10 mg/day, or 15 mg/day 
at the investigator’s discretion based on subject’s clinical response and 
tolerability. 
Lorazepam could be administered to treat agitation and anxiety, up to 
6 mg/day, but not to be given in the morning before scheduled 
assessments. Zolpidem tartrate (up 10 mg/day was permitted to treat 
sleep disturbance throughout the study; all other sleep medications 
were prohibited. Antidepressant (SNRIs/SSRIs) was also allowed 
except for fluoxetine and paroxetine. Anticholinergics could be used to 
treat emergent EPS but prophylactic use was not permitted. 
The introduction of other antipsychotic or psychoactive drugs during 
the study was prohibited, and must be discontinued at least 1 week 
before Day 1. Use of drugs that induce or inhibit the hepatic 
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metabolising cytochrome 3A4 enzymes were also not permitted from 
14 days prior to Day 1 until the end of treatment period. Depot and 
long-lasting antipsychotics must be stopped within at least two and 
preferably three dosing intervals prior to Day 1 and are prohibited 
during treatment period. 
The patients were hospitalised if required for treatment and 
assessment based on the investigator’s judgement. If patient was 
hospitalised, patient could be discharged from the hospital if the 
investigator believed that it was clinically appropriate to discharge the 
patient, and the patient could reasonably be expected to continue in 
the study on an outpatient basis. 
vi). Follow-Up Evaluation  
A follow-up evaluation was scheduled on day 4, 7 and 14 after the 
beginning of the study. If subjects could not attend the scheduled visit, 
subject was given appointment on the subsequent day.  
 At each follow-up evaluation, patients were assessed with Positive 
and Negative Symptoms Scale (PANSS) and Clinical Global 
Impression Scale-Severity of Illness (CGI-S). The methamphetamine 
withdrawal symptoms were assessed using Amphetamine Withdrawal 
Questionnaire (AWQ) Rating Scale and Brief Substance Craving Scale 
(BSCA). Any adverse event was recorded and patients were also 
evaluated with Abnormal Involuntary Movement Scale (AIMS), Barnes 
Akathasia Scale (BAS) and Simpson Angus Scale (SAS). For Hospital 
Anxiety Depression Scale (HADS) the assessment was on day 14.  
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If subjects experienced significant side effects from aripiprazole, the 
principal investigator would have the option to reduce the dose for 
aripiprazole, depending on the clinical interview. Acceptable dose 
reduction for aripiprazole was from one tablet per day (10 mg/day) to 
half tablets per day 5 mg/day. Upward titration following a dose 
reduction was allowed during the trial. Dose titration was documented 
in the study chart along with the clinical rationale. At the end of the 
study drug treatment period, study drug was discontinued without 
tapering. 
The concomitant medications were reviewed.  Finally pill count was 
done, the unused study drug was collected from the previous follow up 
and dispensed the new study drug. During the study visit, the study 
termination form was completed in case of discontinuation of patient 
from this study (Table 5.1). 
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Table 5.2: Study visit plan for the treatment of aripiprazole among 
methamphetamine-induced psychosis patients 
 
Visit 1 2 3 4 5 
Visit Description Screening Treatment 
Started 
  Final 
visit 
Day < Up to – 1 day 1 4 7 14 
Visit Window (± No. Days)     ± 2 
Informed consent X     
Medical history X     
Inclusion/Exclusion 
criteria 
X X    
Physical examination X    X 
Vital signs/Weight X X X X X 
Urinalysis/Drug Test X     
PANSS X X X X X 
CGI-S  X X X X X 
AWQ  X X X X 
BSCS  X X X X 
HADS  X   X 
AIMS  X X X X 
SAS  X X X X 
BARS  X X X X 
Dispense study medication  X X X X 
Concomitant medication X X X X X 
Adverse events X X X X X 
 
vii). Subject Compliance Monitoring 
The research coordinator conducted pill counts at the follow-up visit of 
all study patients. Unused amounts were documented. Proper drug 
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dosing were reviewed with patients at each visit with clear instructions 
to take all study drugs as directed. 
viii). End of medication evaluation 
This evaluation was scheduled on the day 14 study drug treatment 
period. At this meeting, the following evaluations were completed:  
1) PANSS 
2) CGI-S 
3) AWQ 
4) BSCS 
5) BARS 
6) SAS 
7) AIMS 
8)HADS 
9) Physical examination  
10) Vital signs  
 
5.4.16. Early withdrawal of subjects 
Any patients experiencing a serious adverse event felt to be related to 
study drug were withdrawn from the study. Patients were also 
withdrawn if they required hospitalization for addiction or psychiatric 
treatment, received other psychotropic medications, or if 
discontinuation from the study was deemed by the principal 
investigator based on their best interest. Any patient withdrawing their 
consent to participate in the study or their authorization to use their 
protected health information was withdrawn from the study. Patients 
discontinued from the clinical trial were given appropriate treatment 
referrals to the outpatient psychiatric clinic, UMMC. Patients were 
instructed to return all unused medications. For the early withdrawal, 
patients had all final assessments that originally were scheduled for 
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the end of study visit. Patients withdrawn might be replaced, at the 
discretion of the principal investigator. 
All patients were included in the final study analyses. Patients were not 
dropped from any study activities unless they requested not to be 
contacted or could not be located for the 1-week follow-up 
assessment. Patients were informed at the consent session that 
treatment might be discontinued due to:  
i). Intolerable side effects 
ii). Development or exacerbation of psychiatric symptoms 
necessitating inpatient admission or a more aggressive 
therapeutic intervention than was provided by the protocol  
iii). Methamphetamine or other substance abuse necessitating 
inpatient admission or a more aggressive treatment than was 
provided by the protocol 
iv). Clinical deterioration for any reason or any clinical status that 
necessitates inpatient admission 
v). Incarceration for more than 1 week 
vi). Failure to attend 2 consecutive outpatient evaluation visits 
vii).  Failure to provide laboratory specimens 
Reasons why patients discontinued from the clinical trial were 
documented on the Study Termination Form, along with any referrals 
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that were made. A final safety evaluation was conducted as soon as 
possible on all patients who have been discontinued from the study.  
5.4.17. Safety and Adverse Events  
Recording of Adverse Events 
During the research evaluation visit, the patient was asked on adverse 
events through specific questioning and by examination. Information 
on all adverse events was recorded immediately in the case report 
form (CRF). Each adverse event was followed up until resolution or 
stabilization has been achieved. 
In the case of the occurrence of serious adverse event (SAE), it was 
followed up to determine the final outcome. Any serious adverse event 
that occurred after the study period was considered possibly related to 
the study drug, was recorded and reported immediately.   
5.4.17.1 Reporting of Serious Adverse Events 
Ethic Committee (EC) Notification by Principle 
Investigator 
A serious adverse event must be reported to the EC within 24 hours 
(one working day) of the event. The principal investigator would keep a 
copy of the SAE form in the file. Within the following 48 hours, the 
principal investigator would provide further information and progress on 
the serious adverse event to the EC.   
In the SAE form, the following information should be provided: 
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i). Study identifier 
ii). Subject number 
iii). A description of the event 
iv). Date of onset 
v). Current status 
vi). Whether study treatment was discontinued 
vii). The reason why the event was classified as serious 
viii). Principle investigator assessment of the association between 
the event and study drug 
5.4.17.2 Medical Monitoring 
The principal investigator was responsible to oversee the safety of the 
study. This safety monitoring would include careful assessment and 
appropriate reporting of adverse events. Medical monitoring would 
include a regular assessment of the number and type of serious 
adverse events. 
6.4.14.5 Protection of Subjects 
Additional procedures would be conducted to protect the safety of the 
study patients. Potential patients would be screened for medical 
illnesses that would preclude the use of aripiprazole. Patients selected 
for the study would be evaluated for AE while receiving study drug. 
Venipuncture was carried out with good aseptic technique by an 
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experienced nurse or physician. Before initiating study medication, a 
physical examination, ECG and a urine pregnancy test (if female of 
childbearing capability) were performed. Patients were given a 24-hour 
emergency number form them to call if necessary. The principle 
investigator would follow all patients who were discontinued due to a 
serious AEs until the AE resolved and become completely stable, 
unless a referral to another physician or specialist was clinically 
indicated or requested by the patient.  
5.4.18. Data Handling and Record Keeping 
i). Data Management 
The data were checked before ending each interview session and 
before compilation to ensure completeness. If missing data was found, 
the patient will be contacted through telephone. Raw data obtained 
were coded and entered into Statistical Package for Social Sciences 
(SPSS) Version 16.0. The data were summarized by running 
frequency distributions and simple descriptive statistics (means and 
standard deviations). Cleaning for double entry and outliers before 
analysis was done.   
ii). Confidentiality 
Information about study patients was kept confidential and managed 
according to the requirements of the EC.  
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iii). Source Data and Case Report Form 
Source data was all information, original records of clinical findings, 
observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data were contained 
in source documents such as hospital records, clinic charts, laboratory 
results, pharmacy dispensing records, recorded data from automated 
instruments, microfilm or magnetic media, x-rays, subject files, records 
kept at the pharmacy, at the laboratories, at medical record department 
and other related documents. 
The study case report form (CRF) was the primary data collection 
instrument for the study. All data requested on the CRF were recorded 
and all missing data were explained. “N/D” was written if a space on 
the CRF was left blank because the procedure was not done or the 
question was not asked. “N/A” was written if the item was not 
applicable to the individual case. All entries should be printed legibly in 
black ink. If any entry error has been made, to correct such an error, a 
single straight line was drawn through the incorrect entry and the 
correct data was entered above it. All such changes were initialed and 
dated.  
5.4.19. Statistical Analysis 
i). Univariate analyses 
Descriptive statistics were used to summarize demographic variables, 
past medical and surgical history, history of drug use and adverse 
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events. For nominal independent variables, they were described in the 
form of frequencies and percentages. For continuous independent 
variables, they were summarized and described as means, standard 
deviations and median.  
ii). Bivariate analysis   
The paired t-test was used to examine changes in PANSS and 
subscale,CGI-S, AWQ, BSCS, BARS, SAS and AIMS scores, by 
pairing scores at i) baseline before initiating aripiprazole and those at 
day 4, ii) baseline before initiating aripiprazole and those at day 7,and 
iii) baseline before initiating aripiprazole and those at day 14. The 
paired t-test HADS rating scale was between baseline before initiating 
aripiprazole and those at day 14. An alpha level of significance 0.05 
was set for all analyses.     
iii). Multivariate Analysis  
To examine changes in PANSS total,CGI-S, AWQ and BSCS scores 
over time we employed  mixed-model repeated measures (MMRM).  
The dependent variables were the total PANSS total,CGI-S, AWQ, 
BSCS scores. Time (four levels, ie, at baseline and at day 4, 7 and 14)  
were fitted as main effects for MMRM. 
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5.5  Results  
Patients 
In total, 145 patients were screened and 73 were eligible. However 
only 49 agreed to participate and proceeded to receive the study 
medication. Out of the 49 patients who received the study medication, 
8 (16.3%) discontinued treatment early due to: loss to follow up (n=4), 
adverse event/akathisia (n=2), withdraw consent (n=1) and detention 
by the police (n=1). Forty-one patients completed the study (Figure 
5.3).  
There were more male than female patients in the study (46 vs 3); 
Malay and Chinese patients accounted for more than 85.7% of subject 
population. Mean age of patients was 34.2±8.4 (SD) years. Only 
38.8% of the patients were married, while the rest were either single or 
divorced. Majority of the patients received education up to secondary 
level and have fulltime job. The mean income for the patients was RM 
3,310 per month (Table 5.3). 
Based on the DSM-IV Diagnosis Criteria, all the subject fulfilled the 
criteria for methamphetamine dependence. Three patients (6.1%) had 
medical history; two were in the past being treated for pneumonia and 
hepatitis C respectively, and one was under current medication for the 
condition of HIV. Two patients (4.1%) had surgical history in the past 
but were not under any current medication.  
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The key baseline characteristics, including efficacy and safety baseline 
measurements of PANSS scores CGI scores, HADS scores, BSCS 
scores, AWQ scores, BARS scores, SAS scores and AIMS scores of 
study subjects were summarized in Table 5.4.
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Figure 5.3   Disposition of patients in the treatment of aripiprazole 
for methamphetamine-induced psychosis 
Screened 
N = 145  
Received 
Treatment 
N = 49 (100.0%) 
Failed Screening 
N = 72   
Reasons for failed screening: 
Other Psychotic disorder N= 46 
Poly-substance abuse  N= 23 
Unstable medical illness N=3 
 
 
Discontinued treatment early 
N = 8 (16.3%) 
Reasons for discontinuation  
Loss to follow up   4 (8.2%) 
Adverse events   2 (4.1%) 
Withdraw consent   1 (2.0%) 
Detention by police   1 (2.0%)  
   
Completed study 
N = 41 (83.7%) 
Fulfil inclusion criteria 
and does not have 
exclusion criteria 
N=73 
Decline participation 
N=24 
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Table 5.3:  Socidemographic and drug history of methamphetamine-
induced  psychosis subjects  
Demographic characteristics 
 
N=49 
 
 
Sex, n (%) 
Male 
Female 
 
46 (93.9) 
    3 (6.1) 
Age, mean years (SD) 34.2 (8.4)  
 
Race, n (%) 
Malay 
Chinese 
Indian 
 
 
 
30 (61.2) 
12 (24.5) 
 7 (14.3) 
Marital Status, n (%) 
              Married 
              Single 
              Divorced 
 
Education Level, n (%) 
              Tertiary 
              Secondary 
              Primary 
 
Employment Pattern, n (%) 
               Full Time Job 
               Part Time Job 
               Student 
               Unemployed    
 
Duration of Employment, mean years (SD) 
 
Income, mean Ringgit Malaysia (SD) 
  
19 (38.8) 
24 (48.9) 
 6 (12.3) 
 
 
9 (18.4) 
   37(75.5) 
       3(6.1) 
 
 
38 (77.6) 
    1 (2.0) 
        3 (6.1) 
 7 (14.3) 
 
43.6 (51.4) 
 
3,310.0 (4,079.3) 
Past Medical/Surgical History, n (%) 
Medical history (Hep C, HIV, Pneumonia)  
Surgical history (Kidney stone, MVA) 
 
3(6.1%) 
     2(4.1%) 
 
Methamphetamine Use History 
Onset Age, mean years (SD) 
Duration Used, mean years (SD) 
Amount Used Monthly, mean Ringgit Malaysia (SD) 
 
Route of Use, n (%) 
Oral 
Nasal 
Smoking 
 
29.0 (9.0) 
5.6 (4.4) 
1,386.1 (1,846.8) 
 
 
  5 (10.2) 
14 (28.6) 
22 (61.2) 
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Table 5.4:    Baseline characteristics of efficacy and safety measures 
 
  
  
Baseline efficacy measurements, mean (SD) 
 
PANSS-Total score 
PANSS-P score 
PANSS-N score 
PANNS-General psychopathological score 
 
CGI-S score 
 
AWQ score 
 
BSCS score 
 
HADS – Depression score 
 
HADS – Anxiety score 
  
 
 
79.2 (13.7) 
21.7 (5.2) 
16.8 (3.6) 
40.6 (7.2) 
 
4.3(0.5) 
 
17.0 (8.8) 
 
6.4(3.9) 
 
4.5 (5.0) 
 
4.5 (4.9) 
 
Baseline EPS symptoms, mean (SD) 
 
AIMS score 
 
BARS score 
 
SAS score 
 
 
0 
 
0.1(0.5) 
 
0 
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Mean dose of aripiprazole 
The mean dose of aripiprazole was 7.0 + 2.9 mg on day 1, 7.2 + 3.3 
mg on day 4, 9.2 + 3.1 mg on day 7 and 9.4 + 3.6 mg on day 14. 
Concomitant medications 
None of the patients received medication prior to the study. All the 
patients were neuroleptic naïve. 
A total of 13 (26.5%) patients received concomitant therapies during 
the study. The most common concomitant therapies used was 
lorazepam (n=9, 18.4%). Lorazepam were given for akathisia (n=4, 
8.2%), agitation (n=3, 6.1%) and insomnia (n=2, 4.1%). 2 patients 
(4.1%) were given zolpidem for insomnia and 2 patients (4.1%) were 
given escitalopram for depression. 
Efficacy 
Efficacy analyses were based on the intention-to-treat (ITT) population. 
Primary efficacy variable 
The primary variable was the change from baseline in PANSS-Total 
score to the end of treatment (day 14) where baseline was defined as 
the day subject first received study medication (day 1, visit 2). Other 
primary variables include change from baseline in PANSS positive 
subscales, PANSS negative subscales, PANSS general 
psychopathology subscales and CGI-S to the end of treatment (day 14).  
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Results showed that there was a steady decline in the mean PANSS-
Total score over the course of the study, with a mean reduction of 27.6 
± 21.4 point (p < 0.05, 95% CI [- 34.8, -20.4] from baseline at day 14 
(Table 5.7), thus indicating a statistically significant improvement in 
patients after receiving aripiprazole. For the CGI scale there were also 
significant decline with the mean reduction of  2.0 ± 1.2 point (p < 0.05, 
95% CI – 2.4, -1.6] from baseline at day 14.  
Similar statistically significant reduction can also be seen in all the 
PANSS subscales scores from baseline at day 14 (Table 5.7). 
Statistically significant improvement were also noted in PANSS-Total, 
all PANSS subscales and CGI-S scores from baseline at day 4 (Table 
5.5) and at day 7 (Table 5.6). 
Secondary efficacy variables 
The secondary efficacy measures were changed from baseline in the 
AWQ score, BSCS score and HADS score. 
Results showed that there was a statistically significant decline in the 
mean AWQ score over the course of the study, with a mean reduction 
of -8.5 ± 9.6 point (p < 0.05, 95% CI [-11.8, -5.2] from baseline at day 
14 (Table 5.7). For the BSCS scale, the mean reduction was 2.8 ± 3.8 
point (p < 0.05, 95% CI -4.0, -1.5] from baseline at day 14, thus 
indicating a statistically significant improvement in patients after 
receiving aripiprazole. 
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The HADS anxiety subscales (Table 5.7) showed a statistically 
significant improvement with a mean reduction of 3.9 ± 4.8 points (p < 
0.05, 95% CI -5.6, -2.4). Similarly, the HADS depression subscales 
showed a statistically significant improvement with a mean reduction of 
3.5 ± 5.5 points (p < 0.05, 95% CI -5.4, -1.7). 
Statistically significant reductions in mean score were also noted for the AWQ 
and BSCS scales from baseline at day 4 (Table 5.5), and day 7 (Tables 5.6).  
 
Table 5.5:  Primary and secondary efficacy variables – Changes from 
baseline at Day 4* 
Variables Baseline score ± SD Day 4 score ± 
SD 
Mean ± SD 95% 
Confidence 
interval 
 
Primary efficacy 
PANSS-Total 
 
 
 
79.2 ± 13.7 
 
 
71.7 ± 12.3 
 
 
-7.4 ± 15.7 
 
 
- 12.7, -2.2 
Secondary efficacy 
PANSS-P 
PANSS-N 
PANSS-G 
 
 
21.7 ± 5.2 
16.8 ± 3.6 
40.6 ± 7.2 
 
19.0 ± 4.1 
15.5 ± 3.6 
37.2 ± 6.7 
 
 
-2.7 ± 5.1 
-1.3 ± 2.8 
-3.4 ± 8.5 
 
-4.4, -1.0 
-2.2, -0.4 
-6.2, -0.5 
 
CGI-S 
 
AWQ 
 
BSCS 
 
 
4.3± 0.5 
 
17.0 ± 8.8 
 
6.4± 3.9 
 
3.8 ± 0.9 
 
15.0 ± 8.8 
 
5.6± 3.9 
 
-0.5 ± 1.0 
 
-15.0 ± 8.8 
 
5.6 ± 3.9 
- 0.8, -0.2 
 
-3.8, -0.3 
 
-1.5, -0.1 
 
*All changes from baseline at Day 4 were statistically significant with p<0.001. T-test was used to 
compare mean changes from baseline for PANSS total score, PANSS subscales scores, CGI-S score, 
AWQ score and BSCS score  
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Table 5.6:   Primary and secondary efficacy variables – Changes from 
baseline at Day 7* 
 
Variables Baseline score±SD Day 7 score±SD Mean±SD 95% Confidence 
interval 
 
Primary efficacy 
PANSS-Total 
 
 
 
79.2 ± 13.7 
 
 
61.7 ± 11.9 
 
 
-17.4 ± 17.1 
 
 
-23.1, - 11.7 
Secondary efficacy 
PANSS-P 
PANSS-N 
PANSS-G 
 
 
21.7 ± 5.2 
16.8 ± 3.6 
40.6 ± 7.2 
 
 
 15.7 ± 3.8  
13.5 ± 3.6 
32.5 ± 6.2 
 
-6.0 ± 5.9 
-3.2 ± 3.7 
-8.1 ± 8.9 
 
-8.0, -4.0 
-4.5, -2.0 
-11.0, -5.1 
 
CGI-S 
 
AWQ 
 
BSCS 
 
 
4.3± 0.5 
 
17.0 ± 8.8 
 
6.4± 3.9 
 
 
2.9 ± 0.8 
 
11.5 ± 7.8 
 
4.5 ± 3.3 
-1.4 ±1.1 
 
5.6± 8.2 
 
1.9 ± 2.5 
 
- 1.8, -1.0 
 
-8.3, -2.8 
 
-2.7, -1.0 
 
 
*All changes from baseline at Day 7 were statistically significant with p<0.001. T-test was used to 
compare mean changes from baseline for PANSS total score, PANSS subscales scores, CGI-S score, 
AWQ score and BSCS score  
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Table 5.7:   Primary and secondary efficacy variables – Changes from 
baseline at Day 14* 
Variables Baseline score ± 
SD 
Day 14 score ± 
SD 
Mean ± SD 95% Confidence 
interval 
 
Primary efficacy 
PANSS-Total 
 
 
 
 79.2 ± 13.7 
 
 
51.6 ± 14.7 
 
 
-27.6 ± 21.4 
 
 
- 34.8, -20.4 
Secondary efficacy 
PANSS-P 
PANSS-N 
PANSS-G 
 
 
21.7 ± 5.2 
16.8 ± 3.6 
40.6 ± 7.2 
 
 
12.3 ± 4.4 
11.2 ± 3.3 
27.8 ± 7.7 
 
 
-9.5 ± 7.0 
-5.6 ± 4.7 
-12.8 ± 10.9 
 
-11.8, -7.1 
-7.2, -4.0 
-16.4, -9.2 
 
CGI-S 
 
AWQ 
 
BSCS 
 
HADS – Depression 
 
HADS – Anxiety  
4.3± 0.5 
 
17.0 ± 8.8 
 
6.4± 3.9 
 
8.1 ± 5.0 
 
8.8 ± 4.9 
 
2.3 ± 1.0 
 
8.5 ± 8.0 
 
3.6 ± 3.4 
 
4.6± 4.5 
 
3.9 ± 4.8 
-2.0 ± 1.2 
 
-8.5 ± 9.6 
 
-2.8 ± 3.8 
 
-3.5 ± 5.5 
 
-3.9 ± 4.8 
- 2.4, -1.6 
 
-11.8, -5.2 
 
-4.0, -1.5 
 
-5.4, -1.7 
 
-5.6, -2.4 
 
 
*All changes from baseline at Day 14 were statistically significant with p<0.001. T-test was used to 
compare mean changes from baseline for PANSS total score, PANSS subscales scores, CGI-S score, 
AWQ score, BSCS score and HADS subscales scores. 
 
Table 5.8:   Mixed-model repeated measures (MMRM) analyses of primary 
and secondary efficacy at baseline, day 4, day 7 and day 14.   
Variables  Baseline score 
± SD  
Day 4 score 
± SD 
Day 7 score 
±SD 
Day 14 score 
± SD 
F p 
       
Primary efficacy       
PANSS-Total 79.2 ± 13.7 71.7 ± 12.3 61.7 ± 11.9 51.6 ± 14.7 45.569 <0.05 
       
Secondary efficacy       
CGI-S 4.3 ± 0.5 3.8 ± 0.9 2.9 ± 0.8 2.3 ± 1.0 42.223 <0.05 
       
AWQ 17.0 ± 8.8 15.0 ± 8.8 11.5 ± 7.8 8.5 ± 8.0 15.473 <0.05 
       
BSCS 6.4 ± 3.9 5.6 ± 3.9 4.5 ± 3.3 3.6 ± 3.4 4.395 <0.05 
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Safety and tolerability 
Adverse events (AE) 
Aripiprazole was generally well tolerated during the study. Adverse 
events were reported in 10 (20.4%) patients during the study period, 
after 14 days of study exposure.  
The reported AEs were akathisia, insomnia, agitation, sedation and 
depression (Table 5.9). Most AEs were mild to moderate in intensity. 
Akathisia was rated as moderate in 2 patients and mild in 2 other 
patients. Insomnia was rated as mild in all 4 patients. Agitation was 
rated as mild in all 3 patients. Sedation and depression were all rated 
as moderate. The AEs of akathisia and insomnia were judged by the 
investigator to be associated to the study medication. Two patients 
discontinued from the study due to akathisia. There was no serious 
adverse event during the study period. 
Table 5.9: Number (%) of Patients reporting Adverse Events – 
Safety Population 
 
  
All Subjects (N=49) 
 
Study exposure, mean (min, max) days 11.7 (4,14) 
  Number of patients experienced AE, n (%) 10 (20.4%) 
  ADVERSE EVENT, n (%) 15 (30.6%) 
Akathisia 4 (8.1%)   
Insomnia 4 (8.1%) 
Agitation 3 (6.1%) 
Sedation 2 (4.1%) 
Depression 2 (4.1%) 
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Table 5.10:  Primary Safety variables – Changes from baseline at Day 4, 7 
and 14 
 
Variables Baseline 
score±SD 
Day 4±SD Day 7±SD Day 14±SD 
 
BARS 
 
SAS 
 
AIMS 
 
0.7 ± 0.5 
 
0 
 
0 
 
0.2 ± 0.8 
 
0 
 
0 
 
0.3 ± 1.2 
 
0 
 
0 
 
 
0.7 ± 2.1 
 
0 
 
0 
P > 0.05 for all safety data 
 
Extrapyramidal side effects 
There were no significant changes in BARS, SAS, AIMS scores 
between baseline and day 4, 7 and 14 (Table 5.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Aripiprazole and Methamphetamine-Induced Psychosis 
 
 194 
5.6 Discussion 
The present study can be considered the first pilot study in Malaysia to 
investigate the safety and potential efficacy of aripiprazole in treating 
individuals with methamphetamine-induced psychosis. While the 
number of patients included in the study was small (49 patients), the 
patients were reasonably homogenous in terms of: i) all patients had 
methamphetamine induced psychosis, without any history of other 
psychotic disorders, and ii) as such, those patients were never 
exposed to any antipsychotics before (i.e. neuroleptic naïve patients). 
However, it should be noted that the subjects in the present study do 
not represent a general population of methamphetamine abuse, 
including habitual users. Thus, the present study has a methodological 
limitation, which is that only methamphetamine dependent with 
psychotic symptoms was examined.   
Our data indicated moderate to severe psychotic symptoms among the 
subjects at baseline.  The mean baseline scores on the PANSS total 
score and the CGI scores were above the cut-off points. Following the 
treatment with aripiprazole for 2 weeks, statistically and clinically 
significant reductions across the assessment instruments used in this 
study were noted. The reduction in symptoms were noted as early as 
in day 4 and maintained until the end of the study (day 14). Our data 
suggests that aripiprazole may be a potentially effective 
pharmacological treatment for methamphetamine psychosis. We 
believe that these results may have to do with the efficacy of 
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aripiprazole relating to the positive and negative symptoms, as well as 
the associated depressive and anxiety symptoms. It is not clear why 
aripiprazole may have a positive effect on symptoms of depression and 
anxiety. Aripiprazole have an effect on both the dopaminergic and 
serotonergic systems. Both of these neurotransmisson pathways have 
been implicated in both depression and anxiety, and agents that have 
an effect on these systems may ameliorate these symptoms(Stein et 
al., 2002). The effects of aripiprazole may be given rise from its activity 
at the serotonin 1A (5-HT1A) receptor (Carli et al., 1993, Collinson and 
Dawson, 1997), and its partial agonist and dopaminergic stabilising 
qualities(Adson et al., 2005). 
 Our study also showed that aripiprazole might have treatment effect 
on methamphetamine withdrawal syndrome and cravings. In our study 
subjects, treatment with aripiprazole led to a significant decline in AWQ 
and BSCS scores, indicating a reduction the severity of drug 
withdrawal syndrome and substance cravings. This effect began as 
early as day 4, suggesting a rapid onset of action of aripiprazole. 
This particular finding of our study substantiates the results from an 
earlier study by Beresford (Beresford et al., 2005) in which treatment 
with aripiprazole significantly alleviate cocaine and alcohol cravings in 
schizophrenia subjects. In their prospective, 8-week, open-label study 
involving poorly compliant schizophrenia patients with cocaine 
dependence, treatment with aripiprazole led to a significant decline in 
the cocaine craving scores (as measured by BSCS) and substance 
use, as reflected in a significant drop in positive urine tests after 2 
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weeks. Psychosis scores in those patients declined, corresponding to 
the decline in cocaine craving. Both our study and theirs suggests 
possible aripiprazole effects in lowering the desire for and the use of 
substance in patients with co-morbid psychiatric disorder, including 
subjects with methamphetamine induced psychosis. 
In our study, the initial dose of aripiprazole used was 5-10mg mg/day, 
and was gradually titrated to higher doses of 10 mg/day or 15 mg/day 
over the study period. The doses used in our patient population 
appeared to be effective, as reflected in the significant improvements 
across the efficacy parameters. However, a double-blind study by 
Newton (Newton et al., 2008) to evaluate the effects of aripiprazole 
treatment on abstinence-related craving and cue-induced craving 
among non-treatment seeking, methamphetamine dependent users, 
reported that aripiprazole given at 15 mg is unlikely to be efficacious 
for the treatment of methamphetamine dependence. Whether this 
discrepancy is purely due to study design or could be attributed to a 
genetic reason (e.g. different ethnicities have different therapeutic dose 
of aripiprazole) remains to be ascertained through further research. 
Our study also showed that aripiprazole was well tolerated in most 
patients and safe to be used in antipsychotic-naïve patients, as shown 
by the low incidence of adverse effects associated with aripiprazole 
and the high retention rate (83.6%) in this study. 
The reported AEs (akathisia, insomnia, agitation, sedation and 
depression) were in agreement with the most common adverse effects 
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found in other clinical trials of aripiprazole in schizophrenia (Kern et al., 
2006, Kane et al., 2002).  All the AEs were of mild to moderate 
severity. 
There was a non-significant increase in BARS, mainly due to four 
patients who reported akathisia. Akathisia is not uncommon with 
aripiprazole. While second-generation antipsychotic drugs have been 
reported to cause fewer incidences of extrapyramidal symptoms 
(EPSs) than typical antipsychotic drugs, AEs such as akathisia have 
been observed with atypical antipsychotic drugs (Iqbal et al., 2007, 
Kane et al., 2009).  
Aripiprazole is known to have a relatively low rate of EPSs and a low 
propensity for weight gain and prolactin-related adverse events 
(Chrzanowski et al., 2006, Marder et al., 2003, Kolotkin et al., 2008, 
Findling et al., 2008). This may offer an advantage in terms of 
treatment compliance, especially when patients have to be put on a 
longer duration of treatment.   
While no incidence of tardive dyskinesia (TD) was reported in our 
study, aripiprazole has been implicated as a cause of TD in patients 
never exposed to other dopamine receptor-blocking agents. In a recent 
review of studies using comparable doses of antipsychotics, the 
annualised incidence of TD was estimated to be 3.9% for atypical 
antipsychotics compared with 5.5% for conventional antipsychotics 
(Correll and Schenk, 2008). For this reason, caution should be 
exercised when aripiprazole is used in neuroleptic-naïve patients.   
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Currently, the data on efficacy of antipsychotics in methamphetamine- 
induced psychosis is very limited. Only one small randomised 
controlled trial (Leelahanaj et al., 2005) involving 58 participants has 
been published. The study compared the efficacy and tolerability of two 
antipsychotic drugs, olanzapine and haloperidol, in treating 
amphetamine-induced psychosis. Both drugs at clinically relevant 
doses were efficacious in resolving psychotic symptoms associated 
with amphetamine use.  
In Malaysia, there has been no similar study conducted. Whether the 
limited evidence from our current study using aripiprazole can be 
applied for all methamphetamine psychotic patients is not yet known. 
The treatment of methamphetamine-induced psychosis with 
aripiprazole should be further investigated. Further studies of 
methamphetamine-induced psychotic symptoms and the prevalence of 
relapse to psychosis in the presence of methamphetamine are also 
crucial for developing study designs appropriate for treatment studies 
of methamphetamine psychosis. 
Although our current study is hampered by a small sample size, the 
responses of our study subjects to the pharmacotherapy of aripiprazole 
are noteworthy. We foresee to obtain more defining and valuable data 
from an extension of this study that will recruit more subjects and be 
conducted over a longer treatment period. 
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Limitation and Errors 
i). Adequacy of Sample Size  
The required sample size was 33, when the calculated study sample 
was based on 80% power of the study; the difference of mean was 10 
and standard deviation of 20. The actual completed study subjects 
were 41 and have maintained the power of study.                                               
ii). Conduct of study   
This was an open label single arm intervention study. The efficacy 
outcomes measured were not superior as randomized double blind 
study.            
iii). Representative and Generalisation 
The findings of this study could only generalize with caution because 
the study population was from the inpatient and outpatient clinic 
located in a hospital in Kuala Lumpur. The study population differs 
from the patients in the community because of the treatment seeking 
behavior. To make generalized inferences of the findings of this study 
to the methamphetamine dependence induced psychosis patients in 
community would be inappropriate because the setting in this study 
had introduced selection bias. 
For a better generalization of the findings, it would be ideal to conduct 
a community survey. Unfortunately, such a study is not feasible to 
conduct due to the legal implication.  
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iv). Instruments of the study 
All the scales have been used widely in this country however until now, 
there was no paper being published regarding the validation of the 
scales in the local population.  
v). Comparing Findings With Other Studies 
Comparison of the findings of this study to other studies may be 
inaccurate, although other studies examined the same variables, but 
the inclusion and exclusion criteria used to identify subjects or sampled 
population could differ, or study could be conducted with difference 
study design. 
5.7 Conclusions 
This 2-week, open-label study shows that aripiprazole given once-daily 
at 10 mg/day to 15 mg/day improved the psychotic symptoms 
associated with methamphetamine use, as measured with PANSS 
scores. In addition, the treatment also improved the depressive and 
anxiety symptoms, as well as reduced drug withdrawal symptoms and 
substance craving severity. The treatment was generally well tolerated 
with mild to moderate AEs comparable to other aripiprazole studies. 
Aripiprazole may be a potential pharmacotherapy for 
methamphetamine-induced psychosis, but its efficacy needs to be 
confirmed by larger and longer-duration trials.  
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Chapter SIX: Randomized Placebo-Controlled Trial of the Safety 
and Efficacy of Aripiprazole in the Treatment of Methamphetamine 
Dependence Patients  
 
6.1  Abstract 
 
Introduction: There is a great need in the treatment of 
methamphetamine dependence. The goals of methamphetamine 
dependence treatment are to reduce further drug use, improve the 
patient’s ability to function, minimize the medical and social 
complications of drug abuse and dependence, and ultimately to achieve 
lasting abstinence.  
Objectives:  The objective of this study was to determine the efficacy 
and safety of aripiprazole among methamphetamine dependence 
patients.  
Methodology:  
Design: This was a double blind randomized controlled trial.   
Setting: Patients were recruited from the inpatient psychiatric 
wards and outpatient psychiatric clinic in University 
Malaya Medical Centre (UMMC), Kuala Lumpur.    
Patients: The study population included male or female with a 
current Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV) diagnosis of methamphetamine 
dependence.  
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Intervention: Eligible patients were treated with the initial dose of 10 
mg Aripiprazole. From day 2 to day 56, aripiprazole was 
flexible dosed (5-10mg/day) at the discretion of the 
treating psychiatrist.   
Measures: The primary outcome measure was to determine the 
efficacy of aripiprazole in maintaining of abstinence and 
retention among methamphetamine dependence 
patients. Other scales included in this study were the 
Positive and Negative Syndrome Scale (PANSS) and 
Clinical Global Impression scale(CGI), the Brief 
Substance Craving Scale (BSCS), Barnes Akathasia 
Scale (BAS), Simpson Angus Scale (SAS), Abnormal 
Involuntary Movement Scale (AIMS) and Hospital 
Anxiety Depression Scale (HADS). Intention-to-treat was 
used for the data analysis.   Generalized Estimating 
Equation (GEE) and Mixed-Effects Model Repeated-
Measures (MMRM) analysis was utilized to examine 
changes in outcome measures over time with the 
treatment aripiprazole. 
 
Results: Nineteen patients were randomized to aripiprazole and 18 to 
placebo. About 84.2% of participants randomized to aripiprazole 
completed the 8 weeks study compared to only 50% of the placebo 
group completed the study (p < 0.05). There was a statistically 
significant difference between groups in the amount of time spent in 
treatment (p < 0.05), with those given aripiprazole retained for an 
7  Overall Conclusions and Recommendations  
 203 
average of 48.7 days (+ 4.0) compared with only 37.1 days (+ 5.0) for 
the placebo group. The survival curves results showed that participants 
in the aripiprazole group were less likely to drop out of the study than 
those in the placebo group. The difference was statistically significant 
(p =0.02, X2 =5.3). Psychotic symptoms as measured by PANSS and 
CGI were decreased among participants who were randomized to 
aripiprazole treatment but those who were randomized to placebo 
showed an increased in the total PANSS and CGI score (p < 0.05). 
However there were no statistically significant effects for aripiprazole 
relative to placebo on methamphetamine use verified by urine drug 
screen. The generalised estimation equation analysis showed that the 
different between aripiprazole and placebo in the urine analysis was 
not significant (p = 0.41). Aripiprazole treatment was not associated 
with any serious adverse event. Adverse event were generally mild and 
consistent with known pharmacological effects.  
Conclusion: Aripiprazole was no more effective than placebo in 
maintaining abstinence from methamphetamine use. However, it 
facilitated treatment retention and reduced the occurrence of psychotic 
symptoms in this study population. Aripiprazole was generally safe and 
well tolerated. It might have a role in the treatment of methamphetamine 
dependence with psychotic symptoms.  
 
Keywords: Randomized controlled trial, Placebo Controlled, 
Methamphetamine dependence, Aripiprazole, Psychosis, 
Safety, Efficacy 
7  Overall Conclusions and Recommendations  
 204 
6.2  Introduction 
Treatment of methamphetamine dependence   
Methamphetamine dependence, and drug dependence in general, is a 
treatable brain disease. The goals of drug dependence treatment are to 
reduce further drug use, improve the patient’s ability to function, 
minimize the medical and social complications of drug abuse and 
dependence, and ultimately to achieve lasting abstinence (Kay-
Lambkin et al., 2010).  
Managing methamphetamine dependence, as well as to recover from 
it, does not involve a brief detoxification and discharge, but a long-term 
process to help individuals free themselves from illicit substance use 
(Bruce, 2000). Through tailored treatments many people with drug use 
disorders are able to recover and lead productive lives. 
Psychosocial and behavioural approaches are currently the primary 
treatments for methamphetamine dependent individuals. Medications 
may also be used alone or in combination with behavioural therapy. 
Meanwhile, research continues to investigate the potential roles of 
replacement pharmacotherapies in drug dependence. 
Psychosocial and behavioural therapies 
At present, the most effective treatments for ATS dependence 
addiction are behavioural therapies (Nhduh, 2005), such as cognitive 
behavioural and contingency management interventions, which have 
been successfully used in treating cocaine addiction (Rawson et al., 
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2002b) and may have some benefit in treating methamphetamine 
addiction. 
i). Cognitive behavioural therapy 
The Matrix Model is an individualized outpatient regimen that has been 
used successfully to treat patients who abuse stimulants (Shoptaw et 
al., 1994, Rawson et al., 2004). It is a comprehensive 16-week 
behavioural treatment approach that combines behavioural therapy, 
family education, individual counselling, 12-step support, relapse 
analysis, urine testing, and encouragement for non-drug-related 
activities. The Center for Substance Abuse Treatment 
Methamphetamine Treatment project (Rawson et al., 2004) has shown 
that the Matrix approach is effective in reducing methamphetamine 
abuse, where patients were more likely to stay in treatment, complete 
treatment, and more likely to have negative methamphetamine urine 
test results compared with those who received standard outpatient 
treatment.    
ii). Contingency management program 
Contingency management rewards methamphetamine-dependent 
patients when they engage in treatment and maintaining abstinence 
(e.g submitting drug-free urine samples). This intervention has also 
been shown to be effective by reducing methamphetamine abuse and 
high-risk sexual behaviour (Shoptaw et al., 2005).   
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In short, behavioural therapies help patients stay on to the treatment 
process, modify their attitudes and behaviours related to drug abuse, 
and increase healthy lifestyle skills (Kay-Lambkin et al., 2010). If 
patients are on medications, behavioural treatments can also help 
enhance the effectiveness of the medications and help them stay in 
treatment longer (Kay-Lambkin et al., 2010). 
iii). Pharmacotherapy  
Besides specific behavioural therapies, medications can be used to 
target different aspects along the treatment process. Medications can 
be used to help re-establish normal brain function, and to ebb cravings 
and prevent relapse throughout the treatment process (Kay-Lambkin et 
al., 2010). 
However, there is currently no approved medication by the Food and 
Drug Administration (FDA) or the Malaysian Drug Authority to be used 
in the treatment of methamphetamine dependence. All the treatments 
that are being used at this moment are off label usage. 
Treating withdrawal symptoms and addiction 
The overall therapeutic process of drug dependence often begins with 
detoxification, followed by treatment and relapse prevention (Kay-
Lambkin et al., 2010). During the detoxification stage, withdrawal 
symptoms such as intense craving, fatigue, dysphoric mood, 
anhedonia, depression and agitation, are common among 
methamphetamine users (Mcgregor et al., 2005). These symptoms 
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may last several days to weeks after cessation or reduction in heavy 
and prolonged use of methamphetamine, and may present a critical 
factor leading to relapse of methamphetamine use. 
Medications play a role here by helping to suppress the withdrawal 
symptoms (i.e. medically assisted withdrawal). This can be very 
important in the initiation of treatment to prevent relapse.  
At present, no available treatment has been demonstrated to be 
effective in the treatment of methamphetamine withdrawal. In clinical 
practice, treatment for cocaine withdrawal has been recommended for 
the management of ATS withdrawal (Cretzmeyer et al., 2003) despite 
the difference in the pharmacodynamic and pharmacokinetic properties 
of these two substances. 
While there are already medications available for opioid and tobacco 
addiction, evidence on treatment for ATS dependence is scarce.   
A Cochrane review concluded that fluoxetine and imipramine have very 
limited benefits for amphetamine dependence and abuse 
(Srisurapanont et al., 2001a). While fluoxetine may decrease craving in 
short-term treatment, imipramine may increase duration of adherence 
to treatment in medium-term treatment. Apart from these, no other 
benefits, in particular proximal benefits can be found.  
While one small randomised controlled trial found bupropion decreased 
subjective effects of methamphetamine and cravings in a laboratory 
setting (Newton et al., 2006), risperidone was shown to be well 
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tolerated and associated with decreased methamphetamine use in an 
open-label pilot study (Meredith et al., 2007). 
A recent study (Jayaram-Lindstrom et al., 2008) conducted in Sweden 
observed that naltrexone, an opioid agonist, in amphetamine-
dependent patients significantly attenuated the subjective effects 
produced by dexamphetamine in those patients. Pre-treatment with 
naltrexone also significantly blocked the craving for dexamphetamine.  
Modafinil, a novel non-amphetamine-type stimulant approved in 
Australia for the treatment of narcolepsy and sleep apnoea-related 
fatigue, may be moderately beneficial in reducing methamphetamine 
use in selected subjects. When compared with placebo in treating 
methamphetamine dependence in a study conducted by Shearer and 
colleagues (Shearer et al., 2009), modafinil led to the greatest 
reductions in methamphetamine use in methamphetamine -dependent 
subjects who had no other forms of substance dependence. However, 
no differences were reported between modafinil and placebo in 
retention, methamphetamine abstinence, methamphetamine craving or 
severity of dependence.   
Dexamphetamine has also been studied in the treatment of 
methamphetamine dependence. A preliminary study investigating the 
safety and efficacy of once-daily sustained-release dexamphetamine in 
people dependent on methamphetamine found that a maintenance 
pharmacotherapy programme of daily sustained-release amphetamine 
is both feasible and safe (Longo et al.). Compared with placebo, 
7  Overall Conclusions and Recommendations  
 209 
treatment of methamphetamine dependence using sustained-release 
dexamphetamine was associated with significantly better retention and 
lower degree of dependence. There was also a general decrease in 
methamphetamine use and withdrawal symptom severity. 
Mirtazapine, a noradrenergic and specific serotonergic antidepressant 
that causes blockade of inhibitory α2-adrenergic autoreceptors on 
noradrenaline and serotonin neurones, was studied by Cruickshank 
and colleagues in the management of methamphetamine withdrawal 
(Cruickshank et al., 2008).Their 2-week study concluded that 
mirtazapine is not more effective than placebo in improving treatment 
and retention, or alleviating methamphetamine withdrawal symptoms in 
an out-patient setting.   
Bupoprion, a dopamine and norepinephrine reuptake inhibitor that has 
been approved as an antidepressant and a smoking cessation drug, 
was also found to be no more effective than placebo in reducing 
methamphetamine cravings, depressive symptoms, and 
methamphetamine use in a study conducted by Shoptaw et al 
(Shoptaw et al., 2008). However, another study (Elkashef et al., 2008) 
reported that bupoprion, when used in combination with behavioural 
group therapy, was effective for increasing the number of weeks of 
abstinence in individuals with low-to-moderate methamphetamine 
dependence. 
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Relapse prevention 
Preventing relapse is necessary for maintaining the treatment effects 
and keeping the patient away from illicit drug use. As with other chronic 
conditions, episodes of relapse may sometimes require a return to prior 
treatment components.  
In relapse prevention measures, patients are educated to raise 
awareness on relapse causing factors and high-risk situations, and 
learn to avoid or cope with those situations. Sometimes 
pharmacotherapy is used (Bruce, 2000). Antidepressants, for example, 
are administered when mood is a constant trigger for relapse. Lastly, 
patients need to make lifestyle changes to steer away from drug 
misuse to a more normalised and socialised lifestyle (Bruce, 2000).  
Aripiprazole in the treatment of methamphetamine dependence   
While effective agonist and antagonist pharmacotherapies, as well as 
symptomatic treatments, exist for opioid dependence, no 
pharmacological treatment has been found effective and approved for 
the treatment of methamphetamine abuse or dependence (Grabowski 
et al., 2004).  
A treatment that is able to normalize the altered systems due to 
methamphetamine abuse could have a beneficial clinical effect on 
methamphetamine dependence. A ‘replacement’ strategy paralleling 
that for opioid dependence that may be effective in treating 
methamphetamine dependence is the use of partial agonists, which 
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have significant receptor affinity but low intrinsic activity (Childress and 
O'brien, 2000).  
Under conditions of low neurotransmitter tone, as is observed for 
dopamine during initial abstinence from chronic stimulant 
administration (Volkow et al., 2001, Weiss et al., 1992), a partial 
agonist should produce some receptor stimulation, and may therefore 
function as a replacement medication. A partial agonist may also act as 
an antagonist when there are higher levels of neurotransmitter present 
in the synapse, as would occur following use of a stimulant upon 
relapse. 
Due to its unique mechanism of action, partial agonist aripiprazole is 
hypothesized to be able to restore neurotransmitter balance and the 
normal function of the mesolimbic dopamine system (Lile et al., 2005), 
and thus a promising replacement medication for psychostimulant 
addiction.   
The effect of aripiprazole in psychostimulant abuse has been studied in 
both animals and human beings. In animals, for example, Leite and 
colleagues showed that aripiprazole inhibited the motor hyperactivity 
induced by amphetamine and cocaine in mice, but without causing 
significant motor impairment (Leite et al., 2008).   
An interesting study by Schwabe and Koch (Schwabe and Koch, 2007) 
recently investigated whether aripiprazole could restore animals’ 
responding for reward pellets after amphetamine withdrawal. 
Withdrawal from repeated amphetamine administration has been 
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shown to decrease the motivation to work for a natural reward in rats, a 
phenomenon thought to be associated with hypofunction of the 
mesolimbic dopamine system. Their study showed that low doses of 
aripiprazole prevented this effect, suggesting that aripiprazole may 
have potential use as a treatment for the motivational effects of the 
acute withdrawal stage of ATS addiction cycle. 
In humans, aripiprazole has been studied in schizophrenic cocaine-
dependent subjects. While traditional antipsychotic medications (i.e. D2 
dopamine receptor antagonist) may leave patients with a shortage of 
dopamine activity, worsened by receptors that have already been 
damaged by chronic cocaine use (Zimmet et al., 2000), aripiprazole 
was able to reduce the actual cocaine use and lessen the desire for 
cocaine in this patient population (Beresford et al., 2005). 
In the context of amphetamine abuse and addiction, aripiprazole has 
been demonstrated to attenuate many of the behavioral effects of d-
amphetamine, including studies by Stoops et al (Stoops et al., 2006, 
Stoops, 2006) that showed aripiprazole attenuated some abuse-related 
behavioral effects of d-amphetamine in healthy volunteers.  
While Stoops’ study (Stoops et al., 2006) result indicated the clinical 
utility of aripiprazole in the management of ATS abuse and 
dependence, it should be noted that their experiments used acute 
aripiprazole administration in combination with d-amphetamine. In a 
clinical setting, aripiprazole would be administered chronically to 
methamphetamine abusers. Therefore, further laboratory studies 
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should investigate the ability of chronically administered aripiprazole to 
attenuate the behavioral effects of methamphetamine. 
However, there were two studies that failed to show the effectiveness 
of aripiprazole in the treatment of methamphetamine dependence. 
In the study by Tiihonen and colleagues (Tiihonen et al., 2007), 
individuals with amphetamine/ methamphetamine dependence were 
randomly assigned to receive aripiprazole (15 mg/day), slow-release 
methylphenidate (54 mg/day) or placebo for 20 weeks. The study was 
terminated prematurely because patients allocated to aripiprazole had 
significantly more amphetamine-positive urine samples than patients in 
the placebo group. Aripiprazole was not effective in that trial, but the 
investigators could not draw any conclusion on its potential efficacy. 
Another small 2-week study conducted by Newton et al (Newton et al., 
2008) showed similar results. When aripiprazole 15 mg/day was 
administered to 16 methamphetamine dependent patients, the drug 
appeared to increase some of the rewarding and stimulatory effects 
produced by acute methamphetamine, suggesting that 15 mg 
aripiprazole is unlikely to be efficacious for the treatment of 
methamphetamine dependence. However, the study group concluded 
that further research to evaluate the efficacy of lower doses of 
aripiprazole in relapse prevention should be conducted before ruling 
out aripiprazole as a treatment for this group of patient population. 
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Methamphetamine dependence and psychosis  
Psychosis is a known complication of methamphetamine abuse and 
dependence. While transient psychotic symptoms may occur during 
intoxication with methamphetamine use, it is possible that psychotic 
symptoms will persist (Van Kampen and Katz, 2001).  When the 
psychotic symptoms persist and interfere with the patient's social and 
occupational functioning, treatment should be targeted to psychiatric 
symptoms present (Larson, 2008). 
Aripiprazole, the sixth atypical antipsychotic medication, was first 
approved by the Food and Drug Administration (FDA) in 2002 for the 
treatment of schizophrenia. Available as tablets for oral administration, 
aripiprazole is also indicated for the treatment of acute manic episodes 
associated with bipolar 1 disorder since 2004.  This makes aripiprazole 
a good candidate for the treatment of methamphetamine dependence 
who presented with psychotic symptoms. 
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6.3 Systematic review on the aripiprazole as treatment of 
amphetamine  and methamphetamine dependence patients 
 
6.3.1. Methods 
6.3.2. Search strategy  
This systematic review included literature published between January 
2000 and April 2011.  An electronic search on the following databases 
was carried out:  PUBMED, Web of Science, OVID Medline (R), the 
Cochrane Central Register of Controlled Trials and the Cochrane 
Database of Systematic Review, using the search terms: 
Systematic review 1 
(d) Methamphetamine or Methamfetamine 
(e) Aripiprazole  
(f) Drug dependence   
Systematic review 2 
(d) Amphetamine  
(e) Aripiprazole  
(f) Drug dependence   
Where Medical Subject Headings (MeSH) terms were available, they 
were exploded and combined. Reference lists from retrieved papers 
were also searched. 
 
7  Overall Conclusions and Recommendations  
 216 
6.3.3.  Type of studies  
Only publication in English for experimental studies (e.g. randomized 
clinical trials) and systematic review were included if: 
(a) Participants were treated with aripiprazole 
(b) Methamphetamine or amphetamine dependence  
6.3.4.   Types of participant 
Male or female patients, of any age or ethnic origin, who has 
methamphetamine or amphetamine dependence. 
6.3.5.    Types of interventions 
The treatment group was aripiprazole and the comparison groups were 
either any antipsychotic drugs or placebo or non-drug treatment. 
6.3.6.   Types of outcome measures  
The changes in craving, the retention rate of the study or treatment 
response rate. 
6.3.7.   Data extraction 
Information was extracted on data source such as participants, 
interventions, results and outcome.   
6.3.8.   Results 
A total of 5 experimental studies for methamphetamine dependence and 12 
experimental studies for amphetamine dependence were identified by the 
search and cross-referencing strategies. 
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Figure 6.1   Flow chart showing the article-identification process for 
methamphetamine dependent   
 
 
 
 
  
 
 
 
 
Figure 6.2   Flow chart showing the article-identification process for 
amphetamine dependent   
 
 
 
 
  
 
 
 
 
 
Papers not meeting inclusion criteria 
based on abstract =4 (animal study)  
 
 
Final number of paper 
included in the study = 1 
Total number of potential 
relevant papers = 5 
Papers not meeting inclusion criteria 
based on abstract =8 (animal study)  
 
 
Final number of paper 
included in the study = 4 
Total number of potential 
relevant papers = 12 
7  Overall Conclusions and Recommendations  
 218 
T
a
b
le
 6
.1
  
 S
y
s
te
m
a
ti
c
 r
e
v
ie
w
 o
n
 t
h
e
 a
ri
p
ip
ra
z
o
le
 a
s
 t
re
a
tm
e
n
t 
o
f 
m
e
th
a
m
p
h
e
ta
m
in
e
 d
e
p
e
n
d
e
n
c
e
 p
a
ti
e
n
ts
 
C
o
m
m
e
n
ts
 
S
u
g
g
e
s
te
d
  
e
x
p
e
ri
m
e
n
ta
l 
s
tu
d
y
 
w
it
h
 l
o
w
e
r 
d
o
s
e
 o
f 
a
ri
p
ip
ra
z
o
le
 
R
e
s
u
lt
s
 
A
ri
p
ip
ra
z
o
le
 
a
s
s
o
c
ia
te
d
 w
it
h
 
in
c
re
a
s
e
d
 c
ra
v
in
g
 
in
d
e
p
e
n
d
e
n
t 
o
f 
m
e
th
a
m
p
h
e
ta
m
in
e
 
d
o
s
in
g
. 
 
O
u
tc
o
m
e
 
A
b
s
ti
n
e
n
c
e
 r
e
la
te
d
 
c
ra
v
in
g
 
 
In
te
rv
e
n
ti
o
n
 
i)
 i
n
tr
a
v
e
n
o
u
s
 
m
e
th
a
m
p
h
e
ta
m
in
e
  
1
5
m
g
 t
h
e
n
 
ra
n
d
o
m
iz
e
d
 t
o
 o
ra
l 
a
ri
p
ip
ra
z
o
le
 1
5
m
g
 
o
r 
p
la
c
e
b
o
 
2
 d
a
y
s
 l
a
te
r 
 
ii)
 i
n
tr
a
v
e
n
o
u
s
 
m
e
th
a
m
p
h
e
ta
m
in
e
  
3
0
m
g
 t
h
e
n
 
ra
n
d
o
m
iz
e
d
 t
o
 o
ra
l 
a
ri
p
ip
ra
z
o
le
 1
5
m
g
 
o
r 
p
la
c
e
b
o
 
 
S
tu
d
y
 S
u
b
je
c
ts
 
M
e
th
a
m
p
h
e
ta
m
in
e
  
d
e
p
e
n
d
e
n
c
e
 
1
6
 p
a
rt
ic
ip
a
n
ts
 
S
tu
d
y
 
 (N
e
w
to
n
 e
t 
a
l.
, 
2
0
0
8
) 
  
7  Overall Conclusions and Recommendations  
 219 
T
a
b
le
 6
.2
  
 S
y
s
te
m
a
ti
c
 r
e
v
ie
w
 o
n
 t
h
e
 a
ri
p
ip
ra
z
o
le
 a
s
 t
re
a
tm
e
n
t 
o
f 
a
m
p
h
e
ta
m
in
e
 d
e
p
e
n
d
e
n
c
e
 p
a
ti
e
n
ts
 C
o
m
m
e
n
ts
 
T
h
is
 s
tu
d
y
 w
a
s
 s
to
p
 
d
u
e
 t
o
 s
a
fe
ty
 i
s
s
u
e
 
d
u
ri
n
g
 i
n
te
ri
m
 
a
n
a
ly
s
is
(a
c
tu
a
l 
s
a
m
p
le
 s
iz
e
 2
1
0
 
s
u
b
je
c
ts
) 
T
h
e
 p
re
c
lin
ic
a
l 
fi
n
d
in
g
s
 c
a
n
 b
e
 u
s
e
d
 
to
 i
n
v
e
s
ti
g
a
te
 t
h
e
 
a
b
ili
ty
 o
f 
a
ri
p
ip
ra
z
o
le
 
fo
r 
o
th
e
r 
s
ti
m
u
la
n
ts
 
d
e
p
e
n
d
e
n
c
e
. 
T
h
e
 f
in
d
in
g
s
 o
f 
e
x
p
e
ri
m
e
n
ta
l 
1
 i
s
 
s
im
ila
r 
w
it
h
 L
ile
 a
t 
a
l 
s
tu
d
y
.(
L
ile
 e
t 
a
l.
, 
2
0
0
5
) 
R
e
s
u
lt
s
 
A
ri
p
ip
ra
z
o
le
 h
a
d
 
s
ig
n
if
ic
a
n
tl
y
 m
o
re
 
a
m
p
h
e
ta
m
in
e
-p
o
s
it
iv
e
 
u
ri
n
e
 s
a
m
p
le
s
 t
h
a
n
 
p
a
ti
e
n
ts
 i
n
 p
la
c
e
b
o
 
g
ro
u
p
, 
th
e
 p
a
ti
e
n
ts
 
a
llo
c
a
te
d
 w
it
h
 
m
e
th
y
lp
h
e
n
id
a
te
 h
a
d
 
fe
w
e
r 
p
o
s
it
iv
e
 u
ri
n
e
 
s
a
m
p
le
 t
h
a
n
 p
a
ti
e
n
ts
 
re
c
e
iv
in
g
 p
la
c
e
b
o
  
 A
ri
p
ip
ra
z
o
le
 s
ig
n
if
ic
a
n
tl
y
 
a
tt
e
n
u
a
te
d
 t
h
e
 
d
is
c
ri
m
in
a
ti
v
e
-s
ti
m
u
lu
s
 
a
n
d
 c
a
rd
io
v
a
s
c
u
la
r 
 
e
ff
e
c
ts
 o
f 
D
-
a
m
p
h
e
ta
m
in
e
. 
E
x
p
e
ri
m
e
n
ta
l 
1
: 
h
ig
h
e
r 
d
o
s
e
 o
f 
A
ri
p
ip
ra
z
o
le
 
s
ig
n
if
ic
a
n
tl
y
 a
tt
e
n
u
a
te
d
 
th
e
 d
is
c
ri
m
in
a
ti
v
e
-
s
ti
m
u
lu
s
 
E
x
p
e
ri
m
e
n
ta
l 
2
: 
lo
w
e
r 
d
o
s
e
 o
f 
A
ri
p
ip
ra
z
o
le
 
s
ig
n
if
ic
a
n
tl
y
 a
tt
e
n
u
a
te
d
 
th
e
 d
is
c
ri
m
in
a
ti
v
e
-
s
ti
m
u
lu
s
 
O
u
tc
o
m
e
 
p
ro
p
o
rt
io
n
 o
f 
 
a
m
p
h
e
ta
m
in
e
-p
o
s
it
iv
e
 
u
ri
n
e
 s
a
m
p
le
s
  
 R
a
ti
n
g
 s
c
a
le
 o
f 
a
c
ti
v
e
, 
a
le
rt
 a
n
d
 e
n
e
rg
e
ti
c
, 
b
lo
o
d
 p
re
s
s
u
re
 a
n
d
 
h
e
a
rt
 r
a
te
. 
R
a
ti
n
g
 s
c
a
le
 o
f 
a
c
ti
v
e
, 
a
le
rt
 a
n
d
 e
n
e
rg
e
ti
c
. 
In
te
rv
e
n
ti
o
n
 
  
 3
 a
rm
s
 
i)
 o
ra
l 
a
ri
p
ip
ra
z
o
le
 1
5
m
g
 /
d
a
y
 
ii)
 s
lo
w
-r
e
le
a
s
e
 
m
e
th
y
lp
h
e
n
id
a
te
 5
4
m
g
/d
a
y
  
iii
) 
p
la
c
e
b
o
 
F
o
r 
2
0
 w
e
e
k
s
  
 
i)
T
o
 d
is
c
ri
m
in
a
te
  
b
e
tw
e
e
n
 1
5
 
m
g
 o
ra
l 
D
-a
m
p
h
e
ta
m
in
e
 o
r 
p
la
c
e
b
o
 l
a
te
r 
ii)
to
 a
s
s
e
s
s
 t
h
e
 e
ff
e
c
ts
 o
f 
a
 
ra
n
g
e
 o
f 
d
o
s
e
s
 o
f 
 D
-
a
m
p
h
e
ta
m
in
e
 (
0
,2
.5
,5
,1
0
 a
n
d
 
1
5
 m
g
 )
a
lo
n
e
 a
n
d
 i
n
 
c
o
m
b
in
a
ti
o
n
 w
it
h
 
a
ri
p
ip
ra
z
o
le
(0
 a
n
d
 2
0
 m
g
) 
T
o
 d
is
c
ri
m
in
a
te
  
b
e
tw
e
e
n
 1
5
 
m
g
 o
ra
l 
D
-a
m
p
h
e
ta
m
in
e
 o
r 
p
la
c
e
b
o
 l
a
te
r 
E
x
p
e
ri
m
e
n
ta
l 
1
: 
to
 a
s
s
e
s
s
 t
h
e
 
e
ff
e
c
ts
 o
f 
a
 r
a
n
g
e
 o
f 
d
o
s
e
s
 o
f 
 
D
-a
m
p
h
e
ta
m
in
e
 (
0
,2
.5
,5
,1
0
 
a
n
d
 1
5
 m
g
 )
a
lo
n
e
 a
n
d
 i
n
 
c
o
m
b
in
a
ti
o
n
 w
it
h
 
a
ri
p
ip
ra
z
o
le
(0
 a
n
d
 2
0
 m
g
) 
E
x
p
e
ri
m
e
n
ta
l 
2
:t
o
 a
s
s
e
s
s
 t
h
e
 
e
ff
e
c
ts
 o
f 
a
 r
a
n
g
e
 o
f 
d
o
s
e
s
 o
f 
 
D
-a
m
p
h
e
ta
m
in
e
 (
0
,2
.5
,5
,1
0
 
a
n
d
 1
5
 m
g
 )
a
lo
n
e
 a
n
d
 i
n
 
c
o
m
b
in
a
ti
o
n
 w
it
h
 
a
ri
p
ip
ra
z
o
le
(0
 a
n
d
 1
0
 m
g
) 
 
S
tu
d
y
 S
u
b
je
c
ts
 
D
S
M
-I
V
 c
ri
te
ri
a
 f
o
r 
a
m
p
h
e
ta
m
in
e
  
d
e
p
e
n
d
e
n
c
e
 
5
3
 p
a
rt
ic
ip
a
n
ts
 
7
 h
e
a
lt
h
y
 s
u
b
je
c
ts
 w
it
h
 a
 
lif
e
ti
m
e
 h
is
to
ry
 o
f 
n
o
n
th
e
ra
p
e
u
ti
c
 u
s
e
  
o
f 
a
 
s
ti
m
u
la
n
t 
H
e
a
lt
h
y
 s
u
b
je
c
ts
 w
it
h
 a
 
lif
e
ti
m
e
 h
is
to
ry
 o
f 
n
o
n
th
e
ra
p
e
u
ti
c
 u
s
e
  
o
f 
a
 
s
ti
m
u
la
n
t 
E
x
p
e
ri
m
e
n
t 
1
 h
a
s
 7
 s
u
b
je
c
ts
 
E
x
p
e
ri
m
e
n
t 
2
 h
a
s
 6
 s
u
b
je
c
ts
 
S
tu
d
y
 
(T
iih
o
n
e
n
 e
t 
a
l.
, 
2
0
0
7
) 
(L
ile
 e
t 
a
l.
, 
2
0
0
5
) 
(S
to
o
p
s
, 
2
0
0
6
) 
 
7  Overall Conclusions and Recommendations  
 220 
T
a
b
le
 6
.2
  
 S
y
s
te
m
a
ti
c
 r
e
v
ie
w
 o
n
 t
h
e
 a
ri
p
ip
ra
z
o
le
 a
s
 t
re
a
tm
e
n
t 
o
f 
a
m
p
h
e
ta
m
in
e
 d
e
p
e
n
d
e
n
c
e
 p
a
ti
e
n
ts
(c
o
n
’t
) 
C
o
m
m
e
n
ts
 
T
h
e
 f
in
d
in
g
s
 o
f 
th
is
 
s
tu
d
y
 s
im
ila
r 
w
it
h
 
e
x
p
e
ri
m
e
n
ta
l 
2
 i
n
 
S
to
o
p
s
 s
tu
d
y
.(
S
to
o
p
s
, 
2
0
0
6
) 
  
1
0
 m
g
 o
f 
a
ri
p
ip
ra
z
o
le
 
w
o
u
ld
 b
e
 r
e
a
s
o
n
a
b
le
 
s
ta
rt
in
g
 d
o
s
e
 f
o
r 
th
e
 
tr
e
a
tm
e
n
t 
o
f 
s
ti
m
u
la
n
t 
a
b
u
s
e
 a
n
d
 
d
e
p
e
n
d
e
n
c
e
. 
 
R
e
s
u
lt
s
 
A
ri
p
ip
ra
z
o
le
 s
ig
n
if
ic
a
n
tl
y
 
a
tt
e
n
u
a
te
d
 t
h
e
 
d
is
c
ri
m
in
a
ti
v
e
-s
ti
m
u
lu
s
 
a
n
d
 c
a
rd
io
v
a
s
c
u
la
r 
 
e
ff
e
c
ts
 o
f 
D
-
a
m
p
h
e
ta
m
in
e
. 
O
u
tc
o
m
e
 
R
a
ti
n
g
 s
c
a
le
 o
f 
a
c
ti
v
e
, 
a
le
rt
 a
n
d
 e
n
e
rg
e
ti
c
, 
b
lo
o
d
 p
re
s
s
u
re
 a
n
d
 
h
e
a
rt
 r
a
te
. 
In
te
rv
e
n
ti
o
n
 
i)
T
o
 d
is
c
ri
m
in
a
te
  
b
e
tw
e
e
n
 1
5
 
m
g
 o
ra
l 
D
-a
m
p
h
e
ta
m
in
e
 o
r 
p
la
c
e
b
o
 l
a
te
r 
ii)
to
 a
s
s
e
s
s
 t
h
e
 e
ff
e
c
ts
 o
f 
a
 
ra
n
g
e
 o
f 
d
o
s
e
s
 o
f 
 D
-
a
m
p
h
e
ta
m
in
e
 (
0
,2
.5
,5
,1
0
 a
n
d
 
1
5
 m
g
 )
a
lo
n
e
 a
n
d
 i
n
 
c
o
m
b
in
a
ti
o
n
 w
it
h
 
a
ri
p
ip
ra
z
o
le
(0
 a
n
d
 1
0
 m
g
) 
S
tu
d
y
 S
u
b
je
c
ts
 
6
 h
e
a
lt
h
y
 s
u
b
je
c
ts
 w
it
h
 a
 
lif
e
ti
m
e
 h
is
to
ry
 o
f 
n
o
n
th
e
ra
p
e
u
ti
c
 u
s
e
  
o
f 
a
 
s
ti
m
u
la
n
t 
S
tu
d
y
 
(S
to
o
p
s
 e
t 
a
l.
, 
2
0
0
6
) 
7  Overall Conclusions and Recommendations  
 221 
6.3.9. RESEARCH QUESTION 
Is aripiprazole has better safety and efficacy compare to placebo in 
methamphetamine dependence patients? 
6.3.10. STUDY OBJECTIVES  
Primary Objective  
To determine the efficacy of Aripiprazole in maintaining of abstinence 
and retention among methamphetamine dependence patients.  
Secondary objective 
To determine the safety of Aripiprazole in the treatment of 
methamphetamine dependence patients.  
Tertiary objective 
i). To determine whether Aripiprazole treatment will reduce 
methamphetamine withdrawal symptoms. 
ii). To determine the efficacy of Aripiprazole in reducing anxiety and 
depressive symptoms among methamphetamine dependence 
patients.  
iii). To determine the efficacy of Aripiprazole in preventing psychotic 
symptoms among methamphetamine dependence patients.  
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6.3.11. HYPOTHESES 
Hypothesis for primary objective:   
i). The aripiprazole-treated subjects have lower proportion of 
positive urine samples than subjects given placebo between 
baseline, day 7, day 14, day 28, day 42 and day 56.  
ii). The proportion of retention for subjects treated with aripiprazole 
was higher compare to placebo-treated subjects. 
iii). The mean duration of follow-up among  aripiprazole-treated 
subjects was longer than compare placebo-treated subjects.   
Hypothesis for secondary objective:   
i). There was no difference in the proportions of adverse events between 
aripiprazole-treated and placebo-treated subjects. 
ii). Aripiprazole-treated subjects will not show a significantly increase in 
BAS, SAS, AIMS scores between baseline, day 14 and day 42. 
Hypothesis for tertiary objective:   
i). Aripiprazole-treated subjects have a significantly greater reduction in 
PANSS means scores than subjects given placebo between 
baseline, day 14 and day 56.  
ii). Aripiprazole-treated subjects have a significantly greater reduction 
in CGI means scores than subjects given placebo between 
baseline, day 14 and day 56.  
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iii). Aripiprazole-treated subjects have a significantly greater 
reduction in HADS-anxiety means scores than subjects given 
placebo between baseline, day 14 and day 42.  
iv). Aripiprazole-treated subjects have a significantly greater 
reduction in HADS-depression means scores than subjects 
given placebo between baseline, day 14 and day 42.  
v). Aripiprazole-treated subjects have a significantly greater 
reduction in Brief Substance Craving Scale (BSCS) means 
scores than subjects given placebo between baseline, day 7, 
day 14, day 28, day 42 and day 56.  
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6.4  Methodology 
 
6.4.1. Study Design 
This study was a randomized double-blind placebo-controlled parallel 
trial. This study was the continuity from the open-label study in chapter 5. 
Figure 6.3   The overall study design for methamphetamine-induced 
psychosis and methamphetamine dependence study 
 
6.4.2. Study Period 
The study period was from July 2007 until June 2011. Data was 
collected from September 2008 to December 2010.  
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6.4.3. Location of Study 
This study was conducted at the outpatient psychiatric clinic in 
University Malaya Medical Centre (UMMC).  
6.4.4. Study Population 
The study population included male or female with current DSM-IV 
diagnoses of methamphetamine dependence.  
6.4.5. Inclusion Criteria 
i). Male or female, aged 18 – 60 years.  
ii). Primary diagnosis of methamphetamine dependence confirmed by 
DSM-IV. Patient must not have current dependence with other 
substances such as alcohol, cocaine, opiates and marijuana except 
for nicotine. However, abuse of these drugs was allowed for this 
study. 
iii).  Urine positive for methamphetamine and within 30 days of last use 
of the methamphetamine. 
iv). Must have been using methamphetamine at least once a week for 
the past three months at enrollment. 
v). History of having psychotic symptom prior to randomization. 
vi). History of treatment with aripiprazole at least 2 weeks prior to 
randomization.   
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vii). Present without any current intoxification effects of 
methamphetamine to provide written consent at the time of the 
baseline session and to comply with study procedures.  
viii). No diagnosis of schizophrenia, schizoaffective disorder, bipolar 
affective disorder, major depression with psychotic symptoms, 
delusional disorder, organic brain disease, dementia, or any 
diseases that require other antipsychotics. If they have a history of 
a mood and anxiety disorder, they were not on pharmacological 
treatment for at least the previous two weeks.  
ix). Patient was not currently taking psychotrophics such as 
antipsychotic except for aripiprazole, mood stabilizer, anti-anxiety or 
antidepression medications. 
x). Using a barrier (diaphragm or condom) with spermicide, intrauterine 
device (IUD), or complete abstinence as a method of birth control (if 
a woman of child-bearing capacity).  
xi). Patient was not suicidal or homicidal. 
6.4.6. Exclusion Criteria 
i). Serious medical illnesses that potentially progress to life-
threatening medical illness which may compromise patient safety or 
study conduct. 
ii). Known hypersensitivity or allergy to Aripiprazole. 
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iii). Documented history of schizophrenia, bipolar, organic brain 
disease, dementia, or any diseases that require other 
antipsychotics.  
iv). Clinically significant abnormal laboratory values. 
v). Female who is positive on a urine pregnancy test or lactating. 
6.4.7. Sample size estimation 
 
Based on previous studies (Tiihonen et al., 2007, Newton et al., 2008), 
the minimum sample size required for this study was calculated by 
using the PS software.  
i). The power of the study is taken at 80% level.  
ii). The significance level of the statistic tests done was at 95% 
Confidence Interval level and  was set at 0.05. The Null 
hypothesis was rejected when p < 0.05. 
iii). p0 - The probability of the outcome for the control patient (failure in 
maintaining retention) is 0.95.    
iv). p1 - The probability of the outcome for the intervention patient 
(failure in maintaining retention) is 0.5.    
v). The ratio of case to control is taken as 1 : 1. 
Therefore the sample size obtained for this study as follow: 
Number of treatment arm  = 18 patients 
Number of control arm = 18 patients 
Total number of subjects = 36 patients 
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6.4.8. Study Variables 
The study variables that were considered for analysis in this study 
population were as follows: 
(Operational definitions in ANNEX A) 
6.4.8.1 Primary Study Endpoints  
 Urine toxicology screened for methamphetamine.  
Urine samples were collected during visit day 7, 14, 28, 42 and 
day 56.  
 The proportion of outpatient attending research evaluation visits 
for aripiprazole and placebo. 
Patients were scheduled for research evaluation visits on day 7, 
14, 28, 42 and day 56.  
6.4.8.2 Secondary Study Endpoint  
 The means scores of BAS, SAS, AIMS rating scale to measure 
the safety of aripiprazole  
 To describe all side effects reported by patients during the study. 
Patients were assessed on 14 day 42.  
6.4.8.4 Tertiary Study Endpoint 
 The means score of Brief Substance Craving Scale (BSCS) 
Patients were assessed on day 7, 14, 28, 42 and day 56.  
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 The means score of HADS-anxiety and HADS-depression rating 
scale 
Patients were assessed on 14 day 42.  
 The means score of PANSS and CGI. 
Patients were assessed on 14 day 56.  
6.4.8.4 Descriptive Variables 
Sociodemographic Variables 
i). Age  
ii). Sex  
iii). Race 
iv). Employment pattern (For the past 2 years)  
v). Total family income 
vi). Educational level 
vii). Marital status 
viii). Number of siblings 
Drug dependence and abuse history  
i). Duration of methamphetamine used  
ii). Age of first methamphetamine used  
iii). Amount of money spend monthly for methamphetamine  
iv). Route of methamphetamine  
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v). History of nicotine dependence 
vi). History of alcohol abuse 
vii). History of other drug used  
6.4.9. Study Instruments 
Major Axis I psychiatric disorder assessment  
i). MINI International Neuropsychiatric Interview (M.I.N.I.) 
(Sheehan et al., 1998b)  
This was a face-to-face structured interview for the Major Axis I 
psychiatric disorder in DSM-IV and ICD-10. The M.I.N.I. is a short 
structured diagnostic interview for DSM-IV or ICD-10 psychiatric 
disorders for the Major Axis I psychiatric disorder including suicidality. It 
has been widely used in international clinical trials and epidemiological 
studies (Joling et al., 2008, Van't Veer-Tazelaar et al., 2009). The MINI 
was available in local language (Sheehan et al., 1998a).  
ii). Brief Substance Craving Scale (BSCA) (Somoza E, 1999b) 
The BSCS uses Likert scales, ranging from 0 to 4, to assess 
methamphetamine craving on 3 dimensions of craving: intensity, 
length, and frequency. A composite score is derived from the total of 
these items. 
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iii). Positive and Negative Symptoms Scale (PANSS) (Kay et al., 
1987) 
The Positive and Negative Syndrome Scale (PANSS) is a medical 
scale used for measuring symptom severity of patients with 
schizophrenia. It refers to the two types of symptoms in schizophrenia, 
as defined by the American Psychiatric Association: positive 
symptoms, which refer to an excess or distortion of normal functions 
(e.g. hallucinations and delusions), and negative symptoms, which 
represent a diminution or loss of normal functions. A face-to-face 
interviewed of the scale will capture three components: positive scale 
(7 items), negative scale (7 items) and general psychopathology scale 
(16 items). 
iv). Abnormal Involuntary Movement Scale (AIMS) (Rush, 2000) 
The Abnormal Involuntary Movement Scale (AIMS) is a rating scale  
that was originally designed in Italian language in the 1980s,(Burti et 
al., 1981) to measure involuntary movements known as tardive 
dyskinesia (TD). TD is a disorder that sometimes develops as a side 
effect of long-term   treatment with neuroleptic (antipsychotic) 
medications. The AIMS test is used not only to detect tardive 
dyskinesia but also to follow the severity of a patient's TD over time. It 
is a valuable tool for clinicians who are monitoring the effects of long-
term treatment with neuroleptic medications and also for researchers 
studying the effects of these drugs. The AIMS test was originally 
developed for administration by trained clinicians. 
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v). Barnes Akathasia Scale (BAS) (Barnes, 1989)  
The Barnes Akathisia Scale (commonly known as BAS or BARS) is a 
rating scale that is administered by physicians to assess the severity of 
drug-induced akathisia. The Barnes Akathisia Scale is the most widely 
used rating scale for akathisia. This scale includes objective and 
subjective items such as the level of the patient's restlessness. It 
comprises items for rating the observable, restless movements which 
characterise the condition, the subjective awareness of restlessness, 
and any distress associated with the akathisia. In addition, there is an 
item for rating global severity. A standard examination procedure is 
recommended. The inter- rater reliability for the scale items (Cohen's 
kappa) ranged from 0.738 to 0.955. 
Akathisia is a syndrome of motor restlessness, principally seen in 
association with antipsychotic medication. It is characterized by a 
subjective experience of mental unease and the urge to move, and 
manifests physically as particular patterns of restless movement. 
vi). Simpson Angus Scale (SAS) (Simpson and Angus, 1970)  
Simpson-Angus Scale (SAS) is a 10-item rating scale that has been 
used widely for assessment of Neuroleptic-InducedParkinson in both 
clinical practice and research settings. It consists of one item 
measuring gait (hypokinesia), six items measuring rigidity and three 
items measuring glabella tap, tremor and salivation, respectively. Items 
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are rated for severity on a 0-4 scale, with definitions given for each 
anchor point. It is an established rating scale. SAS is a reliable and a 
valid instrument. It performs well and similarly to DSM-IV in Neuroleptic 
Induce Parkinsonism case detection (Janno et al., 2005). 
vii). Clinical Global Impression Scale (CGI)  
The Clinical Global Impression rating scales are commonly used 
measures of symptom severity, treatment response and the efficacy of 
treatments in treatment studies of patients with mental disorders (Guy, 
1976). Many researchers, while recognizing the validity of the scale, 
consider it to be subjective as it requires the user of the scale to 
compare the subjects to typical patients in the clinician experience 
(Haro et al., 2003, Huber et al., 2008). 
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point 
scale that requires the clinician to rate the severity of the patient's 
illness at the time of assessment, relative to the clinician's past 
experience with patients who have the same diagnosis. Considering 
total clinical experience, a patient is assessed on severity of mental 
illness at the time of rating 1=normal, not at all ill; 2, borderline mentally 
ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, 
extremely ill. 
viii). Hospital Anxiety Depression Scale (HADS)  
The Hospital Anxiety and Depression Scale (HADS) was developed by 
Zigmond and Snaith (Zigmond and Snaith, 1983) in 1983. Its purpose 
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is to provide clinicians with an acceptable, reliable, valid and easy to 
use practical tool for identifying and quantifying depression and 
anxiety. The role of the scale is dimensional rather than categorical; it 
is best used not to make diagnoses of psychiatric disorders, but for 
identifying general hospital patients who need further psychiatric 
evaluation and assistance (Herrmann, 1997). 
The HADS is a self-report rating scale of 14 items on a 4-point Likert 
scale (range 0–3). It is designed to measure anxiety and depression (7 
items for each subscale). The total score is the sum of the 14 items, 
and for each subscale the score is the sum of the respective seven 
items (ranging from 0–21). It is worth noting that items referring to 
depression symptoms that describe somatic aspects of depression 
(e.g. insomnia and weight loss) are not included in the scale. 
The HADS has been translated and widely used in more than 25 
countries since its original development. Herrmann, in an extended 
review, reported that the HADS has demonstrated reliability and validity 
when used to assess medical patients (Herrmann, 1997). Bjelland 
reached similar conclusions in his review 5 years later (Bjelland et al., 
2002). The HADS has been used in the general population(Mykletun et 
al., 2001), on general hospital patients (Johnston et al., 2000), in 
cancer care settings(Moorey et al., 1991), and even in HIV patients 
(Savard et al., 1998). 
ix). Structured Questionnaires 
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The patients were screened in order to identify methamphetamine 
dependence by using a structured questionnaire, which consists of four 
sections. The first section was to assess the demographic data of the 
study population. The second section was to identify the characteristics 
of crimes/illegal activities. The third section was to obtain the medical 
history and the last section was to assess the social and emotional 
factors among the patients.  
6.4.10. Study Drug  
6.4.10.1 Intervention 
Aripiprazole is a psychotropic drug. It is a light yellow colour, round, 
flat, bevelled edged, uncoated tablets that contain 10mg of 
aripiprazole. Aripiprazole was put in an opaque gelatine capsule in 
order to be identical to the placebo. 
6.4.10.2 Placebo  
The placebo formulation for this study is vitamin B complex in a tablet 
form. In order for the placebo to appear identical to aripiprazole, the 
placebo was put in an opaque gelatine capsule that has same colour, 
shape and size for aripiprazole.  
6.4.10.3 Concomitant Therapy  
The concomitant medications such as benzodiazepine and benzhexol 
were allowed for this study.  
Commitment therapy that not permitted during the study was:  
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i). Carbamazepine  
ii). Ketoconazole  
iii). Quinidine  
iv). Fluoxetine  
v). Paroxetine 
6.4.10.4 Packaging of Study Drug 
Study drug (intervention) was supplied in bulk shipments by a 
pharmaceutical company whereas placebo (vitamin B complex) was 
obtained from a pharmacy. A study coordinator repackaged the bulk 
drug into packs containing seven gelatin capsules per pack (10mg 
each for aripiprazole).  
A separate pack containing seven capsules per pack with 5 mg each 
for aripiprazole was done, in case patient could not tolerate the 10 mg 
of aripiprazole. 
6.4.10.5 Receiving, Storage, Dispensing and Return 
 
i). Receipt of Drug Supplies 
An inventory was performed after accepting the drug shipment. The 
study coordinator counted and verified the shipment containing all the 
items mentioned in the supply. The investigator would notify to the 
pharmaceutical company of any damage of the study drug.  
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ii). Storage 
Stock study drug and drug packaged in patient kits were stored in a 
locked cabinet in the research centre with climate control maintaining 
the temperatures within a range of 20°C to 25°C. Only the study 
coordinator and principal investigator have access to the study drug.  
iii). Dispensing of Study Drug 
The principal investigator or study coordinator would dispense the 
appropriate amount of study drug, according to the number of days of 
follow up of the research subject based on the randomization list. 
Subject compliance monitoring was conducted by doing pill counts at 
every study visit for all patients. 
iv). Return of Study Drug 
At the completion of the study, the final reconciliation of drug shipped, 
drug consumed and drug remaining was done. After appropriate 
accounting the pharmaceutical company was informed, the unused 
study drug was returned to the pharmaceutical company.  
6.4.11. Conduct of study 
i). Training of study coordinator 
The study coordinator was trained with regards to the screening, 
recruitment and interviewing the study patient for the baseline 
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characteristics. She was also trained about the procedure in handling 
the study drug.          
ii). Pre-test 
A pre-test of the structured questionnaires was done on 10 patients 
who were attending the substances dependence clinic at UMMC. 
Some corrections were made to facilitate patients’ understanding of the 
questionnaires. 
iii). Subject recruitment and screening 
All patients from the previous open label study (chapter 5) were 
approached during this study. Some of the patients were recruited from 
the response of this study newspaper advertisement, as well as articles 
written up by principal investigator in newspaper pertaining to 
methamphetamine dependence. Patients were briefed on this study 
and written consent was obtained. Prior to the consent, patient was 
explained detailed information about aripiprazole, the rationale for why 
it was being studied, frequency of dosing, and length of treatment, 
potential benefits, side effects and risks, safeguards and emergency 
procedures. The collections of all laboratory specimens were described 
in detail, as the number and frequency of the research interviews and 
self-assessments. Patients were assured that their participation was 
voluntary and that withdrawal from the study would not jeopardize 
current or future treatment. Randomization was explained to the 
patients, as they would know their treatment assignment at the end of 
the study, after the blind has broken.   
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A M.I.N.I was administered to obtain DSM-IV diagnoses of 
methamphetamine dependence and to rule out other psychiatric 
disorders. All medications taken by the patient for the 30 days prior to 
screening was documented. A face-to-face interview was conducted to 
collect primary data by using a structured questionnaire. Some 
secondary data pertaining to patient and family medical history were 
obtained from patient’s case note. Only patients who were 
methamphetamine positive during urine screening of open-label study 
were included in this study. The principal investigator confirmed and 
signed off on the inclusion and exclusion criteria on a case report form 
(CRF) prior to the patient formally recruited in the study or given study 
medication. 
iv). Baseline visit 
The patients were further assessed with M.I.N.I. for the Major Axis I 
psychiatric disorder and evaluated BSCA, PANSS, AIMS, BAS, SAS, 
CGI and HADS. A complete physical examination was done including 
vital signs and weight. A urine pregnancy test was conducted for 
female patients with childbearing capability. 
v). Randomization  
Patients were assigned to the study drugs according to a 
randomization list. The randomization list in the block of 4 was 
computer generated by Randomization.com programme. Patients were 
randomized to one of two treatment of either aripiprazole 10mg/day (n 
= 19) or placebo (n = 18). Randomization code for aripiprazole and 
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placebo, either A or B was done by an independent person. The 
randomization code was put in an envelope and kept in the Psychiatric 
Unit Research Center, PPUM. It was only can be assessed by principle 
investigator in the case of severe adverse event happen during the 
study. 
vi). Blinding of Study Drug 
Seems this was a double blind study, both patients and the assessor 
were blinded to the study drug.    
vii). Method for assigning subjects to treatment groups  
Patients were randomized according to the following regimen: 
Study drug (Aripiprazole-10mg each or placebo): one tablet orally, 
administered as a single dose, for 56 days (8 weeks). Patients would 
take the study drug daily dose at 8:00 a.m. 
viii). Follow-Up Evaluation  
A follow-up evaluation was scheduled on day 7,14, 28, 42 day 56 after 
the beginning of the study. If subjects could not attend the scheduled 
visit, subject was given appointment on the subsequent day.  
 At each follow-up evaluation, urine sample was collected from patients 
and urine toxicology was performed for methamphetamine. Their vital 
signs and weights were measured, and any adverse event was 
recorded.  Patients were evaluated BSCA, PANSS, AIMS, BAS, SAS, 
CGI and HADS.  
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If subjects experienced significant side effects from the study drug 
(Aripiprazole or placebo), the principal investigator would have the 
option to reduce the dose for aripiprazole or vitamin B Complex during 
the study, depending on the clinical interview. Acceptable dose 
reduction for aripiprazole was from one tablet per day (10 mg/day) to 
half tablets per day 5 mg/day, and for patients receiving placebo, 
vitamin B complex aripiprazole from one tablet per day was reduced to 
half tablet per day. Upward titration following a dose reduction was 
allowed during the trial. Dose titration was documented in the study 
chart along with the clinical rationale. At the end of the study drug 
treatment period, study drug was discontinued without tapering. 
The concomitant medications were reviewed.  Finally pill count was 
done, the unused study drug was collected from the previous follow up 
and dispensed the new study drug. During the study visit, the study 
termination form was completed in case of discontinuation of patient 
from this study.  
ix). Subject Compliance Monitoring 
The research coordinator conducted pill counts at the follow-up visit of 
all study patients. Unused amounts were documented. Proper drug 
dosing was reviewed with patients at each visit with clear instructions 
to take all study drugs as directed. 
x). End of medication evaluation 
This evaluation was scheduled on the day 56 study drug treatment 
period. At this meeting, the following evaluations were completed:  
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1) Physical examination 
2) Vital signs and weight 
3) PANSS 
4) CGI-S 
5) HADS 
6) BARS 
7) SAS 
8) AIMS 
9) BSCS 
  
 
xi). Early withdrawal of subjects 
Any patients experiencing a serious adverse event felt to be related to 
study drug were withdrawn from the study. Patients were also 
withdrawn if they required hospitalization for addiction or psychiatric 
treatment, received other psychotropic medications, or if 
discontinuation from the study was deemed by the principal 
investigator based on their best interest. Any patient withdrawing their 
consent to participate in the study or their authorization to use their 
protected health information was withdrawn from the study. Patients 
discontinued from the clinical trial were given appropriate treatment 
referrals to the outpatient psychiatric clinic, UMMC. Patients were 
instructed to return all unused medications. For the early withdrawal, 
patients had all final assessments that originally were scheduled for the 
end of study visit.  
All patients randomized into the study were included in the final study 
analyses. Patients were not dropped from all study activities unless 
they requested not to be contacted or could not be located for the 2-
weeks follow-up assessment. Patients were informed at the consent 
session that treatment might be discontinued due to:  
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 Intolerable side effects 
 Development or exacerbation of psychiatric symptoms 
necessitating inpatient admission or a more aggressive 
therapeutic intervention than was provided by the protocol  
 Methamphetamine or other substance abuse necessitating 
inpatient admission or a more aggressive treatment than was 
provided by the protocol 
 Clinical deterioration for any reason or any clinical status that 
necessitates inpatient admission 
 Incarceration for more than 2 weeks 
 Failure to attend 3 consecutive outpatient evaluation visits 
 Failure to provide laboratory specimens 
Reasons why patients discontinued from the clinical trial were 
documented on the Study Termination Form, along with any referrals 
that were made. A final safety evaluation was conducted as soon as 
possible on all randomized patients who have been discontinued from 
the study.  
6.4.12. Safety and Adverse Events  
i). Recording of Adverse Events 
During the research evaluation visit, the patient was asked on adverse 
events through specific questioning and by examination. Information on 
all adverse events was recorded immediately in the case report form 
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(CRF). Each adverse event was followed up until resolution or 
stabilization has been achieved. 
In the case of the occurrence of serious adverse event (SAE), it was 
followed up to determine the final outcome. Any serious adverse event 
that occurred after the study period was considered possibly related to 
the study drug, was recorded and reported immediately.   
ii). Reporting of Serious Adverse Events To Ethic Committee 
(EC) by Principal Investigator 
A serious adverse event must be reported to the EC within 24 hours 
(one working day) of the event. The principal investigator would keep a 
copy of the SAE form in the file. Within the following 48 hours, the 
principal investigator would provide further information and progress on 
the serious adverse event to the EC.   
In the SAE form, the following information should be provided: 
 Study identifier 
 Subject number 
 A description of the event 
 Date of onset 
 Current status 
 Whether study treatment was discontinued 
 The reason why the event was classified as serious 
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 Principle investigator assessment of the association between the 
event and study drug 
iii). Unblinding Procedures 
In the event that patients were prematurely discontinued from the trial, 
it was necessary to avoid breaking the blind whenever possible, in 
order to protect the integrity of the study. If an emergency necessitates 
that the blind be broken, only the principal investigator has the authority 
to inform the actual study drug to the relevant party.  
iv). Medical Monitoring 
The principal investigator was responsible to oversee the safety of the 
study. This safety monitoring would include careful assessment and 
appropriate reporting of adverse events. Medical monitoring would 
include a regular assessment of the number and type of serious 
adverse events. 
v). Protection of Subjects 
Additional procedures would be conducted to protect the safety of the 
study patients. Potential patients would be screened for medical 
illnesses that would preclude the use of aripiprazole. Patients selected 
for the study would be evaluated weekly for AE while receiving study 
drug. Venipuncture was carried out with good aseptic technique by an 
experienced nurse or physician. Before randomized medications, a 
physical examination, ECG and a urine pregnancy test (if female of 
childbearing capability) were performed. Patients were given a 24-hour 
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emergency number form them to call if necessary. The principal 
investigator would follow all patients who were discontinued due to any 
serious AEs until the AE resolved and become completely stable, 
unless a referral to another physician or specialist was clinically 
indicated or requested by the patient.  
6.4.13. Data Handling and Record Keeping 
i). Data Management 
The data were checked before ending each interview session and 
before compilation to ensure completeness. If missing data was found, 
the patient will be contacted through telephone. Raw data obtained 
were coded and entered into Statistical Package for Social Sciences 
(SPSS) Version 16.0. Statistical analysis was done on an intention-to-
treat basis. The primary outcome measure was the proportion of 
methamphetamine-positive urine samples during the pharmacological 
treatment. In terms of missing data, they require that the data be 
missing at random. This means that the missing data contains no 
information about treatment outcome, beyond that already contained in 
the observed data. 
The data were summarized by running frequency distributions and 
simple descriptive statistics (means and standard deviations). Cleaning 
for double entry and outliers before analysis was done.   
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ii). Confidentiality 
Information about study patients was kept confidential and managed 
according to the requirements of the EC.  
iii). Source Data and Case Report Form 
Source data was all information, original records of clinical findings, 
observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data were contained 
in source documents such as hospital records, clinic charts, laboratory 
results, pharmacy dispensing records, recorded data from automated 
instruments, microfilm or magnetic media, x-rays, subject files, records 
kept at the pharmacy, at the laboratories, at medical record department 
and other related documents. 
The study case report form (CRF) was the primary data collection 
instrument for the study. All data requested on the CRF were recorded 
and all missing data were explained. “N/D” was written if a space on 
the CRF was left blank because the procedure was not done or the 
question was not asked. “N/A” was written if the item was not 
applicable to the individual case. All entries should be printed legibly in 
black ink. If any entry error has been made, to correct such an error, a 
single straight line was drawn through the incorrect entry and the 
correct data was entered above it. All such changes were initialed and 
dated.  
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6.4.14. Ethical consideration 
Ethical clearance had been obtained earlier from UMMC’s ethical 
committee (ANNEX D). The interviewer was required to introduce 
herself to the subject. Before any interview, patients had been informed 
regarding the nature and purpose of study and ensuring the 
respondent on confidentiality of the information. Written consent was 
obtained from the patients. 
6.4.15. Statistical Analysis 
i). Univariate analyses 
Descriptive statistics were used to summarize demographic variables, 
history of drug use and adverse events. For nominal independent 
variables, they were described in the form of frequencies and 
percentages. For continuous independent variables, they were 
summarized and described as means, standard deviations and 
median.  
ii). Bivariate analysis   
The independent t-test was used to examine changes in means of 
continuous variables and rating scales such as PANSS ,CGI, BSCS, 
BARS, SAS and AIMS. Skewed data was analysed using non 
parametric test. The retention in treatment was analysed using Kaplan 
Meier survivor function. An alpha level of significance 0.05 was set for 
all analyses.     
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iii). Multivariate Analysis  
Categorical repeated measures variables such as primary study 
hypotheses concerning the effect of aripiprazole versus placebo on 
urine methamphetamine screen results were examined using 
generalized estimating equations(GEE). GEE assumes that missing 
data are missing ‘completely at random’. Effect of treatment condition 
on continuous repeated measures such as PANSS, CGI, HADS and 
BSCS were evaluated using mixed model approach.  Mixed-model 
repeated measures (MMRM) were employed because it produces 
unbiased results to the missing data. Drug condition, time and the 
interation between drug and time were fitted as main effects for GEE 
and MMRM.  
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6.5  Results  
 
A total of 145 treatment seeking methamphetamine dependence 
patients were screened. Seventy-three were eligible for the study but 
24 patients declined participations. Forthy-nine patients provided 
informed consent and were treated for two weeks with aripiprazole 
(open label study in chapter 5). After 2 weeks of aripiprazole treatment, 
37 patients fulfil all inclusion criteria and do not have any exclusion 
criteria. 19 patients were randomized to aripiprazole and 18 to placebo 
(Figure 6.4). 84.2% of participants randomized to aripiprazole 
completed the 8 weeks study visit compared to only 50% of 
participants randomized to placebo (p < 0.05). 
 
Baseline Characteristics 
The baseline characteristics of participants randomized to aripiprazole 
and placebo are shown on table 6.3, while the drug history 
characteristics were shown on table 6.4. There were no significant 
difference between the aripiprazole and placebo in terms of baseline 
demographic characteristics and previous drug history. 
Retention 
The maximum length of time in treatment was 56 days. There was a 
statistically significant difference between groups in the amount of time 
spent in treatment (p < 0.05), with those given aripiprazole retained for 
an average of 48.7 days (+ 4.0) compared with only 37.1 days (+ 5.0) 
for the placebo group. Time to dropout was also compared between 
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groups (Figure 6.6). The survival curves results showed that 
participants in the aripiprazole group were less likely to drop out of the 
study than those in the placebo group. The difference was statistically 
significant, according to Cox‘s regression analysis (p < 0.05).   
Urinalysis Results 
 
There were no statistically significant differences between participants 
receiving aripiprazole and those receiving placebo in the GEE analysis 
of urine drug screen results (Figure 6.5, Table 6.5 and Table 6.6).   
Psychotic Symptoms 
 
Psychotic symptoms as measured by PANSS decreased among 
participants who were randomized to aripiprazole treatment but those 
who were randomized to placebo showed an increased in the total 
PANSS score (Table 6.12). There was significant effect of the 
treatment over time in PANSS score during the treatment period 
between participants in the two treatment conditions using a mixed 
model repeated measures (MMRM) (Table 6.13). 
Similarly the CGI score decreased among participants who were 
randomized to aripiprazole treatment but those who were randomized 
to placebo showed an increased in the CGI score (Table 6.12). There 
was significant effect of the treatment over time in CGI score during the 
treatment period between participants in the two treatment conditions 
using MMRM (Table 6.13). 
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Anxiety Symptoms  
 
Anxiety symptoms as measured by HADS decreased among 
participants who were randomised to aripiprazole treatment but those 
who were randomised to placebo showed an increased in the HADS 
score (Table 6.14). There was significant effect of the treatment over 
time in HADS score during the treatment period between participants in 
the two treatment conditions using MMRM (Table 6.15). 
Depressive Symptoms  
 
Depressive symptoms were measured by using HADS scale. 
Depressive symptoms were generally lower in aripiprazole treatment 
arm than in the placebo arm, but the difference was not statistically 
significant except on Day 14 (p=0.02) (Table 6.14). The HADS-
depression score in patients receiving aripiprazole decreased from 2.5 
± 23.6 on day 1 to 1.7±2.8 on day 14, but increased to 2.1±2.8 by day 
42. There was no significant effect of the treatment over time in HADS-
depression score during the treatment period between participants in 
the two treatment conditions using MMRM (Table 6.15). 
Methamphetamine Craving  
 
Craving symptoms were measured by using the BSCS scales. There 
were statistically significant differences in the BSCS score between 
patients in the aripiprazole group and those in the placebo group on 
visit day 28, day 42 and day 56 (Table 6.14). There were also 
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statistically significant effects of the intervention using the BSCS scales 
in the MMRM (Table 6.15). 
 
Adverse Events 
 
Adverse events (AEs) reported in both groups were all mild to 
moderate in intensity. No serious AEs occurred during the study. There 
were no significant differences in the incidence of AEs between the 
aripiprazole arm and the placebo arm in any of the AEs (Table 6.7). In 
the aripiprazole arm, akathisia, insomnia and agitation were the three 
most common AEs reported, while in the placebo arm, psychosis and 
insomnia were the two most common AEs reported.   
 
Concomitant Medications 
There were 7 patients from the aripiprazole arm received concomitant 
medications and 3 from the placebo arm receive concomitant 
medications. Medications given were: lorazepam to treat agitation, 
akathisia and insomnia; zolpidem to treat insomnia; and escitalopram 
to treat depression (Table 6.8). 
 
BARS, SAS and AIMS 
 
The BARS, SAS and AIMS scores were shown in Table 6.9 and Table 
6.10. There were no statistically significant changes between the 
aripiprazole and placebo arm for all the scales. 
 
 
7  Overall Conclusions and Recommendations  
 254 
Aripiprazole Dosage 
The average mean dose for aripiprazole during the study was shown in 
Table 6.11. The patients were started on 10 mg aripiprazole at 
baseline, and were given flexible doses of 5-10 mg/day during the 8-
week study. 
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Figure 6.4   Disposition of patients in the randomized controlled trial 
between aripiprazole and placebo for methamphetamine dependence 
patients 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 were excluded: 
- 46 have other psychiatric diagnosis 
(schizophrenia or bipolar) 
- 23 have polysubstance dependence 
- 3 have significant medical illness 
(unstable diabetes or hypertension) 
 
73 patients Eligible 
24 Patients declined participation 
49 patients entered for open-label treatment 
(2 weeks aripiprazole treatment) 
 
 
- 5 patients loss to follow up 
- 4 patients still psychotic (require long term 
antipsychotic treatment) 
- 2 patients had adverse events (akathisia) 
- 1 patients withdraw consent 
-  
19 assigned to aripiprazole 
37 patients randomized 
18 assigned to placebo 
3 patients loss to 
follow up 
 
10 patients loss to 
follow up 
16 completed treatment 8 completed treatment 
145 patients screened 
7  Overall Conclusions and Recommendations  
 256 
Table 6.3  Sociodemographic characteristics of methamphetamine 
dependence subjects  
Variables Aripiprazole (n=19) Placebo (n=18)  p value 
 
Age , mean + SD 
 
35.5 + 8.5 
 
32.9 + 8.4 
 
p >0.05 
    
Gender, % 
    Male 
    Female 
 
Ethnic, % 
    Malay 
    Chinese 
    ‡Indian 
 
Marital Status, % 
    ‡Married 
    Single 
    Divorced 
 
Education, % 
    ‡Tertiary 
    Secondary 
    Primary 
 
Employment, % 
    Full time 
    Part time 
    Student 
    ‡Unemployed 
 
Income, mean + SD 
(in Ringgit Malaysia 
per month) 
 
Number of sibling, 
mean + SD 
 
 
 
94.7 (18) 
5.3 (1) 
 
 
57.9 (11) 
31.6 (6) 
10.5 (2) 
 
 
42.1 (8) 
42.1 (8) 
15.8 (3) 
 
 
11.2 (2) 
77.8 (14) 
11.1 (2) 
 
 
78.9 (15) 
0 
0 
21.4 (4) 
 
8,047 + 23,172 
 
 
 
4.9 + 2.8 
 
 
 
 
94.4 (17) 
5.6 (1) 
 
 
72.2 (13) 
16.7 (3) 
11.1 (2) 
 
 
44.4 (8) 
38.9 (7) 
16.7 (3) 
 
 
16.7 (3) 
77.7 (14) 
5.6 (1) 
 
 
83.3 (15) 
5.6 (1) 
5.6 (1) 
5.6 (1) 
 
3,441 + 4,801 
 
 
 
5.5 + 2.5 
 
 
 
 
p >0.05 
 
 
 
p >0.05 
 
 
 
 
 
p>0.05 
 
 
 
 
p>0.05 
 
 
 
 
 
p >0.05 
 
  
p >0.05¶ 
 
 
 
p >0.05 
 
 
 
‡Reference group 
¶Mann-Whitney U Test 
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Table 6.4        Drug history of methamphetamine dependence subjects  
Variables Aripiprazole 
(n=19) 
Placebo (n=18) p value 
 
Years methamphetamine 
used,  
mean + SD 
 
Age of first 
methamphetamine used,  
mean + SD 
 
 
 
5.5 + 4.8 
 
 
 
30.8 + 8.2 
 
 
4.8 + 3.6 
 
 
 
28.2 + 9.2 
 
 
p>0.05 
 
 
 
p>0.05 
 
Amount of money spend 
monthly for 
methamphetamine, 
mean + SD in Ringgit 
Malaysia 
 
Route of methamphetamine, 
(%) 
    Smoking 
    Nasal 
    ‡Oral 
 
Nicotine dependence,(%) 
 
Alcohol abuse,(%) 
 
Cannabis abuse,(%) 
 
 
 
1,311 + 1,320 
 
 
 
 
 
61.1 (11) 
27.8 (5) 
8.3 (3) 
 
83.3 (15) 
 
5.3 (1) 
 
27.8 (5) 
 
 
 
 
1,611 + 2,295 
 
 
 
 
 
55.6 (10) 
38.9 (7) 
5.6 (1) 
 
88.9 (16) 
 
5.6 (1) 
 
50.0 (9) 
 
 
 
 
p>0.05¶ 
 
 
 
 
 
p>0.05 
 
 
 
p>0.05 
 
p>0.05 
 
p>0.05 
 
 
    
‡Reference group 
¶Mann-Whitney U Test 
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Figure 6.5        Methamphetamine positive urine screens by visit 
 
 
 
Table 6.5   Proportion of methamphetamine-positive urine screens for 
aripiprazole and placebo 
Visits Aripiprazole (n=19) Placebo (n=18) 
 
 
Screening Visit 
 
Baseline 
 
Day 7 
 
Day 14 
 
Day 28 
 
Day 42 
 
Day 56 
 
100 (19/19) 
 
52.6 (10/19) 
 
46.7 (7/15) 
 
25.0 (4/16) 
 
35.3 (6/17) 
 
35.7 (5/14) 
 
43.8 (7/16) 
 
100(18/18) 
 
55.6 (10/18) 
 
64.3 (9/14) 
 
58.3 (7/12) 
 
46.2 (6/13) 
 
63.6 (7/11) 
 
42.9(3/7) 
 
    
    
 
 
7  Overall Conclusions and Recommendations  
 259 
Table 6.6  Generalized Estimating Equations(GEE) analysis for  
methamphetamine urine screens between aripiprazole and placebo 
Source 
Type III 
Wald Chi-Square df Sig. 
(Intercept) 0.36 1 0.549 
Visit 3.75 4 0.441 
Group 1.86 1 0.173 
Visit * Group 3.94 4 0.415 
Dependent Variable: Urine 
Model: (Intercept), Visit (Baseline, day 7,14, 28, 42 and 56), Group 
(aripiprazole and placebo), Visit * Group 
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Figure 6.6   Kaplan-Meier estimate of the survivor function for retention 
in treatment 
                   Logrank p=0.023 
 
Means and Medians for Survival Time 
 Randomize Mean 95% C.I. Median 95% C.I. 
 Placebo 37.11 
48.74 
43.08 
(27.14, 47.09) 42.0 
 
 
 
(27.54, 56.46) 
 Aripiprazole (40.86, 56.62)   
 Overall (36.50, 49.67) 
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Table 6.7  Number (%) of patients reporting adverse events – safety 
population 
Adverse Events Aripiprazole (n=19) Placebo (n=18) 
 
Akathasia 
 
Insomnia 
 
Agitation 
 
Urinary Retention 
 
Depression 
 
Psychosis 
 
Lethargy 
 
Sedation 
 
Sexual Dysfunction 
 
26.6 (5) 
 
10.6 (2) 
 
10.6 (2) 
 
5.3 (1) 
 
5.3 (1) 
 
0 
 
0 
 
0 
 
0 
 
5.6(1) 
 
11.1 (2) 
 
5.6  (1) 
 
0 
 
0 
 
22.2 (4) 
 
5.6 (1) 
 
5.6 (1) 
 
5.6 (1) 
   
   
p > 0.05 on all items 
 
Table 6.8  Concomitant medications and the indication according to 
treatment group 
Concomitant Medication 
/Indication 
Aripiprazole 
(n=19) 
Placebo (n=18) 
 
Lorazepam / Agitation 
 
5.3 (1) 
 
5.6 (1) 
 
Lorazepam/Akathasia 21.2 (4) 0 
 
Lorazepam / Insomnia 
 
Zolpidem / Insomnia 
 
Escitalopram / Depression 
 
 
0 
 
5.3 (1) 
 
5.3 (1) 
 
11.2 (2) 
 
0 
 
0 
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Table 6.9  BARS safety measures - changes from baseline at day 14, and 
day 42 
BARS Aripiprazole 
(n=19) 
Placebo (n=18) 95% CI ( p value) 
 
Baseline 
 
Day 14 
 
Day 42 
 
 
 
1.0 + 2.5 
 
0.6 + 1.5 
 
0.6 + 1.5 
 
 
 
0.1 + 0.5 
 
0 
 
0 
 
 
 -2.2, 0.3  (p>0.05)          
 
-1.3,0.1    (p>0.05) 
 
-1.3,0.1    (p>0.05) 
 
Table 6.10 SAS and AIMS safety measures - changes from baseline at 
day 14, and day 42 
SAS/AIMS Aripiprazole (n=19) Placebo (n=18) 
 
Baseline 
 
Day 14 
 
Day 42 
 
0 
 
0 
 
0 
 
 
 
0 
 
0 
 
0 
 
 
Table 6.11  Aripiprazole dosage among the methamphetamine 
dependence patients  
Visits Aripiprazole (n=19) 
 
Baseline(Starting Dose) 
 
Day 7 
 
Day 14 
 
Day 28 
 
Day 42 
 
Day 56 
 
10mg/day 
 
9.6 + 3.5 
 
8.7 + 3.0 
 
7.8 + 2.7 
 
7.3 + 3.3 
 
7.9 + 4.5 
 
  
7  Overall Conclusions and Recommendations  
 263 
Table  6.12     PANSS and  CGI  efficacy measure for psychotic symptoms  
 Aripiprazole (n=19) Placebo (n=18) 95% CI ( p value) 
 
PANSS, mean + SD 
Baseline 
Day 14 
Day 56 
 
CGI, mean + SD 
Baseline 
Day 14 
Day 56 
 
 
44.9 + 10.6 
40.9 + 10.2 
38.0 + 10.0 
 
 
2.0 + 0.9 
1.7 + 0.9 
1.3 + 0.6 
 
 
45.8 + 12.2 
51.6 + 20.8 
51.0 + 20.8 
 
 
2.1 + 0.9 
2.5 + 1.3 
2.4 + 1.2 
 
 
-6.8, 8.4    (p>0.05) 
-0.2, 21.5  (p>0.05) 
2.2, 23.8    (p=0.02)* 
 
 
-0.5, 0.7    (p>0.05) 
0.01,1.5    (p=0.04)* 
0.5,1.8      (p=0.004)* 
    
    
 
 
 
Table 6.13  Mixed Model Repeated Measures (MMRM) for  PANSS and 
CGI  among methamphetamine dependence patients  
 
 PANSS CGI 
Source 
F Sig. F Sig. 
Intercept 413.74 0.001 182.54 0.001 
Intervention * Time 6.26 0.004 4.12 0.021 
Intervention 4.94 0.032 6.30 0.017 
Time 0.19 0.825 1.66 0.200 
   
Dependent Variable: PANSS  and CGI 
Model: (Intercept), Time (Baseline, day 14 and 56), Intervention (aripiprazole 
and placebo), Intervention * Time 
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Table 6.14   Brief Substance Craving Scale (BSCS) efficacy measures, 
HADS efficacy  measures for anxiety and depressive symptoms.  
 Aripiprazole (n=19) Placebo (n=18) 95% CI ( p value) 
 
HADS- Anxiety  
Baseline 
Day 14 
Day 42 
 
HADS-Depression 
Baseline 
Day 14 
Day 42 
 
BSCS 
Baseline 
Day 7 
Day 14 
Day 28 
Day 42 
Day 56 
 
 
 
2.6 + 2.8 
1.7 + 2.2 
1.5 + 1.9 
 
 
2.5 + 3.6 
1.7 + 2.8 
2.1 + 2.8 
 
 
2.5 + 2.9 
1.6 + 2.7 
2.3 + 3.0 
1.9 + 2.8 
1.8 + 2.8 
1.5 + 2.3 
 
 
 
3.6 + 3.3 
4.9 + 4.2 
3.6 + 3.7 
 
 
3.8 + 4.5 
4.7 + 4.6 
3.4 + 3.9 
 
 
2.3 + 2.7 
2.0 + 2.9 
2.5 + 3.2 
4.6 + 2.7 
4.4 + 3.1 
4.5 + 2.9 
 
 
 
-1.1, 3.0    (p>0.05) 
0.9, 5.4     (p=0.009)* 
0.1, 4.0     (p=0.04)* 
 
 
-1.4, 3.9    (p>0.05) 
0.4, 5.4      (p=0.02)* 
-0.1, 3.6     (p>0.05) 
 
 
-0.5, 3.2    (p>0.05) 
- 1.4, 5.2    (p> 0.05) 
- 0.5, 4.9    (p>0.05) 
0.7, 4.5     (p=0.007)* 
0.7, 4.7     (p=0.01)* 
1.3, 4.8     (p=0.001)* 
 
 
Table 6.15      Mixed Model Repeated Measures (MMRM) for HADS-
Anxiety, HADS-Depression and BSCS among methamphetamine 
dependence patients 
Source 
HADS-Anxiety HADS-Depression   BSCS 
F Sig. F Sig. F Sig. 
Intercept 44.54 0.001 33.03 0.001 42.11 0.001 
Intervention * Time 3.48 0.037 1.364 0.264 1.62 0.159 
Intervention 6.68 0.014 3.67 0.063 6.51 0.015 
Time 2.87 0.065 0.54 0.584 1.73 0.133 
     
Dependent Variable: HADS-Anxiety, HADS-Depression and BSCS 
Model for HADS-Anxiety and HADS-Depression : (Intercept), Visit (Baseline, day 14 
and 42), Intervention (aripiprazole and placebo), Intervention * Time  
Model for BSCS: (Intercept), Time (Baseline, day 7,14, 28, 42 and 56), Intervention 
(aripiprazole and placebo), Intervention * Time 
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6.5  Discussion 
 
In this randomised, placebo-controlled trial of the safety and efficacy of 
aripiprazole in the treatment of methamphetamine dependence, 
patients still continued taking the stimulant drug despite treatment. Our 
study showed that aripiprazole was not significantly more effective than 
placebo in reducing methamphetamine use, as reflected in the urine 
screening results that showed no statistically significant difference 
between the aripiprazole and placebo groups on the number of urine 
positive samples. The inability of this study to detect any statistical 
significant difference in the urine screening results could possibly be 
due to the small sample size of the study.   
No differences were observed in the depression scores between the 
active treatment and placebo. Aripiprazole has been used alone or with 
other medications to treat manic-depressive disorder, and also been 
used with an antidepressant to treat depression when symptoms 
cannot be controlled by the antidepressant alone (Keck et al., 2007, 
Marcus et al., 2008). In this study, aripiprazole did not show significant 
effects in reducing the depressive symptoms scores in the 
methamphetamine dependent subjects. This is probably because the 
mean score for the depressive items in the HADS scale was already 
low in both placebo and aripiprazole group at baseline. To obtain a 
significant difference we probably need to study a bigger sample and 
follow up the patients over a longer period. 
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However, results favouring the aripiprazole group were found on the 
other primary outcome measure and four of the five tertiary study 
endpoints investigated in this study, namely significantly better 
retention in treatment, improved psychotic symptoms (as measured 
with PANSS and CGI), improved craving symptoms and improved 
anxiety symptoms. 
Even though some patients in the aripiprazole arm remained 
dependent on methamphetamine, the majority of them returned for the 
scheduled evaluation visits, with only 3 patients lost to follow up. This 
has a good clinical implication. As shown by studies, psychosocial 
interventions, such as cognitive behavioural therapy, contingency 
management and the matrix model approach, may provide significant 
benefit to psychostimulant users (Shoptaw et al., 2006, Aharonovich et 
al., 2003, Baker et al., 2005, Rawson et al., 2004). One of the most 
significant problems for the long-term treatment of stimulant 
dependence is the high incidence of relapse to drug seeking and drug 
taking following prolonged periods of abstinence (Dackis and O'brien, 
2001, Wagner and Anthony, 2002). By being able to be retained in the 
treatment for a longer duration, patients have a greater opportunity to 
receive frequent health services provided by their doctors and therefore 
can be given psychological or behavioural therapies to improve 
treatment outcome.   
Aripiprazole is an antipsychotic agent already proven to be successful 
in the pharmacological treatment of positive symptoms in 
schizophrenia (Taylor, 2003).  Our results concurred with that by 
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demonstrating the significant effects of aripiprazole on psychotic 
symptoms among methamphetamine dependent patients in this study. 
Both the PANSS and CGI scores decreased significantly in the 
aripiprazole-treated subjects, while increased in the placebo group. 
Patients enrolled into our study had an average CGI score of 2.0 and 
2.1 in the aripiprazole and placebo groups, respectively at baseline. 
The scores reduced to normal in the aripiprazole arm while showing a 
worsening trend in the placebo group. In fact, four patients in the 
placebo arm (22.2%) developed worsening of psychotic symptoms 
during the study.   
The positive symptoms in schizophrenia are hypothesised to result 
from excess subcortical dopamine release (Taylor, 2003). Disturbed 
mesolimbic dopamine neurotransmission is believed to play a major 
role in psychostimulant dependence (Pulvirenti and Koob, 2002).  It is 
possible that aripiprazole counteract the high dopamine levels found 
during the binging periods of the dependence cycle that caused the 
psychotic symptoms, and thus exert its effect on those symptoms. 
Our study also noted that aripiprazole might have effects on anxiety 
symptoms presented in the methamphetamine dependent patients 
undergoing treatment. Significant differences in the anxiety items 
scores of the HADS could be seen between patients in the aripiprazole 
group and those in the placebo group. This finding corresponds to 
results from studies of aripiprazole in treating refractory generalised 
anxiety disorder (Hoge et al., 2008) or anxiety symptoms in depressed 
patients (Adson et al., 2005).  
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It is not clear why antipsychotic medications may have a positive effect 
on symptoms of anxiety. The second-generation antipsychotics have 
an effect on both the dopaminergic and serotonergic systems. Both of 
these neurotransmisson pathways have been implicated in both 
depression and anxiety, and agents that have an effect on these 
systems may ameliorate these symptoms (Stein et al., 2002). The 
anxiolytic effects of aripiprazole may be given rise from its activity at 
the serotonin 1A (5-HT1A) receptor (Carli et al., 1993, Collinson and 
Dawson, 1997), and its partial agonist and dopaminergic stabilising 
qualities(Adson et al., 2005). 
In this study we found that aripiprazole might be effective in reducing 
methamphetamine craving. There were significant differences in the 
BSCS score between patients in the aripiprazole group and those in 
the placebo group. Previous study supported that aripiprazole was able 
to reduce craving among schizophrenic with cocaine dependence 
(Beresford et al., 2005). However our findings did not support an earlier 
study by Newton et al (Newton et al., 2008) that compared aripiprazole 
(15 mg) with placebo in the treatment of methamphetamine addiction. 
They found that aripiprazole treatment has no effect on 
methamphetamine craving, whether it was cue-induced or daily 
baseline.  The difference could be due to the lower dosage that was 
used in our study. There are few studies that suggested using a lower 
dosage of aripiprazole (Newton et al., 2008, Stoops, 2006, Stoops et 
al., 2006).   
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All in all, the strategy to use a partial agonists in mediating the receptor 
system may be an effective treatment for stimulant dependence 
(Childress and O'brien, 2000). During initial abstinence from chronic 
stimulant administration, the dopamine tone is low (Weiss et al., 1992).  
A partial agonist such as aripiprazole produces some stimulation at the 
D2 receptors, and may therefore act as a replacement medication. 
When there are higher levels of neurotransmitter present in the 
synapse, as would occur following the use of methamphetamine upon 
relapse, aripiprazole act as an antagonist. Therefore using aripiprazole 
to treat methamphetamine dependence may be able to block the acute 
stimulant abuse-related effects, thereby extinguishing drug-seeking 
and drug-taking behaviours over time. However, Lile et al (Lile et al., 
2005) pointed out there is an inherent limitation to the use of 
competitive antagonist to treat drug dependence. If drug-dependent 
patients are maintained on a competitive antagonist, they may increase 
self-administration of the stimulant drug to offset the effects of the 
antagonist (withdrawal symptoms), leading to continued use of the 
stimulant. This could be a possible reason to some of patients in this 
study continued to use methamphetamine while on aripiprazole 
treatment. 
Nevertheless, our study shows that aripiprazole can be safely 
administered to subjects dependent on a stimulant. In general, atypical 
antipsychotics are less likely to cause movement-related side effects, 
such as tardive dyskinesia, but may be associated with other adverse 
effects, including weight gain, sedation, increased levels of prolactin, 
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and glucose and lipid dysregulation (Srisurapanont et al., 2004, Hunter 
et al., 2003). Earlier research that compared aripiprazole with other 
atypical antipsychotics found there was less weight gain, no 
hyperprolactinaemia and lower risk for diabetes and hyperlipidaemia 
with aripiprazole (Mcquade et al., 2004, Marder et al., 2003, 
Chrzanowski et al., 2006).  
In our study, aripiprazole appeared to be safe and well tolerated for the 
treatment of methamphetamine dependence. No medication-related 
serious AE was reported in patients treated with aripiprazole. 
Nevertheless, there were incidences of mild-to-moderate and transient 
akathasia and agitation in both treatment arms, with the aripiprazole 
arm reporting a higher incidence than in the placebo group.  
When comparing the scores of BARS, AIMS, and SAS between the 
two treatment groups, no significant differences were noted.    
There might be conjectures that the dose of aripiprazole used in this 
study was low to elicit apparent effect. However, an earlier study by 
Stoops and colleagues (Stoops et al., 2006) showed that 10 mg 
aripiprazole is a reasonable starting dose for the treatment of stimulant 
abuse and dependence. In their study, aripiprazole given at 10 mg was 
not effective at attenuating the discriminative-stimulus effects of d-
amphetamine in healthy volunteers, but was able to reduce some 
positive subject-rated effects produced by d-amphetamine. This may 
explain why aripiprazole, albeit given at a lower dose, was able to 
attenuate some of the behavioural effects of methamphetamine 
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dependent patients in our study, resulting in better retention rates 
compared to placebo.  
Two previous studies (Tiihonen et al., 2007, Newton et al., 2008) that 
compared aripiprazole and placebo showed that the antipsychotic 
failed to treat methamphetamine dependence. Unlike their studies, this 
study managed to show that aripiprazole is at least significantly more 
effective than placebo in keeping patients in treatment, improving 
psychotic and anxiety symptoms. The difference in our findings and 
theirs may possibly due to several differences in the study designs, in 
terms of the study population, route of administration of 
methamphetamine and dosage used. 
This study included subjects who are methamphetamine-dependent 
with psychotic symptoms, whereas the subjects from the earlier two 
studies did not present with psychotic symptoms. The subjects in our 
study are more likely to represent the type of patients physicians see in 
the real clinical settings.  
The study population in the previous studies used intravenous 
methamphetamine while patients in our study used methamphetamine 
via the smoking/nasal and oral routes. Different routes of 
methamphetamine administration may have different pharmacological 
effects that resulted in the urge for repeated use of the stimulant.   
Ethnic differences could also account for the disparity between this 
study and the other two. Their studies involved Caucasian subjects 
while ours were an Asian sample. The pharmacokinetics and 
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pharmacodynamics of aripiprazole may vary across different ethnic 
populations. 
In terms of dosage, our study used a lower and flexible dose of 5-10 
mg of aripiprazole once daily. The earlier studies used 15 mg fixed 
dose. The more intense withdrawal symptoms caused by a higher dose 
of aripiprazole might have possibly ‘forced’ patients  to increase 
methamphetamine use to overcome those symptoms in one of the 
studies(Tiihonen et al., 2007).  Patients in our study also underwent 
detoxification for 2 weeks with aripiprazole and other symptomatic 
treatment (e.g. benzodiazepine) prior to randomisation to aripiprazole 
or placebo.  
 
The patients in this study have severe dependence and had at least 3 
months of history of drug use; this population was practically similar to 
that found in real-life settings. Therefore this study can be considered 
more of an effectiveness study rather than an efficacy study alone.   
Considering all outcomes in this study, aripiprazole was effective in 
retaining patients in treatment, reducing methamphetamine cravings, 
improving psychotic and anxiety symptoms, but was not effective in 
reducing depressive symptoms and maintaining abstinence in our 
study population. We cannot as yet draw any definite conclusion on its 
potential efficacy in relapse prevention among detoxified patients. 
Future research to include more patients and with a longer study 
duration is needed to ascertain the therapeutic effect of aripiprazole in 
methamphetamine dependence. 
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Limitation and Errors 
While the present results suggest that aripiprazole may have clinical 
utility in the management of methamphetamine abuse dependence, 
several limitations related to the study design should be acknowledged. 
The primary limitations of this study include a small sample size, the 
relatively short study duration, and the omission of behavioural 
measures of reinforcing effects of methamphetamine.   
i). Adequacy of Sample Size  
Although the required sample size was 18 per arm and maintained 
80% power of the study, the small sample size (aripiprazole n=19, 
placebo n=18) might have precluded detection of any but statistically 
large effects.    
We are not able to enroll a larger number of samples due to financial 
limitations. We were only given a small amount of study grants 
(RM150,000) by University of Malaya. In order to get more samples, 
we need to open up more study sites, hire more investigators and 
study coordinators, do more advertisement in mass media and have 
enough funds to buy the study medications.                                                                                      
ii). Conduct of study   
For blinding in this study, the original form of medications (aripiprazole 
and vitamin B complex) was repacked in the capsule. Patient might 
open the capsule and know their assignment either study medication or 
placebo, this might interfere with the compliance.  
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Additionally, it might take a longer than 8 weeks to achieve full benefit 
from aripiprazole treatment. Again, we could not do a longer follow up 
study because of financial limitations. We only have enough funds to 
follow up patients up to 8 weeks.                    
iii). Representative and Generalisation 
The findings of this study could only be generalized with caution 
because the study population was from the inpatient and outpatient 
clinic located in a hospital in Kuala Lumpur. The study population 
differs from the patients in the community because of the treatment 
seeking behavior. To make generalized inferences of the findings of 
this study to the methamphetamine dependence patients in community 
would be inappropriate because the setting in this study had introduced 
selection bias. 
For a better generalization of the findings, it would be ideal to conduct 
a community survey. Unfortunately, such a study is not feasible to be 
conducted due to the legal implication.  
iv). Instruments of the study 
All the scales have been used widely in this country however until now, 
there was no paper being published regarding the validation of the 
scales in the local population.  
v). Comparing Findings With Other Studies 
Comparison of the findings of this study to other studies may be 
inaccurate, although other studies examined the same variables, but 
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the inclusion and exclusion criteria used to identify subjects or sampled 
population could differ, or study could be conducted with different study 
design.  
No behavioural measures of reinforcement intervention were 
incorporated into the design of this study. While treatments 
medications are intended to reduce drug-taking behaviour, other 
studies have proven that modification of subjective effects requires 
behavioural measures of reinforcement, e.g. drug self-administration or 
the multiple-choice procedure (Fischman and Schuster, 1982, Griffiths 
et al., 1993). Our future research would possibly incorporate 
behavioural therapy, but the administration of pharmacotherapy and 
behavioural therapy should be approached in a systematic way (Vocci 
and Appel, 2007) , as the medication may interact selectively with a 
certain type of behavioural therapy (Poling et al., 2006, O'malley et al., 
1992).   
6.6 Conclusions 
 
Aripiprazole was no more effective than placebo in maintaining 
abstinence from methamphetamine use. However, it facilitated 
treatment retention and reduced the occurrence of psychotic symptoms 
in this study population. Aripiprazole was generally safe and well 
tolerated. It might have a role in the treatment of methamphetamine 
dependence with psychotic symptoms. 
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Chapter SEVEN: Overall Conclusions and Recommendations 
7.1   Overall Conclusions  
Methamphetamine dependence and its psychiatric sequelae are 
increasingly rampant in Malaysia.  The widespread occurrence of 
methamphetamine dependence has brought an impact that can be felt 
at various levels, from the individual, to the individual’s family, 
community and society. At the country level, methamphetamine 
dependence gives rise to serious behavioural, medical and psychiatric 
consequences, imposing an immense burden on the medical, public 
health and criminal justice systems. 
Unfortunately there are not many studies done on the issues of 
methamphetamine dependence in Malaysia. We are still lacking in data 
especially in terms of prevalence, psychiatry morbidity, genetic risk 
factors and treatment aspect. Before effective strategy and treatment 
plan can be devised to curb this public health and social burden of the 
country, an understanding of the issue is warranted. 
 
7.1 1   Prevalence of Psychiatric Comorbidity and Suicidality 
The co-occurrence of psychiatric disorder and substance dependence 
disorder is a common condition (Wilson, 2007). The presence of a 
psychiatric disorder increases the risk for the presence of substance 
dependence disorder and vice-versa (Swendsen et al., 2010). Much 
evidence suggest that when these disorders occur together, is 
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associated with worse health outcomes, more complex clinical 
management, and increased health care costs (Wilson, 2007). 
We investigated the prevalence of psychiatric co-morbidity and the 
prevalence of suicidality in methamphetamine dependence patients.  
We also wanted to determine the association between psychiatric co-
morbidity and suicidality.   
The prevalence of psychiatric co-morbidity was 54.4% and the 
prevalence of suicidality in methamphetamine dependence patients 
was 12.1%. Our study demonstrated that methamphetamine 
dependence in Malaysians have high psychiatric comorbidity, with 
antisocial personality disorder being the most prevalently diagnosed 
comorbidity. Psychiatric comorbidities that were significantly associated 
to suicidality in methamphetamine dependence were depression, 
schizophrenia, panic disorder, and current and lifetime psychotic 
disorder.  
The observations from our study supported findings of earlier studies 
that methamphetamine-dependent individuals are at greater risk of 
experiencing particular psychiatric symptoms (Kalechstein et al., 2000, 
Yen and Chong, 2006, Chen et al., 2003), and are more likely to 
experience depressive symptoms and suicidal ideation than non-
methamphetamine dependent individuals. Data from our study and 
studies of other researchers, suggest that when treating 
methamphetamine-dependent individuals, a careful assessment of 
psychiatric history and assessment of suicidal risk are warranted. 
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7.1.2  Prevalence and Association of Methamphetamine Induce 
Psychosis 
 
When used in high dose or repeatedly, methamphetamine can cause 
drug-induced psychosis that display symptoms similar to those of 
paranoid schizophrenia, which is characterised by hallucinations, 
delusions and thought disorders. Methamphetamine induced psychosis 
is one of the most widely known side effects associated with high-dose 
or chronic methamphetamine use (Griffith et al., 1972, Hall et al., 
1996). In general, psychotic symptoms induced by substance use 
resolve within hours or days after withdrawal from the drug (transient 
type), but they may be significantly prolonged (persistent type) in some 
individuals, despite the absence of a known prior history of psychotic 
illness.  
The aims of this study were to investigate the prevalence of psychosis 
among methamphetamine dependent patients and to investigate the 
associated factors. 
Our results showed that 47.9% of the subjects had at least one episode 
of psychotic symptoms after they were dependent on 
methamphetamine. 13.0% of the patients were still having psychotic 
symptoms at the time of assessment. Persecutory delusions, auditory 
hallucinations, strange or unusual belief and delusions of reference 
were the most common symptoms. Our results concur with finding from 
other investigators.  In a cross-country study including Australia, Japan, 
Philippines and Thailand where psychotic symptoms in 
methamphetamine psychotic in-patients were evaluated using the Mini-
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International Neuropsychiatric Interview found high prevalence rate of 
lifetime and current psychotic symptoms (Srisurapanont et al., 2003). 
After multiple logistic regression, the independent risk factors of 
psychosis were mania, antisocial personality disorder, higher amount 
of stimulant use and higher family income. 
The prevalence of psychosis among methamphetamine dependent 
subjects was found to be alarmingly high in our study. These findings 
substantiate the fact that methamphetamine users are a high-risk 
population for psychosis, including those without known history of 
schizophrenia or other psychotic disorders. 
 
7.1.3  Association of Brain-Derived Neurotrophic Factor 
(Val66Met) Genetic Polymorphism with Male 
Methamphetamine Dependence in Malaysia. 
 
Methamphetamine abuse can lead to drug dependence when taken 
often enough and in large enough quantities. However, individuals are 
differentially vulnerable to methamphetamine dependence. The 
probability of continuing drug use varies from individual to individual, 
and the difference is very likely due to both biological and psychosocial 
factors.   
Familial and population genetic studies (Mirin et al., 1991, Rounsaville 
et al., 1991, Luthar and Rounsaville, 1993) have revealed possible 
genetic bases for some of the inter-individual differences in 
vulnerability to substance abuse and addiction risk. The susceptible 
single nucleotide polymorphisms (SNP) in some genes may contribute 
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to addiction vulnerability in several ways, including changing the 
structure or function of specific proteins. A mutant protein causes 
structural or functional changes of specific brain circuits during 
development phase or in adulthood (Nestler, 2000). These altered 
brain circuits may change an individual’s responsiveness to initial drug 
exposure, or alter the adaptations that occur in the brain after repeated 
drug exposure. 
Brain-derived neurotrophic factor (BDNF), a member of the nerve 
growth factor-related family of neutrophins, is widely expressed in the 
adult mammalian brain. Evidence indicates that BDNF may be involved 
in the mechanisms underlying substance abuse (Hofer et al., 1990). 
BDNF plays an important role in the neurodevelopment of 
dopaminergic (DA)-related systems. Recent studies have 
demonstrated that the BDNF gene is associated with vulnerability to 
drug abuse (Itoh et al., 2005). 
We  investigated (i) the association of the BDNF gene Val66Met 
polymorphism with methamphetamine dependence (ii) the association of 
the BDNF gene Val66Met polymorphism with the occurrence of 
psychosis among methamphetamine dependence patients in a 
Malaysian male population with different ethnicities. 
186 male methamphetamine-dependent subjects and in 154 male 
controls of four different ethnicities, namely, Malay, Chinese, Kadazan-
Dusun, and Bajau were recruited in this study. Our results showed that 
the distribution of the BDNF Val66Met genotype in Chinese subjects 
with methamphetamine dependence and methamphetamine psychosis 
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were significant compared with controls. The frequency of the 66Val 
allele in methamphetamine-dependent subjects was higher than that in 
the control group, suggesting that the 66Val carriers are more 
susceptible to methamphetamine dependence.  
However, 66Val allele frequency in other ethnicities was not 
significantly different from the controls. The results of the study also 
showed that in the Chinese methamphetamine dependent subjects, 
there was a difference in allele frequency when comparing those who 
developed psychosis and those who did not. 
Our findings suggest that the BDNF Val66Met polymorphism may 
contribute to methamphetamine dependence and psychosis in the 
Chinese population but not in other Malaysian ethnicities. 
 
7.1.4  Efficacy and Safety of Aripiprazole in the Treatment of 
Methamphetamine Induce Psychosis: An Open Label 
Prospective Study 
 
Although methamphetamine induced psychiatric disorders are typically 
self-limited and usually abate on their own, treatment is still needed in 
cases of emergency situations (i.e. acute episodes of 
methamphetamine induced psychosis), as well as to prevent 
recurrence in long-term.  Recurrence of psychotic symptoms can occur 
due to continued use of methamphetamine or other drug use and also 
due to psychosocial stressors (Yui et al., 1997, Yui et al., 2000).  In 
some cases psychosis may persist and around 5 -15% of users who 
developed methamphetamine psychosis fail to recover completely 
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(Hofmann, 1983). When the psychotic symptoms persist and interfere 
with the patient's social and occupational functioning, treatment should 
be targeted to psychiatric symptoms present (Larson, 2008).  
The objective of this study was to explore the therapeutic effects and 
tolerability of aripiprazole in the occurrence of psychosis among 
methamphetamine dependent patients.  
A total of 49 patients were enrolled and started on aripiprazole out of 
which 83.7% completed the study. There was a statistically significant 
decline in the mean PANSS-total and CGI-S score over the course of 
the study. Aripiprazole was generally well tolerated during the study. 
Adverse events were reported in 20.4% of patients. The reported 
adverse events were akathisia, insomnia, agitation, sedation and 
depression. Most adverse events were mild to moderate in intensity. 
There was no serious adverse event during the study period. 
This 2-week, open-label study shows that aripiprazole given once-daily 
improved the psychotic symptoms associated with methamphetamine 
dependence. The treatment was generally well tolerated with mild to 
moderate adverse events. In this study aripiprazole was an efficacious 
and safe option for the treatment of methamphetamine-induced 
psychosis. 
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7.1.5 Randomized Placebo-Controlled Trial of the Safety and 
Efficacy of Aripiprazole in the Treatment of 
Methamphetamine Dependence Patients  
 
There are great needs in the treatment of methamphetamine 
dependence. The goals of drug dependence treatment are to reduce 
further drug use, improve the patient’s ability to function, minimize the 
medical and social complications of drug abuse and dependence, and 
ultimately to achieve lasting abstinence (Kay-Lambkin et al., 2010). 
Managing methamphetamine dependence, as well as to recover from 
it, does not involve a brief detoxification and discharge, but a long-term 
process to help individuals free themselves from illicit substance use 
(Bruce, 2000). 
The objective of this study was to determine the efficacy and safety of 
aripiprazole among methamphetamine dependence patients.  
84.2% of participants randomized to aripiprazole completed the 8 
weeks study compared to only 50% of the placebo group completed 
the study (p < 0.05). There was a statistically significant difference 
between groups in the amount of time spent in treatment, with those 
given aripiprazole retained for an average of 48.7 days (+ 4.0) 
compared with only 37.1 days (+ 5.0) for the placebo group. The 
survival curves results showed that participants in the aripiprazole 
group were less likely to drop out of the study than those in the placebo 
group. The difference was statistically significant (p =0.02, X2 =5.3). 
Psychotic symptoms as measured by PANSS and CGI were decreased 
among participants who were randomized to aripiprazole treatment but 
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those who were randomized to placebo showed an increase in the total 
PANSS and CGI score (p < 0.05). However there were no statistically 
significant effects for aripiprazole relative to placebo on 
methamphetamine use verified by urine drug screen.  Aripiprazole 
treatment was not associated with any serious adverse event. Adverse 
event were generally mild and consistent with known pharmacological 
effects.  
Aripiprazole was no more effective than placebo in maintaining 
abstinence from methamphetamine use. However, it facilitated treatment 
retention and reduced the occurrence of psychotic symptoms in this 
study population. Aripiprazole was generally safe and well tolerated. It 
might have a role in the treatment of methamphetamine dependence 
with psychotic symptoms.  
7.2   Recommendations 
1. We feel that identification and treatment of comorbid psychiatric 
illnesses in this population is of upmost importance. It is 
unethical not to screen and treat for psychiatric illnesses in this 
population, and cause unnecessary suffering, knowing very well 
the rate of psychiatric illnesses in them is high. Failure to identify 
comorbid psychiatric illnesses here means an opportunity for 
treatment is lost in a population that is otherwise difficult to 
reach in the community. 
2. Identification and treatment of psychiatric illnesses must be 
addressed as the central role in relapse prevention of substance 
use. Comorbid psychiatric illnesses, particularly depression, are 
7  Overall Conclusions and Recommendations  
 285 
often associated with high rates of continued substance usage 
after treatment. 
3. Screening for psychotic symptoms should be employed to 
patients with methamphetamine dependence especially for 
those who had history of mania, personality disorders, high 
amount of stimulant used and high family income. 
4. All psychiatric symptoms especially psychosis and depression 
should be treated adequately.  
5. We would like to suggest conducting genetic polymorphism 
study with a larger sample size in order to provide more 
evidence to confirm the genetic influence of BDNF in 
methamphetamine dependence. 
6. We would like to suggest conducting genetic studies 
investigating other SNPs in methamphetamine dependence. 
This knowledge can help in future development of screening 
tools and pharmacogenomics treatment. 
7. Aripiprazole can be used safely and effectively in the treatment 
of methamphetamine-induced psychosis. 
8. Aripiprazole has a potential benefit and is safe for the treatment 
of methamphetamine dependence. We would like to suggest 
using aripiprazole as one of the treatment alternative in patients 
with methamphetamine dependence who had psychotic 
symptoms. 
9. We would like to suggest conducting further study with a larger 
sample size and a longer duration of follow up to confirm the 
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efficacy and safety of aripiprazole in the treatment on 
methamphetamine dependence. 
10. We would like to recommend conducting a study which 
combined aripiprazole with one of the behavioural treatment 
method (cognitive therapy or contingency management 
program) to confirm if it will yield a better outcome. 
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Appendix A - Operational Definitions 
 
Chapter Two:     Psychiatric co-morbidity and suicidality in 
methamphetamine dependence   
Chapter Three:  Prevalence and association of methamphetamine 
psychosis  
 
Age: 
Age of the methamphetamine dependence patient in years at last 
birthday. 
Race: 
Ethnicity recorded in the medical case record. 
Marital status: 
Legal marital status either single or married, widowed or divorce as 
mentioned by patient during interview.   
Education level: 
Type of education institution last attended by the patient. 
Occupation: 
Patient’s current occupation 
Income:  
The average income of the sum of household income of the family in a 
month mentioned by the patient.   
Suicidality: 
Suicidality was defined as in the present either of having thought wish 
to be dead or want to harm themselves or think about suicide or have a 
suicide plan or attempted suicide in the past month or lifetime, 
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measured by MINI International Neuropsychiatric Interview 
(M.I.N.I)(Sheehan et al., 1998b) 
Mood disorders:  
Major depressive disorder and bipolar disorder in Axis I psychiatric 
disorders assessed by MINI International Neuropsychiatric Interview 
(M.I.N.I)  
Anxiety disorder: 
Generalised anxiety disorder, obsessive compulsive disorder, panic 
disorder and social phobia in Axis I psychiatric disorders assessed by 
MINI International Neuropsychiatric Interview (M.I.N.I) 
Psychotic disorder:  
The present of current or lifetime psychotic disorder. 
Poly-substance use: 
History of using more than one substance such as alcohol consumption 
and illicit drug other than nicotine.  
Criminal record: 
History of arrested or jailed due to illegal activities such as stealing, 
prostitution, fights, assault, rape, arson etc other than drugs.     
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Appendix B - Mini International Neuropsychiatric Interview (M.I.N.I.) 
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Appendix C - Amphetamine Withdrawal Questionnaire (AWQ) 
 
 
Amphetamine Withdrawal Questionnaire 
Initials: 
Date:       Visit: 
 
 DURING THE PAST 24 HOURS:    CIRCLE ONE ANSWER PER QUESTION 
 0 1 2 3 4 
1.  Have you been craving 
amphetamine or 
methamphetamine? 
 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
2.  Have you felt sad? Not at all Very 
little 
A little Quite a 
lot 
Very much 
3.  Have you lost interest in things or 
no longer take pleasure in them? 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
4.  Have you felt anxious? Not at all Very 
little 
A little Quite a 
lot 
Very much 
5.  Have you felt as if your 
movements are slow? 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
6. Have you felt agitated? Not at all Very 
little 
A little Quite a 
lot 
Very much 
7. Have you felt tired? Not at all Very 
little 
A little Quite a 
lot 
Very much 
8. Has your appetite increased, or 
have you eaten too much? 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
9. Have you had any vivid or 
unpleasant dreams 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
10. Have you been craving for sleep or 
sleeping too much? 
Not at all Very 
little 
A little Quite a 
lot 
Very much 
 
1. Hyperarousal subscale score (items1 + 6 + 9)  : 
2. Anxiety subscale score (items3 + 4 + 5)   :  
3. Reversed vegetative subscale score (items7 + 8 + 10) : 
4. Total AWQ score (all three subscale scores + item 2) : 
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Appendix D - Brief Substance Craving Scale (BSCS) 
 
Brief Substance Craving Scale 
 
Initials: 
 
Date: 
 
Visit: 
 
 
Please answer the following questions with regard to your craving for 
methamphetamine. 
 
1. The INTENSITY of my craving, that is, how much I desired this drug in the 
past 24 hours was: 
 
None at all    �0 
Slight     �1 
Moderate    �2 
Considerable    �3 
Extreme    �4 
 
2. The FREQUENCY of my craving, that is, how often I desired this drug in 
the past 24 hours was: 
 
N e v e r    �0 
Almost never    �1 
Several times    �2 
Regularly    �3 
Almost constantly   �4 
 
3. The LENGTH of time I spent in craving this drug during the past 24 hours 
was:  
 
None at all    �0 
Very short    �1 
Short     �2 
Somewhat long   �3 
Very long    �4 
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Appendix E - Abnormal Involuntary Movement Scale (AIMS) 
 
 
Abnormal Involuntary Movement Scales 
 
Initials: 
 
Date: 
 
Visit: 
 
 
 
Instructions: Complete examination procedure before making ratings. 
Rate highest severity observed. 
 
Code:   1 None 
2 Minimal, may be extreme normal 
3 Mild 
4 Moderate 
5 Severe 
 
 
Facial and Oral Movements: 
 
1.  Muscles of facial Expression (e.g., movement of forehead, eyebrows, 
periorbital area, cheeks; include frowning, blinking, smiling, grimacing) 
1  2 3 4  5 
 
2.  Lips and Perioral Area (e.g., puckering, pouting, smacking) 
1  2  3  4   5 
 
3.  Jaws (e.g. biting, clenching, chewing, mouth opening, lateral 
movement) 
1  2  3  4  5 
 
4.  Tongue (Rate only increase in movement both in and out of mouth, 
NOT inability to sustain movement.) 
1  2  3  4  5 
 
Extremity Movements: 
 
5. Upper (arms, wrists, hands, fingers). Include choreic movements (i.e., 
rapid, objectively purposeless, irregular, spontaneous), athetoid 
movements (i.e., slow, irregular, complex, serpentine). Do NOT 
include tremor (i.e., repetitive, regular, rhythmic). 
1  2  3  4  5 
6.  Lower (legs, knees, ankles, toes). (E.g., lateral knee movement, foot 
taping, heel 
dropping, foot squirming, inversion and eversion of foot.) 
1  2  3  4  5 
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Trunk Movements: 
 
7.  Neck, shoulders, hips ( e.g., rocking, twisting, squirming, pelvic 
gyrations) 
1  2  3  4  5 
 
Global judgments 
 
8. Severity of abnormal movements: 
 
1. None, normal 
2. Minimal 
3. Mild 
4. Moderate 
5. Severe 
 
9. Incapacitation due to abnormal movements: 
 
1. None, normal 
2. Minimal 
3. Mild 
4. Moderate 
5. Severe 
 
 
10. Patient’s awareness of abnormal movements (Rate only patient’s 
report) 
 
1. No awareness 
2. Aware, no distress 
3. Aware, mild distress 
4. Aware, moderate distress 
5. Aware, severe distress 
 
Dental Status: 
 
11. Current problems with teeth and/or dentures 
 
1. No 
2. Yes 
 
12. Does patient usually wear dentures? 
 
1. No 
2. Yes 
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Appendix F- Barnes Akathasia Scale (BARS) 
 
 
Barnes Akathisia Rating Scale (BARS) 
 
Initials: 
 
Date: 
 
Visit: 
 
Instructions: Patient should be observed while they are seated, and then standing 
while engaged in neutral conversation (for a minimum of two minutes in each 
position). Symptoms observed in other situations, for example while engaged in 
activity on the ward, may also be rated. Subsequently, the subjective phenomena 
should be elicited by direct questioning. 
 
Objective 
 
0  Normal, occasional fidgety movements of the limbs 
1 Presence of characteristic restless movements: shuffling or tramping 
movements of the legs/feet, or swinging of one leg while sitting, and/or 
rocking from foot to foot or “walking on the spot” when standing, but 
movements present for less than half the time observed 
2  Observed phenomena, as described in (1) above, which are present for at 
least half the observation period 
3  Patient is constantly engaged in characteristic restless movements, and/or 
has the inability to remain seated or standing without walking or pacing, 
during the time observed 
 
Subjective 
Awareness of restlessness 
0  Absence of inner restlessness 
1  Non-specific sense of inner restlessness 
2  The patient is aware of an inability to keep the legs still, or a desire to 
move the legs, and/or complains of inner restlessness aggravated 
specifically by being required to stand still 
3  Awareness of intense compulsion to move most of the time and/or reports 
strong desire to walk or pace most of the time 
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Distress related to restlessness: 
0  No distress 
1 Mild 
2  Moderate 
3  Severe 
 
Global Clinical Assessment of Akathisia: 
 
0  Absent. No evidence of awareness of restlessness. Observation of 
characteristic movements of akathisia in the absence of a subjective report 
of inner restlessness or compulsive desire to move the legs should be 
classified as pseudoakathisia 
 
1  Questionable. Non-specific inner tension and fidgety movements 
 
2  Mild akathisia. Awareness of restlessness in the legs and/or inner 
restlessness worse when required to stand still. Fidgety movements 
present, but characteristic restless movements of akathisia not necessarily 
observed. Condition causes little or no distress. 
 
3  Moderate akathisia. Awareness of restlessness as described for mild 
akathisia above, combined with characteristic restless movements such as 
rocking from foot to foot when standing. Patient finds the condition 
distressing 
 
4  Marked akathisia. Subjective experience of restlessness includes a 
compulsive desire to walk or pace. However, the patient is able to remain 
seated for at least five minutes. The condition is obviously distressing. 
 
5  Severe akathisia. The patient reports a strong compulsion to pace up and 
down most of the time. Unable to sit or lie down for more than a few 
minutes. Constant restlessness which is associated with intense distress 
and insomnia. 
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Appendix G - Simpson Angus Scale (SAS) 
 
 
SIMPSON-ANGUS EXTRAPYRAMIDAL SIDE EFFECTS SCALE 
 
Initials: 
Date: 
Visit: 
 
The exam should be conducted in a room where the subject can walk a 
sufficient distance to allow him/her to get into a natural rhythm (e.g. 15 
paces). Each side of the body should be examined. If one side shows more 
pronounced pathology than the other, this score should be noted and this 
taken. Cogwheel rigidity may be palpated when the examination is 
carried out for items 3, 4, 5, and 6. It is not rated separately and is merely 
another way to detect rigidity. It would indicate that a minimum score of 
1 would be mandatory. 
 
1.  Gait: The patient is examined as he walks into the examining room, 
his gait, the swing of his arms, his general posture; all form the basis 
for an overall score for this item. This is rated as follows: 
 
0 Normal 
1 Diminution in swing while the patient is walking 
2 Marked diminution in swing with obvious rigidity in the arm 
3 Stiff gait with arms held rigidly before the abdomen 
4 Stooped shuffling gait with propulsion and retropulsion 
 
2.  Arm Dropping: The patient and the examiner both raise their arms to 
shoulder height and let them fall to their sides. In a normal subject, a 
stout slap is heard as the arms hit the sides. In the patient with extreme 
Parkinson’s syndrome, the arms fall very slowly: 
 
0 Normal, free fall with loud slap and rebound 
1 Fall slowed slightly with less audible contact and little rebound 
2 Fall slowed, no rebound 
3 Marked slowing, no slap at all 
4 Arms fall as though against resistance; as though through glue 
 
3.  Shoulder Shaking: The subject’s arms are bent at a right angle at the 
elbow and are taken one at a  time by the examiner who grasps one 
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hand and also clasps the other around the patient’s elbow. The 
subject’s upper arm is pushed to and fro and the humerus is externally 
rotated. The degree of resistance from normal to extreme rigidity is 
scored as follows: 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost a frozen shoulder 
 
4. Elbow Rigidity: The elbow joints are separately bent  at right angles 
and passively extended and flexed, with the subject’s biceps observed 
and simultaneously palpated. The resistance to this procedure is rated. 
(The presence of cogwheel rigidity is noted separately.) 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost a frozen elbow 
 
5. Wrist Rigidity or Fixation of Position: The wrist is held in one hand 
and the fingers held by the examiner’s other hand, with the wrist 
moved to extension, flexion and ulnar and radial deviation: 
 
0 Normal 
1 Slight stiffness and resistance 
2 Moderate stiffness and resistance 
3 Marked rigidity with difficulty in passive movement 
4 Extreme stiffness and rigidity with almost frozen 
 
6. Leg Pendulousness: The patient sits on a table with his legs hanging 
down and swinging free. The ankle is grasped by the examiner and 
raised until the knee is partially extended. It is then allowed to fall. The 
resistance to falling and the lack of swinging form the basis for the 
score on this item: 
 
0 The legs swing freely 
1 Slight diminution in the swing of the legs 
2 Moderate resistance to swing 
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3 Marked resistance and damping of swing 
4 Complete absence of swing 
 
7.  Head Dropping: The patient lies on a well-padded examining table 
and his head is raised by the examiner’s hand. The hand is then 
withdrawn and the head allowed to drop. In the normal subject the 
head will fall upon the table. The movement is delayed in 
extrapyramidal system disorder, and in extreme parkinsonism it is 
absent. The neck muscles are rigid and the head does not reach the 
examining table.  
 
0 The head falls completely with a good thump as it hits the table 
1 Slight slowing in fall, mainly noted by lack of slap as head meets the table 
2 Moderate slowing in the fall quite noticeable to the eye 
3 Head falls stiffly and slowly 
4 Head does not reach the examining table 
 
8.  Glabella Tap: Subject is told to open eyes wide and not to blink. The 
glabella region is tapped at a steady, rapid speed. The number of times 
patient blinks in succession is noted: 
 
0 0-5 blinks 
1 6-10 blinks 
2 11-15 blinks 
3 16-20 blinks 
4 21 and more blinks 
 
9. Tremor: Patient is observed walking into examining room and is then 
reexamined for this item: 
 
0 Normal 
1 Mild finger tremor, obvious to sight and touch 
2 Tremor of hand or arm occurring spasmodically 
3 Persistent tremor of one or more limbs 
4 Whole body tremor 
 
10.  Salivation: Patient is observed while talking and then asked to open 
his mouth and elevate his tongue. The following ratings are given: 
 
0 Normal 
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1 Excess salivation to the extent that pooling takes place if the mouth 
is open and the tongue raised 
2 When excess salivation is present and might occasionally result in 
difficulty speaking 
3 Speaking with difficulty because of excess salivation 
4 Frank drooling 
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Appendix H - Hospital Anxiety and Depression Scale (HADS) 
Hospital Anxiety and Depression Scale (HADS) 
Initial: 
Date: 
Visit: 
 
A I feel tense or 'wound up':   
  Most of the time    3 
  A lot of the time    2 
  From time to time, occasionally  1 
  Not at all     0 
 
D I still enjoy the things I used to enjoy:   
  Definitely as much    0 
  Not quite so much    1 
  Only a little     2 
  Hardly at all     3 
 
A I get a sort of frightened feeling as if something awful is about to happen:   
  Very definitely and quite badly  3 
  Yes, but not too badly    2 
  A little, but it doesn't worry me  1 
  Not at all     0 
 
D I can laugh and see the funny side of things:   
  As much as I always could   0 
  Not quite so much now   1 
  Definitely not so much now   2 
  Not at all     3 
 
A Worrying thoughts go through my mind:   
  A great deal of the time   3 
  A lot of the time    2 
  From time to time, but not too often  1 
  Only occasionally    0 
 
D I feel cheerful:   
  Not at all     3 
  Not often     2 
  Sometimes     1 
  Most of the time    0 
 
A I can sit at ease and feel relaxed:   
  Definitely     0 
  Usually     1 
  Not Often     2 
  Not at all     3 
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D I feel as if I am slowed down:   
  Nearly all the time    3 
  Very often     2 
  Sometimes     1 
  Not at all     0 
 
A I get a sort of frightened feeling like 'butterflies' in the stomach:   
  Not at all     0 
  Occasionally     1 
  Quite Often     2 
  Very Often     3 
 
D I have lost interest in my appearance:  
  Definitely     3 
  I don't take as much care as I should  2 
  I may not take quite as much care  1 
  I take just as much care as ever  0 
 
A I feel restless as I have to be on the move:   
  Very much indeed    3 
  Quite a lot     2 
  Not very much    1 
  Not at all     0 
 
D I look forward with enjoyment to things:   
  As much as I ever did    0 
  Rather less than I used to   1 
  Definitely less than I used to   2 
  Hardly at all     3 
 
A I get sudden feelings of panic:   
  Very often indeed    3 
  Quite often     2 
  Not very often     1    
  Not at all     0 
 
D I can enjoy a good book or radio or TV program:   
  Often      0 
  Sometimes     1 
  Not often     2 
  Very seldom     3 
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Appendix I - Positive and Negative Symptoms Scale(PANSS) 
 
 
Positive and Negative Symptoms Scale 
Initials: 
Date: 
Visit: 
 
Positive Symptoms 
P1 Delusions  1 2 3 4 5 6 7 
 
P2 Conceptual disorganisation  1 2 3 4 5 6 7 
 
P3 Hallucinatory behaviour  1 2 3 4 5 6 7 
 
P4 Excitement  1 2 3 4 5 6 7 
 
P5 Grandiosity  1 2 3 4 5 6 7 
 
P6 Suspiciousness/persecution  1 2 3 4 5 6 7 
 
P7 Hostility  1 2 3 4 5 6 7 
 
 
 
Negative Symptoms 
N1  Blunted affect  1 2 3 4 5 6 7 
 
N2  Emotional withdrawal  1 2 3 4 5 6 7 
 
N3  Poor rapport  1 2 3 4 5 6 7 
 
N4 Passive/apathetic social 
withdrawal  
 
1 2 3 4 5 6 7 
 
N5  Difficulty in abstract 
thinking  
 
1 2 3 4 5 6 7 
 
N6  Lack of spontaneity & 
flow of conversation  
 
1 2 3 4 5 6 7 
 
N7  Stereotyped thinking  1 2 3 4 5 6 7 
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General Psychopathology 
G1 Somatic concern  1 2 3 4 5 6 7 
 
G2  Anxiety  1 2 3 4 5 6 7 
 
G3  Guilt feelings  1 2 3 4 5 6 7 
 
G4  Tension  1 2 3 4 5 6 7 
 
G5  Mannerisms & 
posturing  
1 2 3 4 5 6 7 
 
G6  Depression  1 2 3 4 5 6 7 
 
G7  Motor retardation  1 2 3 4 5 6 7 
 
G8 Uncooperativeness  1 2 3 4 5 6 7 
 
G9  Unusual thought 
content  
1 2 3 4 5 6 7 
 
G10  Disorientation  1 2 3 4 5 6 7 
 
G11 Poor attention  1 2 3 4 5 6 7 
 
G12 Lack of judgement & 
insight  
 
1 2 3 4 5 6 7 
 
G13 Disturbance of 
volition  
1 2 3 4 5 6 7 
 
G14  Poor impulse control  1 2 3 4 5 6 7 
 
G15  Preoccupation  1 2 3 4 5 6 7 
 
G16  Active social 
avoidance  
1 2 3 4 5 6 7 
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Appendix J - Clinical Global Impressions Scale (CGI-S) 
 
 
Clinical Global Impressions Scale 
Initials: 
Date: 
Visit: 
 
 
SEVERITY OF ILLNESS 
 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
 
Normal, not at all ill       �1 
 
Borderline mentally ill      �2 
 
Mildly ill        �3 
 
Moderately ill       �4 
 
Markedly ill        �5 
 
Severely ill        �6 
 
Among the most extremely ill patients    �7 
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